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ABSTRACT OF DISSERTATION 
Abstract 
CALCINEURIN; FROM ACTIVATION TO INHIBITION 
  
Calcineurin is a Ser/Thr phosphatase whose function is implicated in critical 
physiological processes such as immune system activation, fetal heart development, and 
long-term depression in neurons. Calcineurin has been implicated in the progression of 
Alzheimer’s disease and cardiac hypertrophy. It is not well understood how calcineurin is 
activated on a molecular level by Ca2+ and its activating protein calmodulin. Previous data 
from our lab show that calmodulin interaction induces the folding of the intrinsically 
disordered regulatory domain of calcineurin in two discrete and distant regions into α-helical 
conformations and that this folding is critical for complete activation of calcineurin. It was 
also discovered that one of the helical elements which we call the “distal helix” was unstable 
at a human body temperature of 37°C in dilute buffer. This raises the question; how can a 
structure critical for the complete activation of calcineurin be unstable at average human 
body temperature? Proteins do not exist in solutions of the dilute buffer, but rather in a 
crowded cosmos that ranges between 200 and 400 g/L of macromolecules such as proteins, 
DNA, and other cellular components. We show here that phenomenon known as 
macromolecular crowding can stabilize the distal helix and that stabilization increases the 
activity of calcineurin at human body temperature. 
Much about intrinsically disordered proteins (IDPs) remains a mystery, especially 
what influences the rate at which they interact with their target molecules. IDPs lack any sort 
of stable three-dimensional structure because of their lack of sufficient hydrophobic or 
aromatic amino acids while having a large proportion of polar and charged amino acids. 
Because of the high degree of charged amino acids, electrostatic forces play a significant role 
in their interaction other proteins. This is known to be the case for calmodulin which is net 
negatively charged protein that has over 300 binding targets of which are usually basic 
amphipathic alpha-helices. The calmodulin-binding site located in the intrinsically 
ii 
disordered regulatory domain of calcineurin is net positively charged, and, interestingly, is 
flanked by acidic patches on either side. These acidic patches might perturb attractive 
electrostatic forces between the calmodulin-binding site and calmodulin. Using fluorescence 
spectroscopy in conjunction with a stopped-flow apparatus to measure the kinetics between 
calmodulin and calcineurin we seek to characterize the influence of the steric and 
electrostatic forces between the two proteins. 
Also, we present data on RCAN1-4 (Regulator of Calcineurin Isoform 1-4) which has 
been shown to be an inhibitor in some contexts and an activator of calcineurin in other. 
RCAN1-4 is expressed in the heart and its upregulation has been shown to prevent 
calcineurin-mediated pathological cardiac hypertrophy suggesting that it plays an inhibitory 
role in this context. The work shown demonstrates that RCAN1-4 is a competitive inhibitor 
of calcineurin and whose binding affinity is modulated by Ca2+/calmodulin. These data unveil 
a binding site utilized by RCAN1-4 which is commonly used among other calcineurin 
substrates. 
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CHAPTER 1: Introduction 
  
1.1 Calcineurin and its Function 
 1.1.1 Calcineurin; History and disease relevance 
 In this dissertation we focus on the potential environmental influences in the 
regulation of calcineurin (CaN) activity. There are several biophysical features of CaN 
regulation which cannot easily be accessed through in vivo or cell-based experimentation. To 
begin to understand CaN regulation we imitate some of possible environments in which CaN 
could be present and measure CaN-substrate binding, activation, and CaN enzyme activity. In 
other words, the CaN activity we observe in vitro is not necessarily the same as that which 
occurs in vivo. Our overall hypothesis is that CaN activity is influenced by its environment (i.e 
cellular environment in which CaN is present). 
 CaN is a Ser/Thr phosphatase and was initially discovered by Wang and Desai and 
independently by Klee and Krinks to be an inhibitor of cyclic adenosine 3’:5’-monophosphate 
phosphodiesterase.1,2 Calcineurin was appropriately named on the basis of its Ca2+-
dependent activation and its high abundance in neuronal tissues.3 Since its initial discovery, 
it was found to play a role in many important signaling pathways such as long-term 
depression, pathological cardiac hypertrophy, and immune system activation.4,5 CaN has also 
been implicated in the development of neurofibrillary tangles, a constituent of Alzheimer’s 
disease.6 CaN was also found to be the target of two commonly used immunosuppressants, 
cyclosporine A and FK506, which are utilized during organ transplantation to prevent organ 
rejection by the host.7 The targeting of CaN by these immunosuppressants helped elucidate 
the signaling pathways in which CaN partake, one of which is immune system activation. Now, 
2 
it is known that CaN is not only expressed in the nervous system and immune cells but is 
expressed ubiquitously in humans and other mammals.4  
 Alterations in CaN activity have been suggested to alter the progression of 
Alzheimer’s disease although through several proposed mechanisms.8 Alzheimer’s disease is 
a chronic and progressive neurodegenerative disease whose symptoms include memory 
impairment, agitation, depression, and behavioral disturbance. Eventually, Alzheimer’s 
disease can progress to a severe form of dementia.  
The exact mechanism which underlies Alzheimer’s disease progression is not known, 
but several CaN-dependent signaling pathways have been implicated.  The microtubule-
associated protein tau (here, it will be called “tau”) has been shown to accumulate in the aging 
brain and is a pathological feature of Alzheimer’s disease.9 Tau helps to organize the assembly 
of microtubules and transport of cell components.10 Phosphorylation of tau increases the 
dissociation rate of tau from microtubules and increases the rate of microtubule 
depolymerization.11,12 Hyperphosphorylation of tau brought on by an imbalance of kinase 
and phosphatase activity leads to a gain in toxic function and its formation into paired-helical 
fragments.9 CaN was shown to be one of the phosphatases capable of dephosphorylating tau, 
and CaN’s downregulation led to an increase in the phosphorylation status of tau.6,13–15 The 
downregulation of CaN could led to an increase in the formation of paired-helical filaments.  
Further evidence that the downregulation of CaN leads to the accumulation of paired-
helical filaments comes from the study of the CaN inhibitor regulator of calcineurin (RCAN). 
The gene for RCAN is located on chromosome 21 and is overexpressed in Down syndrome.16 
This was interesting  finding given that Down syndrome patients have a 6-fold increase in the 
chances of developing Alzheimer’s disease.17 Of course there are over 400 genes located on 
chromosome 21 that also show altered expressed in Down syndrome which may also explain 
the increase risk of Alzheimer’s disease.18 But, the upregulation of RCAN in the brains of mice 
3 
has shown to correlate with an increased abundance of hyperphosphorylated tau.19 RCAN has 
been shown to be a CaN inhibitor, but how it inhibits CaN activity remains to be 
determined.20,21 
CaN/NFAT signaling is also implicated in hypertrophic cardiomyopathy, a common 
cause of heart failure and sudden death.22,23 Cardiovascular disease (CVD) is the leading cause 
of mortality worldwide. In 2008, 30% of deaths worldwide were attributed to CVD or 57 
million people.24 In the US, healthcare costs related to CVD were estimated to be $444 
billion.25 Regardless of race and socioeconomic background, a large percentage of the 
population in every country on Earth will be affected by CVD.26 Thus, research of 
cardiovascular pathologies is critical for the development of novel CVD prevention therapies 
and treatments. The result of such will work to ameliorate both the economic burden and 
fatalities related to CVD. 
 While suppressed activity of CaN may be implicated in Alzheimer’s disease, increased 
activity of CaN has shown to be mediate another pathological condition called pathological 
cardiac hypertrophy.5 Cardiac hypertrophy is growth of the heart muscle, but the stimuli that 
initiates the hypertrophic response will distinguish healthy or unhealthy growth.27 The heart 
can undergo physiological cardiac hypertrophy in response to chronic exercise or during 
pregnancy.28 There is no current evidence to suggest that physiological cardiac hypertrophy 
(also called athlete’s heart) leads to any long term negative consequences and it is generally 
considered to be a healthy adaptation which improves cardiac performance.29 In contrast, 
pathological cardiac hypertrophy occurs in response to aortic stenosis, valvular disease, and 
other cardiac diseases. While both forms of cardiac hypertrophy show increased cardiac 
mass, their morphological features are quite distinct. In pathological cardiac hypertrophy 
there is an increase in cardiomyocyte cell death and fibrosis leading to poor cardiac 
performance and eventual cardiac failure. In mouse models that mimic aortic stenosis-one of 
4 
the underlying cardiac diseases that can lead to pathological cardiac hypertrophy-an increase 
in CaN signaling was observed.30 It was hypothesized that upregulation of the CaN signaling 
pathway was mediating the morphological changes that led to pathological cardiac 
hypertrophy. Several groups later showed that inhibition of CaN or knockout of downstream 
CaN signaling molecules prevented pathological cardiac hypertrophy in mice.31 
Correspondingly, upregulation of the CaN pathway through expression of a constitutively 
active form of CaN led to the phenotypic features of pathological cardiac hypertrophy such as 
an increase in cardiac mass and fibrotic inclusion.32 The CaN signaling pathway appears to be 
a promising target for the treatment or prevention of pathological cardiac hypertrophy.  
 1.1.2 Calcineurin-mediated signaling  
  1.1.2.1 NFAT Signaling Pathway 
 The discovery that the immunosuppressants cyclosporine A and FK506 inhibit CaN 
exposed the CaN-signaling pathway as integral to the activation of the immune system.7 The 
connection between CaN and the immune system is the CaN target and transcription factor 
called nuclear factor of activated T-cells, for NFAT.33 NFATs consist of a family of 5 members, 
NFAT1, NFAT2, NFAT3, NFAT4, and NFAT5, but only NFAT1-4 are acted on by CaN (Figure 
1.1).  
 NFAT family members share a similar structural layout with 3 distinct domains, 
NFAT-homology region (NHR), REL-homology region (RHR), and the C-terminal tail 
domain.33 The NHR domain contains the CaN-binding site including two important motifs 
known as the PxIxIT and LxVP motifs.34–36 The NHR domain also contains serine-rich regions 
which when dephosphorylated send NFAT to the nucleus to allow regulation of target genes. 
The RHR domain confers DNA-binding and specificity to target genes. As of now, the function 
of the C-terminal domain of NFAT is unknown, but it is speculated that because of its variation 
5 
in between the NFAT isoforms, the C-terminal domain may confer isoform-specific gene 
regulation.33 
  In the context of the immune system, CaN signaling starts when an immune cell such 
as a T-cell binds to an antigen through its T-cell receptor.33,37 See Figure 1.2 for illustration of 
CaN signaling pathway in T-cells in response to antigen:T-cell interaction. Binding of the 
antigen to the T-cell receptor initiates activation of phospholipase C-γ (PLC-γ) which cleaves 
phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) into the products diacylglycerol 
(DAG) and inositol-1,4,5-triphosphate (InsP3). InsP3 goes onto to release Ca2+ from stores 
located in the endoplasmic reticulum. Free Ca2+ in the intracellular space binds to and 
activates Ca2+-release-activated Ca2+ channels (CRAC) which are located on the plasma 
membrane of the cell. The opening of CRAC channels causes a greater influx of Ca2+ to the 
intracellular space. Once the intracellular concentration of Ca2+ is sufficiently high, 
calmodulin (CaM) will be activated and interact with and activate the phosphatase CaN.  
 Once CaN is activate it dephosphorylates target substrates, such as NFAT.38 Extensive 
dephosphorylation of the serine-rich domains in the NHR of NFAT lead to the exposure of a 
cryptic nuclear localization signal and translation of NFAT into the nucleus where it interacts 
with other transcriptional partners such as AP1, OCT, and IRF4 to synergistically upregulate 
cytokine gene expression.39–44  
 The levels of NFAT in the nucleus is kept in check by export kinases which 
phosphorylate NFAT to send it back to the cytoplasm. There are several export kinases which 
phosphorylate NFAT at specific serine-rich regions such as GSK3, CK1, p38, and JNK.33,45–47 
Phosphorylation masks the nuclear import signal while exposing a nuclear export signal.33 
NFAT export is mediated by nucleocytoplasmic proteins that shuttle NFAT from the nucleus 
to the cytoplasm including Ran and CRM1.48  
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  1.1.2.2 Cardiac Hypertrophy/RCAN1-4 Pathway 
 
In the developing embryo, CaN/NFAT signaling is activated in a highly organized 
pattern in cells designed to compose the inner lining of the heart and valves.49,50 
Dysregulation of the CaN/NFAT signaling in the hearts of mice results in failure in valve 
formation and incomplete closure of the septum separating the atrial chambers which lead 
to cardiac failure. In adults, CaN/NFAT-signaling in the heart initiates hypertrophy. Cardiac 
hypertrophy is an increase in cardiac mass with a consequent increased contractile force. 
There are two distinct types of cardiac hypertrophy; pathological and physiological 
hypertrophy.  
There are molecular distinctions between pathological and physiological cardiac 
hypertrophy. CaN/NFAT signaling has been noted to regulate pathological hypertrophy, but 
not physiological hypertrophy.30 In pathological hypertrophy brought on by pressure and 
volume overload from cardiac disease, cardiomyocytes have an elevated resting intracellular 
Ca2+ concentration leading to CaN activation.28,51,52 In response to decreasing cardiac 
performance brought on cardiac disease, the heart sends out chemical signals such as 
angiotensin II, endothelin-1 and norepinephrine which bind to AT1, ETA, and adrenergic 
receptors, respectively.28,53–56 AT1, ETA, and adrenergic (β1 and α1, specifically) receptors 
belong to the family of G-protein-coupled 7-transmembrane receptors which are present in 
the plasma membrane of cardiomyocytes.56  Activation of AT1, ETA, β1, by their respective 
ligands eventually leads to the release of Ca2+ into the intracellular space although through 
slightly different signaling transduction pathways (Figure 1.3).33  
Similar to immune cells, CaN activation in cardiomyocytes results in 
dephosphorylation of NFAT and localization of NFAT into the nucleus.5  In cardiomyocytes, 
NFAT’s interaction with GATA4 leads to upregulation of the fetal cardiac genes B-myosin 
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heavy chain and α-skeletal actin rather than genes related to immunity.5 It is common for 
NFAT to have a binding partner (such as the transcription factor GATA4) that assists in its 
targeting to specific genes because the DNA-binding domain of NFAT has a very weak affinity 
for DNA.33   
Inhibition of the CaN/NFAT signaling pathway with the use of the CaN inhibitors 
cyclosporine A and FK506 prevented the development of pathological cardiac hypertrophy 
as well as the detrimental phenotypes associated with that cardiomyopathy.30 Upregulation 
of an endogenous CaN inhibitor called the regulator of CaN (RCAN1) was also shown to 
prevent the development of pathological cardiac hypertrophy. Since RCAN1’s initial 
discovery two other RCAN genes have been discovered (RCAN2 and RCAN3) which all code 
for CaN inhibitors.57 
RCAN proteins are generally a two domain proteins. Depending on the specific 
isoform RCAN’s N-terminus contains an RNA recognition motif domain and the C-terminal 
domain contains the CaN-binding motif (CBM) domain (Figure 1.4).20 The RCAN family 
contains the “FLISPP” motif in the CBM that is the defining sequence of an RCAN family 
member and is very well conserved from yeast to humans.20,57 Despite the high conservation 
of this FLISPP motif, it alone does not confer CaN inhibitory activity.20,58 There at least 3 other 
known motifs that confer CaN binding and inhibition.20,21,59 There are two main RCAN 
isoforms transcribed from the RCAN1 gene, RCAN1-1 and RCAN1-4, and they are expressed 
ubiquitously.60 The expression of RCAN1-4 is driven by activation of the CaN-signaling 
pathway and NFAT-assisted transcription. Also, RCAN1-4 represents the major isoform in the 
heart.61 Thus, RCAN1-4 upregulation could represent a negative-feedback mechanism that 
prevents runaway CaN activity. In this dissertation, we will specifically investigate the 
interaction of CaN with RCAN1-4, but the amino acid sequence of the RCAN is very similar 
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throughout all the isoforms, especially the CBM. Thus, with the data collected on RCAN1-4, 
we can speculate about the interaction of CaN with other RCAN isoforms.  
 
1.2 The Structure of Calcineurin 
 1.2.1 The Calcineurin Heterodimer 
 CaN is a heterodimer composed of a catalytic A chain (CaNA) (58-64 kDa) and a 
regulatory B chain (CaNB) (19 kDa).62 The structure of heterodimeric CaN was solved by 
Kissinger, et. al. (Figure 1.5). CaNA houses the catalytic, B-chain binding helix (BBH), 
regulatory, and autoinhibitory (AID) domains (Figure 1.5). The regulatory domain of CaNA 
(shown as a dotted line in Figure 1.5) is an intrinsically disordered region located in between 
the BBH and the AID and contains a calmodulin-binding site.63,64 CaNB contains 4 EF-hand 
motifs that allow a single CaNB to bind 4 Ca2+ Figure 1.5), and is bound to the BBH of CaNA 
even in the absence Ca2+.3 
  1.2.1.1 A chain of Calcineurin 
 The structure of CaN was solved by Kissinger et al (Figure 1.5). CaN’s catalytic domain 
was found to resemble other protein phosphatases such as PP1 and PP2A.65,66 The catalytic 
domain of CaN is a mix of α-helices and β-sheets all wrapped around a Fe3+ and Zn2+ core 
coordinated by Asp90, His92 (bind to Fe3+), Asn150, His199, and His281 (bind to Zn2+).  Fe3+ 
and Zn2+ are both necessary for CaN phosphatase function and are proposed to interact with 
the phosphate group of the target substrate needed for hydrolysis.4  
 Extending out from the catalytic domain of CaNA is the BBH to which the CaNB 
subunit interacts. C-terminal to the BBH is the RD (regulatory domain) and autoinhibitory 
domain (AID). The RD is an intrinsically disordered region with a calmodulin (CaM)-binding 
site.63 The AID interacts with the catalytic site when the RD is not bound to CaM. Aside from 
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being a potential regulatory mechanism, occlusion of the active site by the AID is also thought 
to prevent Fe3+ and Zn2+ from diffusing out of the active site in its inactive state.  
 There are three isoforms of CaNA; CaNAα, β, and γ. The three isoforms of CaNA are 
83% identical with a high degree of variability in the N- and C-terminal tails.62 The functions 
of the N- and C-terminal tails are currently unknown, but the proline-rich N-terminal tail 
inherent to the β-isoform has been shown to modulate substrate specificity to CaN targets.67  
The α- and β-isoforms have been described as broadly distributed and ubiquitous and the γ-
isoform largely testis-specific. Recent evidence shows that the γ-isoform is expressed in 
neurons and is critical for synaptic vesical recycling.68 
  1.2.1.2 B chain of Calcineurin 
 CaNB is an EF-hand containing protein that can bind 4 ions of Ca2+ which modulates 
the activity of CaN towards target substrates.62 It is a dumbbell-like protein structurally 
homologous to calmodulin (CaM) with two lobes separated by a flexible linker.66 There are 
two Ca2+-binding sites on each of the two lobes of CaNB with the Ca2+-binding sites on the C-
terminus having on average >70x fold higher affinity for Ca2+ than the two Ca2+-binding site 
located on the N-terminus.69 These Ca2+-binding constant of CaNB were determined in the 
absence of CaNA which may alter the affinity of each of the Ca2+-binding sites for Ca2+. Also, 
the C-terminal lobe of CaNB binds to CaNA with a higher affinity compared to the N-terminal 
lobe.64 In fact, the C-terminal lobe of CaNB binds to CaNA even in the absence of Ca2+.     
 There are two isoforms of CaNB, CaNB1 and CaNB2. Both isoforms are expressed 
ubiquitiously62 CaNB1 has been shown to be myristoylated on the N-terminus and that 
myristylation and Ca2+ binding affects CaN ability to associate with the membrane.70 
Localization of CaN to the plasma membrane could increase CaN’s ability to dephosphorylate 
its membrane-bound substrates including adenylyl cyclase, GAP-43, and dynamin-1.71–74  
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  1.2.1.3 Conservation of CaN 
CaN is well conserved from humans to lower eukaryotes such as A. fumigatus.4 A. 
fumigatus is a ubiquitous fungus that can cause aspergillosis, a potentially fatal and 
debilitating respiratory disease, in immunosuppressed patients.75 In A. fumigatus the CaN 
pathway regulates hyphal growth and nutrient collection from the environment as well as 
reproduction and cell wall morphogenesis.76–79 The CaN inhibitors cyclosporine A and FK506 
utilized in humans are effective in suppressing both A. fumigatus CaN and H. sapiens signaling 
due to the high sequence conversation of CaN between the species.80 These CaN inhibitors 
were effective at decreasing cell viability of A. fumigatus and CaN deletion in A. fumigatus 
eliminates its pathogenicity in immunosuppressed mice.78,81 Thus, CaN inhibition in A. 
fumigatus is a worthwhile avenue of research for drug targeting, but CaN’s high-degree of 
similarity with human CaN is problematic. Understanding the function of the weakly 
conserved regions of CaN between the species could unveil methods for species-specific CaN 
inhibition.  
 
1.3 Activation of Calcineurin and Substrate-Binding 
 1.3.1 Activation of Calcineurin 
 In low concentrations of intracellular Ca2+, CaN is inactive and the AID occupies the 
active site of the catalytic domain. This keeps phosphorylated residues from binding to the 
active site (Figure 1.6, A).82,83 Limited proteolysis of the regulatory domain (RD) suggests it 
is folded or protected by the rest of CaN when CaNB is not bound to Ca2+.64 As Ca2+ levels rise, 
CaNB becomes saturated with Ca2+ and the RD is released from the CaNB:CaNA interface 
(Figure 1.6, B).  
 When Ca2+ saturates the Ca2+-binding sites of CaNB, it undergoes a conformational 
rearrangement which releases the RD from the CaNA:CaNB interface.64 When CaNB is 
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saturated with Ca2+, this results in a small, but significant increase in CaN activity.84 A much 
greater increase in activity is observed when calmodulin (CaM) binds to the CaM-binding site 
located on the RD. 
 The RD of CaN is intrinsically disordered which means it cannot be described by a 
stable three-dimensional structure.63 Intrinsically disordered proteins lack stable three-
dimensional structure because they contain a high proportion of hydrophilic and charged 
amino acids and a low proportion of hydrophobic and aromatic residues. Disordered proteins 
when not interacting with binding partners typically take on an ensemble of states of which 
no one particular state dominates. Figure 1.7 shows a Uversky plot of proteins that are known 
to be either intrinsically disordered (red) or folded (blue) with the protein’s mean net charge 
plotted against the mean hydrophobicity.85 There are clear areas where the mean hydropathy 
vs. net charge are consistent with a disorder or folded state separated by a border (green 
line). The mean hydropathy and net charge of the RD is plotted in Figure 1.7 and represented 
as an orange dot. The RD is shown to be grouped with the “natively folded” proteins, but the 
RD is known to be an intrinsically disordered protein.63 Analysis of parts of the RD (namely 
analyzing each half of the RD) reveals that the N-terminal half of the RD (gray, Figure 1.7) is 
predicted to be disordered, and the C-terminal half of the RD (pink, Figure 1.7) is predicted 
to be ordered. In chapter 4 we will investigate in more detail the possible structural 
differences in the N-terminal and C-terminal half of the RD. The Uversky plot’s accuracy in 
predicting whether a protein is disordered or ordered is not absolute. Many proteins that are 
known to be disordered or ordered do not fit into their corresponding Uversky plot regions, 
such as the RD. The Uversky plot does show a general trend and illustrates that the content 
of polar and non-polar amino acids is different for intrinsically disordered protein vs. natively 
folded proteins. 
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That is not to say that all proteins are either entirely disordered or entirely folded. At 
least 33% of eukaryotic proteins are predicted to contain a disordered segment of at least 30 
residues.86 Intrinsically disordered proteins are common and can be involved in forming 
physical linkers between protein domains, sites of post-translational modification, or—such 
is the case for the RD—sites of protein:protein interaction.87  
 The CaM-binding site is located on the N-terminal end of the RD and undergoes a 
disorder to order transition when binding to CaM.63,88 CaM binds to the RD with a relatively 
high affinity relative to other CaM-substrates with a KD in the low picomolar range.89,90 The 
binding of CaM induces the CaM-binding site to fold into an α-helix. In Figure 1.8 CaM is in 
grey and a peptide of CaM-binding site from CaN is in blue. The peptide of the CaM-binding 
site from CaN is known as pCaN. Our lab determined the structure (Figure 1.8) and it shows 
that one pCaN binds to one CaM, but other published structures show that different 
stoichiometries are possible. Figure 1.8B shows the 2:2 CaM:CaM-binding site structure 
solved by Ye, Q., et al.91 The reason why two different crystal structures (1:1 vs. 2:2) were 
determined is not known, but it is hypothesized to be due to a difference in crystallization 
conditions.92 Solution studies of the CaM:CaM-binding site complex using size-exclusion 
chromatography, small angle X-ray scattering, and time-resolved fluorescence suggest that 
the 1:1 stoichiometry is the dominant form.92,93 
Recently, our lab discovered that another site on the RD folds upon binding to CaM 
(Figure 1.6, C) which was named the “distal helix” because it is located 30 residues 
downstream of the CaM-binding site. The distal helix is proposed to be an amphipathic α-
helix  Kinetic and enzymatic activity analysis revealed that ablation of the distal helix through 
disruptive mutations decreased CaN activity.88 The distal helix is hypothesized to promote 
CaN activity by interacting with CaM and creating a hairpin in the RD. This would restrict the 
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AID away from the active site of the catalytic domain and allow for target substrate 
dephosphorylation (Figure 1.6, C).  
   
 1.3.2 Interaction with substrates; LxVP- and PxIxIT-binding sites 
 Many known CaN-substrates bind to CaN in a similar fashion through the use of three 
binding sites on CaN. These three binding sites are the LxVP-binding, PxIxIT-binding, and 
active sites. The LxVP-binding and PxIxIT-binding sites are so named because those are the 
consensus motifs with which they interact. The LxVP or PxIxIT motifs are found in many 
known CaN substrates including NFAT, RCAN,  A238L, Drp1, and the RII subunit of PKA21,34,94–
96 The structure of the PxIxIT-binding site bound to a PxIxIT motif from NFAT (Figure 1.9B) 
has been solved.95,97 Figure 1.8B shows a stick representation of the PxIxIT motif from NFAT 
(shown in beige) forming a β-strand with β-sheet 14 from the catalytic domain of CaNA 
(shown in yellow).  
 The LxVP motif was discovered as a well conserved motif in the C-terminal tail of 
NFAT proteins where mutations decrease NFAT’s affinity for CaN.34 Initial structural 
evidence for the LxVP-binding site of CaN showed that LxVP binding to CaN required both 
CaNA and CaNB suggesting its location is at the interface between the A and B chain of CaN 
(Figure 1.9A, Figure 1.10A, purple).35 The location of the LxVP-binding site at the interface of 
CaNA and CaNB was supported by alanine mutations designed to disrupt the LxVP-binding 
site. Computational modeling using AutoDock (vina.scripps.edu) predicted the binding site of 
the LxVP motif to be located at the interface between the A and B chain.35 Recently, a structure 
of the LxVP-like motif from A238L with the sequence “LCVK” bound to CaN was determined 
which resembled the computationally determined LxVP motif:CaN interaction (Figure 
1.10B).95 
 There are CaN substrates such as microtubule-associated protein tau and Bcl2-
associated death promoter (BAD) with no known LxVP or PxIxIT motifs, and it is not known 
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how these CaN substrates interact with CaN. Thus, either tau and BAD have LxVP and/or 
PxIxIT motifs which are not apparent, or they interact with CaN with an unknown binding 
mode. 
 
1.4 Overview of Dissertation 
While research on CaN in the past 50 years has uncovered a vast amount of 
information on the structure and function of CaN, there are still important questions to be 
investigated. This dissertation focuses on the interaction between CaN and its ligands. One 
ligand, calmodulin (CaM), is critical for activation of CaN and in chapter 3, I shall focus on the 
intracellular environmental forces that potentially stabilize the interaction between CaN and 
CaM. We hypothesize that macromolecular crowding of the cell stabilizes the CaM:CaN 
interaction and that this increase in stability results in an increase in CaN activity. While CaM 
has over 300 known binding targets, CaN is one of its highest affinity substrates, and chapter 
4 is dedicated to understanding this high-affinity interaction.89,90,98 In chapter 4, we 
hypothesize that electrostatic forces drive the fast association between CaM and CaN. We also 
hypothesize that the conformational ensemble of the intrinsically disordered RD of CaN plays 
a direct role in determining the association rate constant by modulating the accessibility of 
the CaM-binding site. In chapter 5 the focus will turn to CaN interaction with target ligands. 
Chapter 5 discusses the interaction between CaN and the regulator of calcineurin (RCAN), a 
known endogenous CaN inhibitor, and its mode of binding and inhibition. Here, we 
hypothesize that RCAN1-4 has two LxVP motifs that bind and inhibit CaN activity. Finally, 
chapter 6 will cover the future directions of the studies discussed in chapters 3-5. The future 
directions will emphasize what questions remain as it pertains to the study of CaN and the 
eventual biomedical rewards of such studies. 
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1.5 Chapter 1 figures 
 
 
 
 
Figure 1.1 Domain architecture for the NFAT family of transcription factors.  
NLS- nuclear localization signal, RHR- Rel-homology region. The NFAT5 construct 
lacks many of the shared features common to other NHR of the other NFAT family 
members. 
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Figure 1.2 CaN/NFAT signaling pathway.33  
Adapted from: Macian, F. (2005) NFAT proteins: key regulators of T-cell development and 
function. Nature reviews. Immunology, 5, 472–84. Reused with permission. License number: 
3884241137829. 
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Figure 1.3. Molecular and biochemical events following activation of G-protein coupled 
receptors (GPCRs) of the cardiomyocyte. 
 
Kang, M., Chung, K.Y. and Walker, J.W. (2007) G-protein coupled receptor signaling in 
myocardium: not for the faint of heart. Physiology (Bethesda, Md.), 22, 174–184. Reused with 
permission. 
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RCAN2_isoform_1     ------------------------------------------------------------  
RCAN2_isoform_2 -----------------------------------MRGESYFIGMRSPGQQGHVPEDGGL 
RCAN1_isoform_e MNSTVRQLRVPSHVPLRDPSWESLRNVPKLKKSRGMQGEQGRRLF----RLLLNDLPGRD 
RCAN1_isoform_d ------------------------------------------------------------ 
RCAN1_isoform_c ------------------------------------------------------------ 
RCAN1_isoform_a -------------------------------MEDGVAGPQLGAAAEAAEAAEARARPGVT 
RCAN1_isoform_b ------------------------------------------------------------ 
RCAN3_isoform_2 ------------MLRDTMKSWND-----------------------------------SQ 
RCAN3_isoform_3 ------------MLRDTMKSWND-----------------------------------SQ 
RCAN3_isoform_1 ------------MLRDTMKSWND-----------------------------------SQ 
RCAN3_isoform_5     ------------------------------------------------------------  
 
 
 
RCAN2_isoform_1 -------------------------------MPAPSMDCDVSTLVACVVDVEVFTNQEVK 
RCAN2_isoform_2 FLLCCID----------RDWAVTRCFAEEAFQAITDFNDLPNSLFACNVHQSVFEGEESK 
RCAN1_isoform_e RLPCSYPQPHVEQASTSASPRLLAV-----NIPEDTLLSYPESSLPL--QRHCAFHRFSK 
RCAN1_isoform_d ---------------------------------------------------------MVY 
RCAN1_isoform_c -------------------------------MHFRNFNYSFSSLIACVANSDIFSESETR 
RCAN1_isoform_a LRPFAPLSGAAEADEGGGDWSFIDC-----EMEEVDLQDLPSATIACHLDPRVFVDGLCR 
RCAN1_isoform_b ------------------------------------------------------------ 
RCAN3_isoform_2 SDLCSTDQEEEEEMIFGENE---DD-----LDEMMDLSDLPTSLFACSVHEAVFEAREQK 
RCAN3_isoform_3 SDLCSTDQEEEEEMIFGENE---DD-----LDEMMDLSDLPTSLFACSVHEAVFEAREQK 
RCAN3_isoform_1 SDLCSTDQEEEEEMIFGENE---DD-----LDEMMDLSDLPTSLFACSVHEAVFEAREQK 
RCAN3_isoform_5     ------------------------------------------------------------  
 
 
 
RCAN2_isoform_1 EKFEGLFRTYDDCVTFQLFKSFRRVRINFSNPKSAARARIELHETQFRGKKLKLYFAQVQ 
RCAN2_isoform_2 EKFEGLFRTYDDCVTFQLFKSFRRVRINFSNPKSAARARIELHETQFRGKKLKLYFAQVQ 
RCAN1_isoform_e AKFESLFRTYDKDITFQYFKSFKRVRINFSNPFSAADARLQLHKTEFLGKEMKLYFAQTL 
RCAN1_isoform_d AKFESLFRTYDKDITFQYFKSFKRVRINFSNPFSAADARLQLHKTEFLGKEMKLYFAQTL 
RCAN1_isoform_c AKFESLFRTYDKDITFQYFKSFKRVRINFSNPFSAADARLQLHKTEFLGKEMKLYFAQTL 
RCAN1_isoform_a AKFESLFRTYDKDITFQYFKSFKRVRINFSNPFSAADARLQLHKTEFLGKEMKLYFAQTL 
RCAN1_isoform_b ---------------------------------------------------MKLYFAQTL 
RCAN3_isoform_2 ERFEALFTIYDDQVTFQLFKSFRRVRINFSKPEAAARARIELHETDFNGQKLKLYFAQ-- 
RCAN3_isoform_3 ----------------------------------------------------------VQ 
RCAN3_isoform_1 ERFEALFTIYDDQVTFQLFKSFRRVRINFSKPEAAARARIELHETDFNGQKLKLYFAQVQ 
RCAN3_isoform_5     ------------------------------------------------------------  
 
    
 
RCAN2_isoform_1 TPETDGDKLHLAPPQPAKQFLISPPSSPPVGWQPINDATPVLNYDLLYAVAKLGPGEKYE 
RCAN2_isoform_2 TPETDGDKLHLAPPQPAKQFLISPPSSPPVGWQPINDATPVLNYDLLYAVAKLGPGEKYE 
RCAN1_isoform_e HIGS----SHLAPPNPDKQFLISPPASPPVGWKQVEDATPVINYDLLYAISKLGPGEKYE 
RCAN1_isoform_d HIGS----SHLAPPNPDKQFLISPPASPPVGWKQVEDATPVINYDLLYAISKLGPGEKYE 
RCAN1_isoform_c HIGS----SHLAPPNPDKQFLISPPASPPVGWKQVEDATPVINYDLLYAISKLGPGEKYE 
RCAN1_isoform_a HIGS----SHLAPPNPDKQFLISPPASPPVGWKQVEDATPVINYDLLYAISKLGPGEKYE 
RCAN1_isoform_b HIGS----SHLAPPNPDKQFLISPPASPPVGWKQVEDATPVINYDLLYAISKLGPGEKYE 
RCAN3_isoform_2 --------SYLLPPQPVKQFLISPPASPPVGWKQSEDAMPVINYDLLCAVSKLGPGEKYE 
RCAN3_isoform_3 MSGEVRDKSYLLPPQPVKQFLISPPASPPVGWKQSEDAMPVINYDLLCAVSKLGPGEKYE 
RCAN3_isoform_1 MSGEVRDKSYLLPPQPVKQFLISPPASPPVGWKQSEDAMPVINYDLLCAVSKLGPGEKYE 
RCAN3_isoform_5     MSGEVRDKSYLLPPQPVKQFLISPPASPPVGWKQSEDAMPVINYDLLCAVSKLGPGEKYE 
 
 
 
 
 
RCAN2_isoform_1 LHAGTESTPSVVVHVCDSDIEEEEDP----KTSPKPKIIQTRRPGLPPSVSN-------- 
RCAN2_isoform_2 LHAGTESTPSVVVHVCDSDIEEEEDP----KTSPKPKIIQTRRPGLPPSVSN-------- 
Calcineurin-binding motif domain 
Calcineurin-binding motif domain 
RNA recognition motif domain 
RNA recognition motif domain 
RNA recognition motif domain 
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RCAN1_isoform_e LHAATDTTPSVVVHVCESDQEKEEEEEMERMRRPKPKIIQTRRPEYTPIHLS-------- 
RCAN1_isoform_d LHAATDTTPSVVVHVCESDQEKEEEEEMERMRRPKPKIIQTRRPEYTPIHLS-------- 
RCAN1_isoform_c LHAATDTTPSVVVHVCESDQEKEEEEEMERMRRPKPKIIQTRRPEYTPIHLS-------- 
RCAN1_isoform_a LHAATDTTPSVVVHVCESDQEKEEEEEMERMRRPKPKIIQTRRPEYTPIHLS-------- 
RCAN1_isoform_b LHAATDTTPSVVVHVCESDQEKEEEEEMERMRRPKPKIIQTRRPEYTPIHLS-------- 
RCAN3_isoform_2 LHAGTESTPSVVVHVCESETEEEEE-----TKNPKQKIAQTRRPDPPTAALNEPQTFDCA 
RCAN3_isoform_3 LHAGTESTPSVVVHVCESETEEEEE-----TKNPKQKIAQTRRPDPPTAALNEPQTFDCA 
RCAN3_isoform_1 LHAGTESTPSVVVHVCESETEEEEE-----TKNPKQKIAQTRRPDPPTAALNEPQTFDCA 
RCAN3_isoform_5     LHAGTESTPSVVVHVCESETEEEEE-----TKNPKQKIAQTRRPDPPTAALNEPQTFDCA  
 
 
 
RCAN2_isoform_1  –  
RCAN2_isoform_2  –  
RCAN1_isoform_e  –  
RCAN1_isoform_d  –  
RCAN1_isoform_c  –  
RCAN1_isoform_a  –  
RCAN1_isoform_b  –  
RCAN3_isoform_2  L  
RCAN3_isoform_3  L  
RCAN3_isoform_1  L  
RCAN3_isoform_5  L 
 
Figure 1.4 CLUSTAL Omega alignment of confirmed RCAN transcripts from RCAN1, RCAN2, 
and RCAN3 genes.  
Protein sequences were obtained from NCBI GenBank 
(http://www.ncbi.nlm.nih.gov/genbank/) by using the search term “RCAN”. 
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Figure 1.5 The structural layout of calcineurin.  
The linear domain architecture of CaN (bottom) is colored by domain and mapped onto the 
three dimensional structure determined by Kissinger, et. al.66 PDB ID: 1AUI. 
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Figure 1.6 Activation scheme for CaN 
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Figure 1.7 Uversky plot of folded and unfolded proteins.  
Uversky plot of known natively disordered (red) and folded (blue) proteins with the mean 
net charge plotted against the mean hydrophobicity. Folded proteins tend to have a low mean 
net charge and a high mean hydrophobicity and vice versa for disordered proteins. The full-
length regulatory domain of CaN is plotted at an orange dot. The two halves of the RD were 
also plotted. The N-terminal half of the RD is shown as a gray dot, and the C-terminal half of 
the RD is shown as a pink dot.  
 
Uversky VN, Gillespie JR, Fink AL (2015) Uversky , V . N ., Gillespie , J . R . & Fink , A . L . Why 
are “ natively unfolded ” proteins unstructured under physiologic conditions ? Proteins 41 , 
415- Why Are “ Natively Unfolded ” Proteins Unstructured Under Physiologic Conditions ? 
415–427. Reused with permission. License number: 3886030264985 
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Figure 1.8 Multiple binding modes of CaM and the CaM-binding region from CaN.   
A) Crystal structure of CaM bound to the CaM-binding site of CaN solved by Dunlap et. al. 
(2014) showing a “wrap-around” mode of binding for CaM.92 PDB ID: 4Q5U. The CaM-binding 
site from CaN is shown blue, and CaM is shown in grey. B) The 2:2 CaM:pCaN structure solved 
by Ye Q., et al (2006).91 CaM is shown in light and dark gray. The two CaMs were shaded 
differently so they can be easily be distinguished by the reader. The two CaM-binding sites 
are shown in blue. 
A 
B 
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Figure 1.9 PxIxIT motif from NFATc1 bound to the PxIxIT-binding site of CaN.  
A) The structure of CaN determined by Kissinger (PDB ID: 1AUI) with the PxIxIT-binding site 
highlighted in yellow and the LxVP-binding site in purple. B) Zoom image of the interface 
between the PxIxIT-binding site of CaN (yellow) and the PxIxIT motif (beige). C) The 
structure of the PxIxIT peptide from NFAT (beige) bound to the PxIxIT-binding site from CaN 
(yellow) (PDB ID: 2P6B). Extensive hydrogen bond network between the PxIxIT motif and 
CaN mediates β-strand stability. Hydrogen bonds are shown as black dotted lines. 
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Figure 1.10 LxVP motif from NFATc1 bound to the LxVP-binding site of CaN.  
A 
B 
C 
Tyr 
Leu 
Ala 
Val 
Pro 
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A) The structure of CaN determined by Kissinger (PDB ID: 1AUI) with the PxIxIT-binding site 
highlighted in yellow and the LxVP-binding site in purple. B) The LxVP motif from NFAT 
(biege) shown bound to the LxVP-binding site of CaN (purple). NFAT LxVP motif was modeled 
using the structure of the LxVP-motif of A238L bound to CaN (PDB ID: 4F0Z). C) CaN and the 
LxVP-binding site shown in a surface representation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright ©  Erik Curtis Cook 2016 
 
28 
CHAPTER 2: Materials and Methods 
2.1 Plasmids, Proteins, Peptides, and Purification 
  2.1.1 Calcineurin (CaN) 
The plasmid pETagHisCN, which contains the gene for αCaNA (A chain) and B1 (B 
chain) that make up full-length human calcineurin (CaN), was purchased from Addgene 
(Cambridge, MA). pETagHisCN plasmid was transformed into BL21 (DE3) CodonPlus RIL 
competent E. coli (Agilent Technologies). Transformed E. coli containing pETagHisCN were 
grown in terrific broth until an OD600 reach between 1.2 and 1.6, and induced with 1mM IPTG. 
Cell pellets were collected by centrifugation and lysis buffer added (20mM Tris (pH 7.5), 
200mM NaCl, 1mM PMSF). Cells were lysed by sonication and cleared using centrifugation. 
After the cleared lysate was passed through a 0.45µm filter, it was applied to a Ni-NTA column 
(EMD Millipore, Billerica, MA).  The Ni-NTA column was washed with 10 column volumes of 
20mM Tris (pH 7.5), 200mM NaCl and eluted with 20mM Tris (pH 7.5), 200mM NaCl, 2mM 
CaCl2, and 250mM imidazole. CaN was purified further by calmodulin (CaM)-sepharose 
chromatography (GE Healthcare, Piscataway, NJ). The elution from the previous Ni-NTA 
purification step was applied to the CaM-sepharose column as washed with 10 columns 
volumes of 20mM Tris (pH 7.5), 200mM NaCl, and 2mM. CaN was eluted from the CaM-
sepharose column with 20mM Tris (pH 7.5), 200mM NaCl, and 2mM EGTA. Purity of CaN was 
assessed by SDS-PAGE and concentration was determined by UV/Vis spectroscopy using an 
ε280nm of 53,415M-1 cm-1. 
  2.1.2 Calmodulin 
The plasmid pETCaM1, which contains the human CALM1 gene and codes for full-
length wild-type CaM, was transformed and expressed in BL-21 (DE3) competent E. coli 
(Agilent, Santa Clara, CA). Cells were grown in TB until an OD600nm of ~1.2-1.6 was reached 
and were induced with 1mM IPTG. Cell lysates were cleared by centrifugation and CaM 
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purified using a 2-trifluoromethyl-10aminopropyl phenothiazine-sepharose (TAPP-
sepharose) column. 63,88 The TAPP-sepharose column was synthesized at the Center for 
Molecular Medicine Organic Synthesis Core Facility at the University of Kentucky.  
  2.1.3 Regulatory Domain (RD) construct 
For our RD construct, a gene coding for residues 373-468 of CaN (NCBI NP_000935) 
was synthesized by GeneScript (Piscataway, NJ) and sub-cloned into a pET303 plasmid (Life 
Technologies, Grand Island, NY) which adds a C-terminal 6xHis tag. The resulting RD plasmid 
was co-transformed with pETCaMI into BL-21 (DE3) (Agilent Tech., Santa Clara, CA.) E. coli 
for protein expression. Cells were grown in TB until an OD600nm of ~1.2-1.6 was reached and 
were induced with 1mM IPTG. RD in the cleared and filtered cell lysates was purified by Ni-
NTA chromatography in which CaM was removed by washing with 5M urea, 2M thiourea, 
20mM Tris (pH 7.5), 200mM NaCl, and 10mM imidazole. Ni-NTA-bound RD was then washed 
with buffers containing 20mM Tris (pH 7.5), 200mM NaCl, 10mM imidazole and serially 
diluted urea/thiourea concentrations. The concentration of urea/thiourea of each wash in 
order was 2.5M urea/1.0M thiourea, 1.3M urea/0.50M thiourea, 0.63M urea/0.25M thiourea, 
0.31M urea/0.13 thiourea, 0.16M urea/0.063M thiourea, and 0.078M urea/0.031M thiourea. 
The Ni-NTA-bound RD was finally washed with 20mM Tris (pH 7.5), 200mM NaCl, and 10mM 
imidazole, then eluted with 20mM Tris (pH 7.5), 200mM NaCl, 2mM CaCl2, and 250mM 
imidazole, and subjected to CaM-sepharose chromatography for final purification. Once the 
Ni-NTA elution was applied to the CaM-sepharose column, the column was washed with 
20mM Tris (pH 7.5), 200mM NaCl, and 2mM CaCl2. The RD was finally eluted off the CaM-
sepharose column with 20mM Tris (pH 7.5), 200mM NaCl, and 4mM EGTA. The purity and 
concentration of the RD were determined by SDS-PAGE and absorbance at 280nm, 
respectively. A tryptophan was added to the C-terminus of the RD construct with a glycine 
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linker to increase the accuracy of protein concentration determination by UV/Vis 
spectroscopy. 
  2.1.4 Calmodulin-binding domain peptide from CaN (pCaN) 
A peptide encompassing the CaM-binding domain (residues 391-414 from 
calcineurin A) was synthesized by Atlantic Peptides (Lewisburg, PA) and will be referred to 
as pCaN. The sequence of pCaN is CGARKEVIRNKIRAIGKMARVFSVLRGGW with a C-terminal 
tryptophan included for peptide concentration determination. An N-terminal cysteine was 
included for future experiments where the peptide will need to be labeled with a thiol-
reactive fluorescent dye. A glycine linker was included between the cysteine and tryptophan 
to reduce structural effects from the added residues.  
  2.1.5 Peptides derived from RCAN1-4 
The HLAPP and FLISP peptides were ordered from Atlantic Peptides (Lewisburg, PA). 
The sequence for the pHLAPP and pFLISPP peptides is CGSSHLAPPNPGW and 
CGKQFLISPPASPPVGW, respectively. A cysteine was added to the N-terminus of each peptide, 
so each peptide could be labeled with thiol-reactive fluorescent dyes. A C-terminal 
tryptophan was added to each peptide for accurate peptide concentration determination 
using UV/Vis.  
  2.1.6 RII peptide 
RII peptide (WGGDLDVPIPGRFDRRV[pS]VAAE) was also synthesized by Atlantic 
Peptides (Lewisburg, PA) and contained a single phosphorylated serine. The RII peptide was 
derived from a known CaN substrate, regulatory subunit type II of protein kinase A. An N-
terminal tryptophan was added to increase the accuracy of protein concentration 
measurements by UV/Vis. 
31 
2.2 Mutagenesis 
Mutagenesis was performed using New England Biolabs (Ipswich, MA) Q5 site-
directed mutagenesis kit. 20-30 base length DNA oligomers were designed to complement 
the DNA region being mutated and contained point mutations to generate the desired codon. 
PCR was performed on the plasmid to be mutated using primers containing point mutations 
using the following PCR cycling setup: 
Step Temperature Time 
1. Initial denaturation 98°C 30 seconds 
2. 25 cycles 98°C 10 seconds 
 50-72°C 20 seconds 
 72°C 30 seconds per kilobase 
3. Final extension 72°C 10 minutes 
PCR products were combined with the KLD reaction mixtures supplied in the NEB Q5 
mutagenesis kit and incubated for 5 minutes at room temperature. This mixture was then 
transformed into XL-1 blue E. coli supplied Agilent Technologies (Santa Clara, CA). 
Transformants were plated on LB agar plates supplemented with required antibiotic and 
were incubated overnight at 37°C. The next day colonies were used to inoculate 5mL of LB 
broth supplemented with antibiotic and were incubated overnight at 37°C. Plasmid DNA was 
extracted from the cultures the next day using a Qiagen MiniPrep kit (Valencia, CA). Mutations 
were confirmed by single-pass primer extension sequencing performed by ACGT Inc. 
(Germantown, MD).  
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2.3 Labeling of Proteins/Peptides 
Cysteines in RCAN1-4 and the peptide derived from RCAN1-4 (pFLISPP and pHLAPP)  
were labeled with Alexa 488-maleimide or acrylodan using thiol-reactive chemistry.  RCAN1-
4 and peptides were exchanged into 20mM Tris (pH 7.5), 200mM NaCl, 2mM EGTA, and 2mM 
TCEP. Five-fold molar excess of Alexa-488 or acrylodan relative to protein/peptide 
concentration was added. Labeling reactions proceeded at 4°C for 48 hours. Labeled 
protein/peptide was subjected to centrifugal filtration using a 3k MWCO concentrator 
column to remove the free dye, and eluted buffer was replaced with 20mM Tris (pH 7.5), 
200mM NaCl after each round. The flow through was examined using UV/Vis and free dye 
was assumed to be removed when the dye was no longer present in the flow-through. Peptide 
and protein concentration was determined using the absorbance at 280nm. Alexa-488 and 
acrylodan concentration was determined using ɛ495nm = 73,000 M-1 cm-1 and ɛ391nm = 20,000 
M-1 cm-1, respectively.  
 For our association rate measurements with CaM and CaM-substrates in chapter 4, 
we decided to label CaM with acrylodan. Acrylodan is a thiol-reactive and environmentally 
sensitive dye which can detect ligand binding when attached to a protein of interest.  CaM 
D3C which contains one and only one cysteine at the 3 position was labeled with acrylodan 
(6-Acryloyl-2Dimethylaminonaphtalene) (Life Technologies, Grand Island, NY) using thiol-
modification chemistry. 200µM Acrylodan dye was combined with 100µM CaM D3C in the 
presence of 6M urea and 2mM EGTA and incubated for 24 hours at 4°C. Acrylodan-labeled 
CaM (CaM-Acr) was exhaustively dialyzed in the presence of 6M urea to remove the 
unconjugated dye.  Finally, CaM-Acr was dialyzed into 20mM HEPES (pH 7.5). The 
concentration of label bound to CaM was determined using UV/Vis spectroscopy by using the 
extinction coefficient at 391nm which is 20,000M-1cm-1.99 The concentration of CaM was 
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determined using UV/Vis spectroscopy and bicinchoninic acid assay (Pierce/ThermoFisher, 
Grand Island, NY). Labeling efficiency CaM-Acr ranged from 70-99%.  
2.4 Circular Dichroism 
A Jasco-810 Spectropolarimeter equipped with a Peltier temperature controller was 
used for circular dichroism (CD) measurements. All samples were contained in a 1mm quartz 
cuvette. Concentrations of all proteins and peptides were 20µM. Spectra of the RD +/- CaM in 
the presence of 0, 50, 100, 150, and 200g/L of dextran 70 or ficoll 70 were taken at 37°C. 
Measurements were also taken of RD+CaM in the presence of 0%, 5%, 10%, 20%, and 40% 
2,2,2-trifluoroethanol (TFE). CD spectra of pCaN+CaM were taken in the presence and 
absence of 200g/L dextran 70, as well as 0%, 5%, 10%, 20%, and 40% TFE. All samples were 
in a buffer consisting of 20mM HEPES (pH 7.5), 200mM NaCl, and 4mM CaCl2.  Each spectrum 
is the average of 4 accumulations taken at a scanning speed of 20nm/min with the sample 
temperature set to 37°C. Raw data were converted to molar ellipticity. 
For thermal denaturation, the ellipticity of RD +/- CaM in the presence and absence 
of 200g/L of dextran 70 was measured at 222nm as the temperature was increased from 5°C 
to 95°C at 1oC/min. The concentrations of RD and CaM were 20µM, and they were in 20mM 
HEPES (pH 7.5), 200mM NaCl, and 2mM CaCl2. HEPES buffer was selected for the low-
temperature dependence of its pKa.100 The global maximum of the first derivative of the 
temperature-dependent melting transition was used to estimate the Tm of the distal helix. 
In chapter 4, we utilized CD to determine if there were any secondary structural 
changes due to ionic strength differences, as well as the structural difference between CaM 
and CaM-Acr to see if labeling perturbed the secondary structure of CaM. We measured the 
CD of CaM and CaM D3C labeled with acrylodan (CaM-Acr) in the presence and absence of 
pCaN. The concentration of CaM, CaM-Acr, and pCaN ranged from 10-20μM when present. 
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pCaN was equamolar to CaM or CaM-Acr when present. Also, the CD of the RD and CaN 
construct was measured. Samples contained either 20μM RD or 5μM CaN. For all samples 
buffer contained the following; 20mM Tris (pH 7.5), 10mM CaCl2, and either 0.25M, 1M, or 
2M NaCl. Sample chamber was equilibrated to 20°C for 10 minutes before spectrum 
collection. 
In chapter 5, the secondary structural content of recombinant RCAN1-4 was 
determined using CD. Sample contained 12-24μM RCAN1-4 and the following buffer 
contents: 20mM Tris (pH 7.5) and 200mM NaCl. Sample chamber was equilibrated to 20°C 
for 10 minutes before spectrum collection. The DichroWeb web service was utilized to 
estimate the content of α-helices, β-sheets, and disordered segments from the CD spectra of 
RCAN1-4.101 This involved comparing the CD spectra of RCAN1-4 to the CD spectra of 
reference proteins with known three-dimensional structures. The reference data set was 
SMP180 and was fit to RCAN1-4 using the Contin-LL software package available from 
DichroWeb. The DichroWeb service is maintained by the Wallace lab in the Department of 
Crystallography at the Institute of Structural and Molecular Biology, Birbeck College, 
University of London, UK (http://dichroweb.cryst.bbk.ac.uk/html/home.shtml).  
2.5 Fluorescence Spectroscopy 
                2.5.1 Fluorescence Emission 
Fluorescent emission spectra were collected using an ISS K2 fluorometer 
(Champaign, IL) with a Hg/Xe lamp as the light source. For acrylodan emission spectra, a 
455nm long-pass filter was placed in the emission path, while the samples were excited at 
365nm. All samples were allowed to equilibrate with the set chamber temperature for 10 
minutes prior to measurement. Emission spectra for calmodulin labeled with acrylodan 
(CaM-Acr) were collected at 37°C. CaM-Acr was present at 200nM in the presence and 
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absence of 2µM pCaN, RD, or CaN. These samples contained 20mM HEPES (pH 7.5), 250mM 
NaCl, and 10mM CaCl2.  
In chapter 4 the Ca2+-binding constant of each CaM lobe as a function of [NaCl] was 
determined using fluorescence spectroscopy described by VanScyoc, et. al.102 The 
macromolecular Ca2+-binding constant for the N-terminal lobe of CaM was determined from 
the phenylalanine fluorescence intensity (excitation: 250nm/emission: 280nm) which 
shown quenching as [Ca2+] increased. The macromolecular Ca2+-binding constant for the C-
terminal lobe of CaM was determined from the tyrosine fluorescence intensity (excitation: 
277nm/emission: 320nm) which showed an increase in fluorescence intensity as [Ca2+] rose. 
Samples were equilibrated at 37°C prior to measurement. The Ca2+-binding constant for each 
lobe of CaM was determined in two different buffer conditions: 
1. Low salt buffer: 20mM HEPES (pH 7.5), 0.25M NaCl 
2. High salt buffer: 20mM HEPES (pH 7.5), 2M NaCl 
The concentration of CaM was 6µM in all samples. The fluorescence intensity of 
phenylalanine and tyrosine were plotted against [Ca2+]. The fluorescence intensities plotted 
represent the average of 2 independent experiments. 
2.5.2 Fluorescence Anisotropy 
Fluorescence anisotropy was performed on an ISS K2 multifrequency cross-
correlation phase and modulation fluorometer with built-in polarizers (Champaign, IL). All 
anisotropy measurement were performed at 20°C and in 20mM Tris, 200mM NaCl, and 2mM 
CaCl2. For RCAN1-4-488:CaN binding measurements, the anisotropy of 50nM RCAN1-4-488 
(excitation: 469nm/emission: 520nm) was measured and CaN was varied from 0-5µM in the 
presence of either 2mM EGTA, 2mM CaCl2, or 10μM CaM/2mM CaCl2. The binding of the 
RCAN1-4-derived peptides pHLAPP-Acr and pFLISPP-Acr (present at 50nM) to CaN was 
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measured using anisotropy (excitation: 365nm/emission: 515nm) with a 455nm long pass 
filter placed in the emission line. Anisotropies were plotted against the concentration of CaN 
and fitted to a ligand binding model: 
 𝑟 =
𝑎∗[𝐶𝑎𝑁]
𝐾𝐷+[𝐶𝑎𝑁]
+  𝑟[0]      
 
where r is equal to the observed anisotropy, a is the saturating anisotropy observed, KD is the 
dissociation constant, and 𝑟[0] is the y-intercept. 
 2.5.3 Dissociation measurements of CaM-Acr and CaM-substrates 
 Dissociation rates of CaM-Acr and CaM-substrates were determined by tracking the 
fluorescence intensity of CaM-Acr using an ISS K2 fluorometer (Champaign, IL). The light 
source was a 300W xenon arc lamp and the excitation wavelength was 365nm with an 8nm 
slit width. Fluorescence emission from sample was collected through a 455nm long pass filter 
(Edmund Optics, Barrington, NJ). Sample chamber was set to 37°C.  To collect a dissociation 
kinetic trace, a solution of 200nM CaM-Acr, 200nM CaM-substrate, 20mM HEPES (pH 7.5), 
10mM CaCl2, and 0.25-2M NaCl was monitored using the above specification. 2µM unlabeled 
CaM was added to the solution and mixed by hand, and the fluorescence intensity was 
measured for at least 3000 seconds. The volume of unlabeled CaM added to induce 
competition binding was less than 5% of final solution volume in all cases.  
Kinetic traces were analyzed using SigmaPlot and data were fit to either single or 
double exponential decays to determine the observed rate using: 
Single exponential rise-to-maximum;  𝑦 = 𝑎(1 − 𝑒−𝑘𝑜𝑓𝑓𝑥)     
Double exponential rise-to-maximum;  𝑦 = 𝑎(1 − 𝑒−𝑘𝑜𝑓𝑓,1𝑥) + 𝑏(1 − 𝑒−𝑘𝑜𝑓𝑓,2𝑥)   
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where 𝑎 and 𝑏 are pre-exponential factors and kon, kon,1, and kon,2 are the calculated on-rate 
constants. Data were analyzed using SigmaPlot and fits of dissociation data are shown in 
Appendix III.  
                2.5.2 Stopped-flow Spectroscopy  
Association rates of CaM with CaM substrates (pCaN, RD, and CaN) were collected on 
an ISS K2 fluorometer (Champaign, IL) using an RX2000 stopped-flow apparatus from 
Applied Photophysics (Leatherhead, United Kingdom) which has a dead time of 8ms. The ISS 
K2 fluorometer and RX2000 were temperature controlled using a circulating water bath. All 
measurements were performed at 37°C. The excitation source was a Hg/Xe lamp with the 
wavelength set to 365nm. Sample emissions were filtered through a 455nm long-pass filter 
(Edmund Optics, Barrington, NJ). The on-rate of CaM-Acr with CaM ligands was determined 
by measuring the fluorescence intensity change of acrylodan as 50nM CaM-Acr was rapidly 
mixed with various concentrations of ligand.  
Kinetic traces were analyzed using SigmaPlot and data were fit to either single or 
double exponential decays to determine the observed rate using: 
Single exponential decay;  𝑦 = 𝑎𝑒−𝑘𝑜𝑛𝑥    
Double exponential decay;  𝑦 = 𝑎𝑒−𝑘𝑜𝑛,1𝑥 + 𝑏𝑒−𝑘𝑜𝑛,2𝑥    
where 𝑎 and 𝑏 are pre-exponential factors and kon, kon,1, and kon,2 are the calculated on-rate 
constants. Statistics and fits of association rate data is shown in Appendix III. A custom script 
was created to quickly and accurately analyze kinetic traces and residual traces and is shown 
in Appendix IV.  
  On-rate constants were determined from the slope of the observed rate vs. the final 
concentration of CaM-ligand utilized. All buffers contained 20mM HEPES (pH 7.5) and 10mM 
CaCl2. The NaCl concentration was modulated to alter the ionic strength of the solutions. The 
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effects of ionic strength on the association rate constants can be described by the Debye-
Huckel-like approximation: 
ln 𝑘𝑜𝑛 = ln 𝑘𝑜𝑛,𝑏𝑎𝑠𝑎𝑙 = (
𝑈
𝑅𝑇
) 
1
1+𝜅𝑎
   
where kon is the on-rate constant, kon,basal is the on-rate constant at infinite ionic strength, U is 
the energy of electrostatic interaction, R is the gas constant, T is temperature, κ is the inverse 
of the Debye length, and 𝑎 is the minimal distance of approach which is set to 6Å.103 
2.6 Enzyme Assays  
2.6.1 pNPP Assay of CaN 
Michaelis-Menten kinetics of CaN and CaNΔAID-CT using para-nitrophenyl phosphate 
(pNPP) (Sigma-Aldrich, St. Louis, MO) as a substrate were determined at various 
concentrations of dextran 70 (0-200g/L) or dextrose (0-200g/L) using a 96-well plate format 
with 100µL final volume per reaction. Final reaction solutions contained 40mM Tris (pH 8), 
100mM KCl, 1mM CaCl2, 30nM CaN, 90nM CaM, 5mM MnCl2, 1mM DTT, and 0-100mM pNPP. 
The CaN enzyme solution and pNPP standards were pre-incubated at 37°C before they were 
mixed. Upon mixing the components, dephosphorylation of pNPP was monitored by 
measuring absorption at 410nm for 2 hours at 37oC. The linear range of pNPP hydrolysis by 
CaN was observed to be between 0 and ~35 minutes, so initial velocities were determined 
from the slope of the curve from 0-30 minutes. Initial velocities vs. [pNPP] were plotted in 
SigmaPlot and Michaelis-Menten kinetics were determined using the SigmaPlot Enzyme 
Kinetics module and the assumed Michaelis-Menten equation: 
𝑉𝑖 =
𝑉𝑚𝑎𝑥∗[𝑆]
𝐾𝑚+[𝑆]
   
where Vmax is the asymptotic velocity at which all binding sites are saturated with substrate, 
Vi is the initial velocity at a given substrate concentration [S], and Km is the concentration of 
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substrate that results in 50% Vmax. Final Michaelis-Menten parameters of each condition (Km 
and Vmax) are representative of 6 replicates and 2 protein preparations of CaN. 
  2.6.2 RII assay of CaN 
The Michaelis-Menten parameters Vmax and Km of CaN were determined using the RII 
peptide as a phosphorylated substrate. Final reactions contained 80mM Tris (pH 7), 200mM 
KCl, 2mM CaCl2, 1mM DTT, 5mM MnCl2, 30nM CaN, 90nM CaM, 0-500µM RII in a final volume 
of 50μM. Solutions containing the RII peptide and the various inhibitors along with a separate 
solution of a master mix containing the CaN, CaM, and the other components were 
preincubated at 30°C before combining the solutions. Reactions proceeded for 7 minutes 
upon which 100μL of BioMol green was added. The OD620nm was measured and compared to 
standard solutions with known free phosphate concentrations to determine the initial 
velocity at each [RII]. Initial velocity was plotted against [RII] and data points were fit to the 
Michaelis-Menten equation: 
𝑉𝑖 =
𝑉𝑚𝑎𝑥∗[𝑆]
𝐾𝑚+[𝑆]
     
where Vi is the observed initial velocity, Vmax is the asymptotic value that represents the 
velocity given a saturating amount of substrate, Km is the concentration of substrate that gives 
an initial velocity equal to half of the Vmax, and [S] is the concentration of substrate.  
2.6.3 IC50 determination 
The IC50 of RCAN1-4, pHLAPP, and pFLISPP was determined by measuring CaN 
activity using the RII peptide as a substrate. Final reactions contained 80mM Tris (pH 7), 
200mM KCl, 2mM CaCl2, 1mM DTT, 5mM MnCl2, 30nM CaN, 90nM CaM, 30μM RII, and 0-25μM 
of inhibitor. Reactions proceeded at 30°C for 7 minutes in a 96-well plate format before 2X 
volume of BioMol green (Enzo Life Sciences, Farmingdale, NY) was added to quench the 
reaction. The OD620nm was measured and compared to a standard curve with known 
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phosphate concentrations to determine the amount of phosphate released. The IC50 was 
determined by fitting the data to a dose-response relationship: 
 
𝑉𝑖 =
max  − 𝑚𝑖𝑛
1+10(𝑙𝑜𝑔𝐸𝐶50−[𝐼])𝐻𝑖𝑙𝑙𝑠𝑙𝑜𝑝𝑒
   
where Vi is the observed initial velocity, max is the maximal Vi observed, min is the minimal 
Vi observed, EC50 is the half-maximal effective concentration (IC50), [I] is the concentration of 
inhibitor, and Hillslope is the Hill coefficient multiplied by -1.  A peptide with the sequence 
CKKAAAGAAAKKW was used as a control and is not a substrate of CaN. 
2.7 Computational Predictions 
The content of disordered residues of our RCAN1-4 construct was predicted using 
Predictor of Naturally Disordered Regions (PONDR) through the web service at 
http://www.pondr.com/. PONDR predicts disordered regions of proteins based on the 
proportion of hydrophobic vs. hydrophilic amino acids calculated over a 21 residue window.  
A PONDR score of 1 predicts a disordered region while a score of 0 predicts a folded region. 
The reader is referred to Molecular Kinetics, Inc. and reference material for precise 
information on prediction algorithms.104–106  
2.8 Isothermal Titration Calorimetry (ITC) 
ITC measurements were made using a MicroCal VP-ITC (Malvern Instruments). The 
jacket temperature was set to 37°C for all ITC experiments. CaM, CaM-Acr, and pCaMKI 
peptide were buffer exchanged into 20mM HEPES (pH 7.5), 250mM NaCl, and 10mM CaCl2 
using a Bio-Rad P-2 column (Bio-Rad, Hercules, CA). Twenty-five injections of 52-120µM CaM 
or CaM-Acr was titrated into 4.5-10µM pCaMKI. Injections were 10µL each and took place 
over 10 seconds. ITC data was analyzed in Origin (OriginLab). Thermodynamic parameters 
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were determined from fitting the isotherms to a one-state binding model. The parameters 
ΔH, KD, and ΔS represent the average of two independent experiments. 
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CHAPTER 3: Calcineurin in a crowded world 
This chapter is reprinted with permission from: 
E. C. Cook and T. P. Creamer, “Calcineurin in a crowded world.,” Biochemistry, vol. 55, no. 22, 
pp. 3092–3101, 2016. 
3.1 Introduction 
 Calcineurin (CaN) is a calmodulin (CaM)-activated protein Ser/Thr phosphatase that 
was discovered in the labs of Wang and Desai, and Klee and Krinks.2,3 Initially thought to be 
expressed only in neurons (hence the name), CaN is now known to be expressed ubiquitously. 
CaN is a key regulator of processes such as activation of the immune system, neuronal 
plasticity, and heart growth.4,30,107 CaN mediates immune system activation through its action 
on members of the transcription factor family Nuclear Factor of Activated T-cells (NFAT), for 
example NFAT1 and NFAT2. Once dephosphorylated, these transcription factors translocate 
to the nucleus where they upregulate the expression of the cytokines IL-2, IL-6, and IFN-γ, 
which are important for further immune system stimulation.108–111  As a result of infection 
and initiation of the CaN/NFAT-dependent pathway releasing of these cytokines, patients can 
experience symptoms of inflammation, including fever which typically ranges from 38°C to 
42°C.112 
 CaN is a heterodimeric protein composed of a catalytic A chain (57-61kDa) and a 
regulatory B chain (19kDa).4,62 From N-terminus to C-terminus the A chain of CaN contains 
the catalytic domain, B-chain-binding helix, and regulatory and autoinhibitory domains. The 
catalytic domain of the A chain contains all the molecular machinery necessary for CaN’s 
catalytic function as a phosphatase.62 Extending out from the catalytic domain is a helix to 
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which the regulatory B chain binds. The regulatory domain (RD) is a ~100 residue domain 
that contains the CaM-binding site.63 The autoinhibitory domain (AID) of CaN occludes the 
catalytic site of catalytic domain in CaN’s inactive state. The B chain of CaN is structurally 
homologous to CaM and is capable of binding up to 4 Ca2+.3 
 In the resting cell intracellular [Ca2+] ranges from 50-100nM and is insufficient for 
CaN activation.113 In the inactive state of CaN, the AID occludes the catalytic site, preventing 
binding of phosphorylated residues. It was suggested by Yang and Klee that the RD is folded 
onto the interface between the A and B chains, which would prevent CaM binding (Figure 3.1, 
A).64 These authors showed that the RD, which contains the CaM-binding site, in full-length 
CaN is protected from limited digestion by trypsin and chymotrypsin in the absence of Ca2+. 
This was not the case for Ca2+-bound CaN. 
 Upon the influx of Ca2+ (e.g. triggered by T-cell receptors binding to an antigen), CaN 
undergoes a multi-step conformational change that results in full activation.64,114,115 Ca2+ 
binds to the B chain causing dissociation of the RD from the A/B-chain interface (Figure 3.1, 
B). Release of the RD results in the domain becoming disordered, exposing the CaM binding 
site.63,64,82 Concurrently, CaM can bind 4 Ca2+ and the newly accessible CaM-binding site. Upon 
CaM-binding the RD undergoes a conformational change that removes the AID from the 
catalytic site and results in full activation (Figure 3.1, C). 
 It was first suggested by Manalan and Klee that the RD containing the CaM-binding 
site is intrinsically disordered in Ca2+-bound CaN.82 The RD and AID in full-length CaN in the 
presence of Ca2+ was readily digested in limited proteolysis experiments. Hydrogen-
deuterium exchange with mass spectrometry (HD/MS) and circular dichroism (CD) analyses 
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performed in our laboratory showed that a protein construct of the RD alone was intrinsically 
disordered.63 
 We also observed that CaM binding led the RD to fold.63 It was known that CaM 
interacts with a ~24-residue sequence located in the N-terminal half of the RD (residues 391-
414), and that CaM binds to this region with a high affinity (KD = 1-28pM).63,89,90,92 The HD/MS 
experiments detected a second RD region (residues 441-459), ~27 residues downstream of 
the CaM binding site, that also folds upon the association with CaM.63,88 CD data revealed this 
distal structured region to be helical. Thus, this was named the distal helix.88 
 The sequence of the distal helix region suggested that it was an amphipathic α-helix 
and it is hypothesized that the hydrophobic face interacts with CaM.88 To investigate the 
structure of the distal helix, the isolated RD was expressed and purified. CD measurements of 
the wild-type RD construct in the presence of CaM revealed that the distal helix had a Tm of 
38°C, close to human body temperature of 37°C.88 To further probe distal helix formation, 
glutamate point mutations (A447E, A451E, and A545E) were made in the putative 
hydrophobic face of the amphipathic α-helix. Glutamate was chosen to replace the native 
alanines because glutamate both introduces a negative charge and is significantly larger. We 
hypothesized that this would disrupt interactions with CaM and weaken distal helix 
formation. Since these mutations were outside of the CaM binding region, CaM could still bind 
to the RD with high affinity. RD constructs that contained Ala-to-Glu mutations were found to 
have significantly weakened, if not abolished, folding of the distal helix. 
 The functional role of the distal helix was assessed by making the same disruptive 
Ala-to-Glu mutations within the distal helix in full-length CaN, and determining the effects on 
enzymatic activity.88 Two substrates are typically used to assess the enzymatic activity of 
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CaN, para-nitrophenol phosphate (pNPP), a generic small molecule phosphatase substrate, 
and RII which is a phosphorylated peptide derived from an endogenous substrate of CaN, 
protein kinase-A regulatory subunit type II (PKA RII).96 Analysis of CaN constructs containing 
Ala-to-Glu mutations revealed that distal helix formation is required for full and robust 
activity of CaN against both pNPP and RII substrates.88 Michaelis-Menton analyses of the 
enzymatic assay data suggested that disruption of the distal helix allowed the AID to occupy 
the active site of the catalytic domain of CaN, thereby directly inhibiting pNPP and RII 
binding.88 
 Interestingly, the Tm of the distal helix is 38°C, which is close to that of the average 
human body temperature (37°C). Based on the thermal transition shown in our CD data, the 
distal helix is predicted to be partially folded at 37°C.88 It is curious that the distal helix would 
not be fully folded at human body temperature when it appears to be critical for robust CaM-
dependent activation of CaN. It seems likely that some factor, or factors, within the cell 
modulate this, allowing for full activation of this essential phosphatase. 
 There are many differences in the way proteins are typically studied in vitro (e.g 
dilute buffers and salts) and how they exist in the context of the cell. One of the most notable 
differences, which we focus on in this paper, is that of macromolecular crowding. The term 
“macromolecular crowding” was coined by Minton and Wilf in 1981 when they observed that 
an increase in concentration of inert proteins (“crowders”) changed the conformational 
equilibrium of GAPDH compared to that observed in dilute buffer.116 Since then, many labs 
have observed that the inclusion of crowding reagents that are thought to approximately 
mimic the cell interior can alter the stability and activity of proteins and enzymes.117–125  
46 
 Crowding has the potential to stabilize the distal helix in CaN, thereby giving us a 
better estimate of its folded state and the activity of the phosphatase in vivo. Our hypothesis 
is that macromolecular crowding stabilizes the distal helix of the CaM/CaN complex. In this 
study we utilized the inert crowding reagents dextran 70 and ficoll 70 with circular dichroism 
(CD) to determine its effect on the distal helix of CaN. Ficoll 70 and dextran 70 were chosen 
because they do not contribute an interfering signal in CD unlike protein crowding agents 
such as BSA or lysozyme. Therefore, dextran 70 and ficoll 70 offer convenient and easily 
interpretable effects of macromolecular crowding on the CaN/CaM system.  In addition, we 
measured the enzymatic function of CaN to show that crowding-induced stabilization of the 
distal helix confers greater activity of CaM-activated CaN.  
3.2 Results 
 3.2.1 Inert polymeric crowding agents increase the thermal stability of the   
           RD:CaM complex 
 Previously, our group has shown that an α-helix forms in the C-terminal region of the 
RD construct, distal to the CaM-binding site, and that this helix formation is important for 
CaM-mediated activation of CaN.88 Our data demonstrated that this “distal helix” is marginally 
stable at human body temperature, and destabilization of the distal helix leads to decreased 
CaN activity. To determine if crowding could stabilize the distal helix, far-UV circular 
dichroism (CD) was performed on the RD construct in the presence of CaM. Dextran 70 and 
ficoll 70 are inert polymers commonly used as crowding agents and were chosen because 
they do not contribute a significant signal in CD spectra at wavelengths typically used to 
characterize protein structure. RD+CaM samples were incubated with varying concentration 
of dextran 70 or ficoll 70 at 37°C, and CD spectra were collected (Figure 3.2A,B). CD spectra 
for the proteins used in this work were only measured down to 215nm due to absorption 
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from HEPES buffer. As the concentration of dextran 70 and ficoll 70 was increased, the 
ellipticity at 222nm decreased in a nearly linear manner suggesting an increase in the 
secondary structural content of the RD:CaM complex (Figure 3.2C). The addition of either 
dextran 70 or ficoll 70 to a solution of the RD:CaM complex gave the same increase in 
ellipticity within error (Figure 3.2C). 
  Previously, the RD fragment was characterized and found to be intrinsically 
disordered.88 CD measurements of the RD fragment displayed a minimum at approximately 
200nm which is often interpreted as being indicative of disorder. This conclusion was 
supported by hydrogen-deuterium exchange/MS (HD/MS) experiments. In contrast to the 
RD:CaM complex, dextran 70 and ficoll 70 had no effect on the ellipticity of the RD construct 
in the absence of CaM (Figure 3.2A,B) which suggests a CaM-dependent structural change. 
Dextrose and sucrose are the monomeric subunits of dextran 70 and ficoll 70, respectively. 
200g/L of dextrose or sucrose did not appear to affect the overall secondary structure of the 
RD:CaM complex  (Figure 3.3A). Thus, the inert polymers dextran 70 and ficoll 70 are able to 
increase the helical content of CaM-bound RD and not the lower molecular weight 
compounds.  
 To determine if any of the observed increase in molar ellipticity from crowding is due 
to structural changes apart from the distal helix, we had a 29-residue peptide synthesized 
corresponding to the CaM-binding site of CaN (peptide is referred to as pCaN). This CaM-
binding site is necessary and sufficient for high-affinity CaM binding in the range of 1-
28pM.89,90 Dextran 70 and ficoll 70 did not appear to have any effect on the ellipticity 
measured for CaM bound to pCaN (Figure 3.3B). Because the distal helix is known to be 
marginally stable88 and is contained in the RD, but not the pCaN peptide63, we surmise that 
the dextran 70 and ficoll 70-dependent change in ellipticity of the RD:CaM complex are due 
48 
to stabilization of the distal helix. Further, the distal helical sequence was the only region 
found to participate in backbone-backbone hydrogen bonding via HD/MS.63 
 The data illustrated in Figure 3.2C indicates that the ellipticity of the RD:CaM complex 
has an almost linear dependence on the dextran 70 concentration from 0-200g/L. This would 
suggest that a higher helical content is possible at a higher dextran 70 or ficoll 70 
concentrations. Thus, 2,2,2-trifluoroethanol (TFE) was used to investigate if an even higher 
helical content was achievable.  While the mechanism of action is not fully understood, TFE 
is capable of stabilizing and inducing α-helical structure in some proteins. TFE was able to 
decrease the ellipticity of the RD:CaM complex at 222nm by 58% (Figure 3.3A) suggesting a 
large gain in α-helical content is possible. In comparison, 40% TFE was only able to induce a 
22% decrease in the ellipticity at 222nm of the CaM:pCaN complex (Figure 3.3B).  Thus, the 
remaining ellipticity change is due to TFE’s influence on the RD outside the CaM-binding site, 
most likely the distal helix given that the remainder of the RD is enriched in glycine and 
proline residues63.  
 To determine if the addition of crowding reagents altered the thermal stability of the 
distal helix, we used CD and measured the ellipticity at 222nm as a function of temperature. 
The first derivative was used to determine the Tm of the distal in each instance (Figure 3.4A). 
All reactions showed reversible folding as the unfolding/folding transition of the distal helix 
was the same when scanning from 5°C-95°C or 95°C-5°C.  The Tm of the distal helix in the 
RD:CaM complex was determined to be ~38°C and ~43°C in dilute buffer and 200g/L of 
dextran 70 or ficoll 70, respectively (Figure 3.4A). The Tm of the distal helix in dilute buffer is 
in good agreement with Dunlap et al. (2013).88 The RD in the absence of CaM showed no 
apparent thermal transition with an increase in temperature even when 200g/L of dextran 
70 or ficoll 70 was added (Figure 3.4B). pCaN:CaM showed no apparent thermal transition in 
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dilute buffer from 5-95°C, but did show a thermal unfolding transition starting around 80°C 
in 8M urea (Figure 3.4C). The fact that the pCaN:CaM has such a high melting temperature 
even in the presence of 8M urea is a result of the high affinity of CaM for the CaM-binding site. 
Thus, the thermal transition in Figure 3.4A is primarily due to structural elements outside the 
CaM:CaM-binding site. 
  3.2.2 Crowding increases the activity of CaN 
Previous research has shown that alterations in the stability of the distal helix can affect the 
enzymatic activity of CaN.88 Enzymatic assays of CaN with pNPP as a substrate indicated that 
destabilization of the distal helix increased the Km (lower affinity). Experimental results 
shown in Figure 3.4A show that crowding with dextran 70 or ficoll 70 can increase the Tm of 
the distal helix. Therefore, we predict that as the distal helix is stabilized through crowding, 
the Km of CaN should decrease, a result of the AID being prevented from binding to the active 
site. Thus, we determined the enzymatic constants Km and Vmax for wild-type CaN in 0, 50, 
100, 150, and 200g/L of dextran 70 and ficoll 70 at 37°C. A generic substrate for 
phosphatases, para-nitrophenylphosphate (pNPP), was used to assess CaN’s enzymatic 
activity. The determined Vmax and Km values for the activity of CaN at dextran 70 and ficoll 70 
concentrations ranging from 0-200g/L are shown in Table 1. While increasing the dextran 70 
and ficoll 70 concentration did not appear to have an effect on Vmax, the Km is reduced ~70% 
and ~91% as the concentration of dextran 70 and ficoll 70 increase from 0 to 200g/L, 
respectively. In contrast, dextrose and sucrose did not induce a significant change in either 
the Km or Vmax at any measured concentrations (Figure 3.5B, Table 3.1). Thus, these enzymatic 
data are consistent with a stabilization of distal helix with the inert polymers, but not the 
small molecules dextrose and sucrose. 
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  3.2.3 CaNΔAIDCT activity does not change in crowded conditions 
Since macromolecular crowding can affect global protein conformation and stability, we 
sought to determine if the increase in CaN activity was due to factors other than stabilization 
of the distal helix.125 To accomplish this, we truncated CaN at the first residue of the AID 
(residue I467).  By truncating CaN at the AID, CaN is constitutively active, although CaM can 
still bind and the distal helix can still form. The Km and Vmax of CaNΔAIDCT were determined 
as a function of dextran 70 and ficoll 70 concentrations. The Km of CaNΔAIDCT does not 
appear to vary significantly from 0-200g/L of dextran 70 or ficoll 70 (Figure 3.5C, Table 3.2). 
Comparing the Vmax of wild-type CaN and CaNΔAIDCT data for each specific crowding 
reagents yields no specific trend in the data as the concentration of the crowding reagent 
increases. The Km and Vmax of CaNΔAIDCT in the absence of crowding reagents were similar 
to that of wild-type CaN in crowded conditions.  
 3.3 Discussion 
 It is important when characterizing an enzyme or macromolecule to consider that its 
native environment is a crowded milieu of various nucleic acids, proteins, and other 
macromolecules that range in concentration from 50-400g/L.120,126,127 While crowding can 
influence enzyme and protein:protein reactions through slower diffusion rates 128–130, this 
study focuses on the effects that macromolecular crowding have on the structure of CaN and 
the effects that structural changes confer on enzymatic activity. There have been many 
studies suggesting that macromolecular crowding can increase the stability of folded 
proteins, and while the mechanism underlying this stability is debated, it nonetheless has 
important implications for understanding the role of structural stability and enzyme 
function.117–119,125,131–135 The Pielak group have published a wealth of information on 
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macromolecular crowding, and recently published data on in-cell NMR of the SH3 domain of 
the Drosphila protein drk.119,131,136–141 Interestingly, they found that this protein does not 
display an increased stability in the intracellular environment of E. coli nor in the presence of 
lysozyme or BSA in in vitro stability measurements.136 No doubt the effects of the cellular 
environment on proteins is complex and there are many contributing factors to be 
considered. Here we are considering just the effects of relatively simple inert polymers, and 
realize that the in vivo situation is significantly more complicated. 
 In a previous study our laboratory found that the activity of CaM-activated CaN is 
influenced by a helical element, called the distal helix, found at the C-terminal end of the 
regulatory domain (RD).63,88 In the presence of Ca2+ but absence of CaM, the RD of CaN is 
disordered and the autoinhibitory domain (AID) is bound in the active site (Figure 3.1). When 
CaM is saturated with Ca2+ it will bind to the CaM-binding site (residues 390-414), located 
toward the N-terminal end of the RD, with a high affinity (KD = 1-28pM).89,90 When CaM binds 
to the RD, the distal helix folds onto CaM and the AID dissociates from the active site.63,88,142,143 
Mutations destabilizing the distal helix were shown to decrease CaN activity toward both 
pNPP and a phosphorylated peptide from the cAMP-dependent protein kinase regulatory 
subunit type II called the RII peptide.88  
 It is important at this point to understand that holo-CaM (calcium-loaded CaM) is a 
very stable protein with no observable melting transition from 5-95°C.144 Holo-CaM binds to 
pCaN, a 29 residue peptide of the CaM-binding site of CaN, with an estimated KD of 1-28pM 
forming an even more stable complex, also with no observable melting transition (Figure 
3.3C).88–90 In fact, it takes the addition of 8M urea to a solution of the CaM:pCaN complex for 
an observable thermal transition to become apparent (Figure 3.4C). In contrast, the RD:CaM 
complex was shown to have a thermal transition at 38°C.88 This transition was assigned to 
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the unfolding of the distal helix. Inspection of the amino acid sequence of the RD reveals that 
region could form an amphipathic α-helix with the hydrophobic face potentially interacting 
with CaM.  By mutating hydrophobic residues at this interface, folding of the distal helix was 
abolished.88 It was also demonstrated that the complex formed when CaM binds to the RD  
has a stoichiometry that is predominantly 1:1.92 Based on these and other data, this region 
was identified as the helical structure that forms when CaM binds.63,88 Mutations that 
disrupted this distal helix resulted in an increase in both the Vmax and Km of CaN using pNPP 
as a substrate.88 Disruption of the distal helix was also shown to decrease the activity of CaN 
against the more physiologically relevant substrate, the RII peptide. 
 The distal helix Tm of 38°C is puzzling since this would suggest that it is not completely 
folded at human body temperature. Yet folding of the distal helix has been shown to be 
essential for full activation of CaN.88 This observation was made using protein in dilute buffer 
at 37°C. It is known, however, that macromolecular crowding can stabilize a protein and 
increase its Tm. Thus, our hypothesis is that by stabilizing the distal helix through 
macromolecular crowding, the activity of CaN will be increased at body temperature. 
 To mimic macromolecular crowding large inert polymers such as dextran 70 and 
ficoll 70 are frequently utilized and have been shown to increase the structural content of 
proteins as well as their thermal stability.125,132  Since the distal helix is marginally stable at 
human body temperature, our goal was to determine if macromolecular crowding could 
increase its stability. This investigation was carried out using CD which can measure the 
secondary structural content of proteins (α-helices, β-sheets, etc.).  The addition of dextran 
70 or ficoll 70 increases the helical content of the RD:CaM complex, but not the RD in the 
absence of CaM (Figure 3.2A, B). Note that the CD signal of RD+CaM at 222nm (the signal 
typically used to measure α-helical content) appears to be approximately linearly dependent 
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on the dextran 70 and ficoll 70 concentrations from 0-200g/L (Figure 3.2C). Further, dextran 
70 and ficoll 70 did not seem to affect the secondary structure of the pCaN:CaM complex 
which would indicate that regions outside the CaM-binding site are amenable to folding 
and/or stabilization by macromolecular crowding. Due to the minimum protein 
concentrations required for CD we could not measure CD spectra at dextran 70 or ficoll 70 
concentrations greater than 200g/L. 
 The distal helix is contained within the RD, C-terminal to the CaM binding region, and 
is known to be a folded structure that is dependent on CaM-binding and is marginally stable 
at 37°C.63,88 Thus, we attribute this gain in structure of the RD:CaM complex using crowding 
reagents to an increase in the folded fraction of the distal helix. An alternative explanation for 
the increase in the CD as the concentration of crowding reagents increases is an increase in 
the affinity of CaM for the RD. We discount this possibility because the dissociation constant 
of CaM for the RD construct is in the low pM range.89,90 Given that, if the protein 
concentrations of CaM and the RD were 20μM each, that would only leave around 20pM of 
RD or CaM are not associated. A small increase in the bound fraction on a scale of this 
magnitude is not detectable using CD.   
 In contrast to the polymers, 200g/L of dextrose or sucrose did not have an observable 
effect on the RD:CaM structure (Figure 3.3A). Dextrose and sucrose can theoretically affect 
the stability of a protein through the osmophobic effect.145 Here, dextrose and sucrose were 
chosen as osmolytes because they represent the monomeric analogues of dextran 70 and 
ficoll 70, respectively. Since dextrose and sucrose did not promote folding of the RD:CaM 
complex, it is likely the osmophobic effect is not the driving force behind the increase in the 
folding of the distal helix.  
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 Also, direct interactions between the chemical groups of ficoll 70 or dextran 70 and 
the proteins are possible and are known as “soft” or intermolecular interactions. Soft 
interactions between proteins have been observed by the Pielak group to destabilize proteins 
and mitigate the stabilizing effect of excluded volume.140 Since we do not observe a change in 
the ellipticity of the RD:CaM complex at 200g/L in the presence of either dextrose or sucrose, 
we hypothesize that these “soft” interactions (along with the osmophobic effect) do not have 
an observable effect on the stability of the distal helix. This would be consistent with a volume 
exclusion model of crowding, where extended unfolded states are less favorable than 
compact folded states.146,147 
 To investigate the propensity of the RD to form α-helical structure and to determine 
if higher helical content was obtainable, we used 2,2,2-trifluoroethanol (TFE). 40% TFE was 
able increase the ellipticity (Figure 3.3A,B) of the RD:CaM complex by 58% and the pCaN:CaM 
complex by 22%. The linear appearance of the data in Figure 3.2C and the fact that TFE is able 
to induce more α-helical content than is achievable at 200g/L of dextran 70 suggests that the 
RD:CaM complex could possess a higher structural content at higher concentrations of 
crowding agent. Estimates of macromolecular crowding in the cell range up to 400g/L, and 
thus the distal helix could be stabilized further in vivo.127 
 Our CD data suggest that the thermal stability of the distal helix is increased ~5°C 
when the RD:CaM complex is in the presence of 200g/L of dextran 70 or ficoll 70(Figure 
3.4A). Since the distal helix is not a part of the pCaN peptide, and because the pCaN:CaM 
complex does not have an observable thermal transition (Figure 3.4C), it is our hypothesis 
that the increase in thermal stability of the RD:CaM complex in the presence of inert crowding 
agents is due to the distal helix. 
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 In dilute buffer, the distal helix has an estimated Tm of 38°C. At 37°C (average human 
body temperature) the distal helix would be partially unfolded. By adding dextran 70 we can 
increase the stability of the distal helix at 37°C and potentially increase CaN activity. A 
common CaN substrate used to assess CaN activity is the RII peptide which is a 19-residue 
peptide corresponding to the CaN-binding region of cAMP-dependent protein kinase 
regulatory subunit type II.148 This peptide has initial velocities typically calculated from a <10 
minute linear range of dephosphorylation vs. time.96 Considering this time restraint, dextran 
70 and ficoll 70 solutions are too viscous to accurately measure the activity of CaN against 
the RII peptide. Thus, we used the generic small-molecule substrate pNPP which has a linear 
range of up to one hour.  
 We have shown previously that CaN activity against pNPP is diminished when distal 
helix disrupting mutations are introduced in the RD.88 This decrease in CaN activity was due 
to an increase in the Km, consistent with competitive inhibition, and was proposed to be due 
to the AID binding to and occluding the active site upon unfolding of the distal helix. Since 
pNPP and the AID are known to only bind to the active site of CaN, we proposed that folding 
of the distal helix promoted CaN activity by preventing the AID from binding. 
 In our activity data for CaN, we observed that the Km decreased when dextran 70 or 
ficoll 70 was added (Table 3.1) consistent with stabilization of the distal helix. When either 
of the small molecules dextrose or sucrose were added, the Km did not appear to change 
(Table 3.1). Such an increase could be due to the sucrose or dextrose competing with pNPP 
for access to the active site at high sugar concentrations. Unlike the CD data shown in Figure 
3.2C, we did not observe a linear decrease in the Km of CaN as dextran 70 or ficoll 70 increased 
from 0-200g/L (Table 3.1). One reason for this difference could be that only a partially folded 
distal helix is required for robust CaN.  Our CD data indicated that dextrose and sucrose were 
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not able to stabilize the distal helix, and thus would not be expected to modulate the Km of 
CaN activity against pNPP. 
 To investigate if crowding was having an effect on the enzymatic activity of CaN aside 
from its effect on the distal helix, we made a constitutively active form of CaN that is CaM-
independent. When CaN is truncated at the AID and C-terminal tail (AID-CT), folding of the 
distal helix and CaM binding is no longer essential for activity. The Vmax and Km of CaNΔAIDCT 
do not change significantly as dextran 70 or ficoll 70 concentration increased between 0-
200g/L (Table 3.2). The Km of CaNΔAIDCT resembles the Km of CaN in the presence of 
crowding reagents. Altogether, this suggests that the distal helix is a heat labile structural 
component needed to disrupt the interaction between AID and the active site cleft of CaN. 
Upon disruption of interaction of the AID with the catalytic cleft, or deletion of the AID (in the 
case of CaNΔAIDCT), pNPP is able to freely diffuse into the active site of CaN for 
dephosphorylation. 
 In the context of immune system activation, CaN activation leads to eventual release 
of so called pyrogens that can lead ultimately to a fever.(6, 9, 8) Typical fevers range from 
38°C to 42°C. Previously, we characterized the distal helix as a heat labile structure whose 
formation is critical for complete activation of CaN.88 Here, we characterized the distal helix 
as having a Tm of ~38°C in dilute buffer, but increases to ~43°C in the presence of dextran 70 
and ficoll 70 which mimic macromolecular crowding of the cell. From these data, we 
hypothesize that the distal helix may impart a feedback mechanism by which CaN activity 
diminishes as a high grade fever is attained. Thus, the distal helix may be a novel and 
important modulatory feature of immune system regulation. 
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3.4 Chapter 3 figures and tables 
 
Figure 3.1. The activation of calcineurin by calmodulin.  
A) The CaM-binding site is located on the regulatory domain (RD) which interacts with the 
A/B-chain interface in the absence of Ca2+. B) The RD is released when the B-chain of CaN 
binds Ca2+. C) When Ca2+/CaM binds to the CaM-binding site of CaN the distal helix folds onto 
CaM, and the AID dissociates from the active site, fully activating the phosphatase. 
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Figure 3.2. Structural Effects of Dextran 70 and Ficoll 70 on the RD:CaM complex using Far-
UV CD.  
The RD construct in the presence and absence of CaM at various concentrations of (A) dextran 
70 and (B) ficoll 70 (0-200g/L), (C) Molar ellipticity at 222nm of RD+CaM as a function of 
[dextran 70] and [ficoll 70] showing similar degrees of crowding agent-induced structural 
increase. CD spectra are the average of three independenet experiments. 
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Figure 3.3. Far-UV CD spectra with small molecular osmolytes.  
A) The RD construct in the presence of CaM and buffer alone, 200g/L dextrose, 200g/L 
sucrose, and 40% TFE, B) pCaN:CaM complex in 200g/L dextran 70, 200g/L sucrose, and 40% 
TFE compared to in buffer alone. CD spectra shown are the average of three independent 
experiments. 
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Figure 3.4. CD temperature scans at 222nm.  
A) The RD:CaM complex in the presence and absence of either 200g/L dextran 70 or 200g/L 
ficoll 70 with first derivatives shown as dashed lines of the same color. B) the RD construct 
alone in the presence and absence of 200g/L dextran 70 or 200g/L ficoll 70, and C) pCaN:CaM 
complex in the presence and absence of 8M urea. Thermal CD melts are the average of three 
independent experiments. 
62 
 
   
 
 
63 
Figure 3.5. Enzyme kinetics data showing the rate of hydrolysis of pNPP as a function of pNPP 
concentration at 37oC.  
A) Dextran 70 and ficoll 70 increases the activity of CaN. B) The small molecules dextrose and 
sucrose do not alter kinetics. C) Truncation of CaN and removal of the AID and CT domains 
and its activity with Ficoll 70 or dextran 70 compared to dilute buffer. All kinetics data shown 
are the average of three independent experiments. 
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Table 3.1. Km and Vmax values for wild-type CaN at 37oC with pNPP as a substrate. 
CaN 
 
 
 
 
 
 Km (mM) Vmax (µmole/min/mg) 
Dilute buffer 56 ± 8 1.4 ± 0.1 
[Dextran 70] (g/L)   
10 36 ± 8 1.2 ± 0.11 
25 26 ± 4 1.0 ± 0.10 
50 22 ± 2  1.6 ± 0.05  
100 21 ± 2 1.7 ± 0.05 
150 23 ± 5 1.2 ± 0.09 
200 17 ± 3 1.1 ± 0.07 
[Dextrose] (g/L)   
50 59 ± 12 1.1 ± 0.11 
100 56 ± 5 0.95 ± 0.04 
150  70 ± 8 0.98 ± 0.06 
200 58 ± 18 1.6 ± 0.2 
[Ficoll 70] (g/L)   
50 38 ± 5 0.92 ± 0.10 
100 10 ± 2 0.83 ± 0.10 
150 19 ± 7 0.99 ± 0.12 
200 9.2 ± 6 1.4 ± 0.3 
[Sucrose] (g/L)   
50 69 ± 8 2.1 ± 0.1 
100 59 ± 4 1.5 ± 0.1 
150 76 ± 11 1.5 ± 0.1 
200 63 ± 5 1.3 ± 0.1 
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Table 3.2. Km and Vmax values for CaNΔAID-CT at 37oC with pNPP as a substrate. 
CaNΔAIDCT 
 Km (mM) Vmax (µmole/min/mg) 
Dilute Buffer 23 ± 4 1.7 ± 0.1 
[Dextran 70] (g/L)   
50 29 ± 7 1.7 ± 0.2 
100 15 ± 3 0.76 ± 0.06 
150 18 ± 2 1.2 ± 0.1 
200 15 ± 3 1.3 ± 0.1 
[Ficoll 70] (g/L)   
50 16 ± 7 1.7 ± 0.5 
100 9 ± 1 1.03 ± 0.1 
150 16 ± 4 1.3 ± 0.2 
200 12 ± 7 1.2 ± 0.3 
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CHAPTER 4: Electrostatic Forces Mediate Fast Association of Calmodulin and the Intrinsically 
Disordered Regulatory Domain of Calcineurin  
 
4.1 Introduction 
 Intrinsically disordered proteins (IDPs) and proteins with intrinsically disordered 
regions (IDRs) are a growing class of proteins that have no well-defined three-dimensional 
structure.149,150 More than 33% of eukaryotic proteins contain an intrinsically disordered 
region of at least 30 residues in length.86 IDPs and IDRs do not adopt a well-defined three-
dimensional structure due to a high proportion of polar and charged residues and low 
abundance of hydrophobic and aromatic residues.149,150 Even though IDPs and IDRs lack a 
specific three-dimensional structure they have a plethora of important roles which include 
sites of post-translational modification, sites of protein:protein interaction (through the 
utilization of short linear motifs or SLiMs), and disordered linkers that physically constrain 
domains of a protein.87   
 Here, we hypothesize that the conformational ensemble of the intrinsically 
disordered RD can influence the binding of CaM to the CaM-binding site. The Pappu lab have 
reported that the conformational ensembles of IDPs can be influenced by the distribution of 
charged residues throughout the linear sequence. IDPs are often polyampholytes and can be 
described by the fraction of negative (f-) and positive (f+) charges (Figure 4.1A).85 The five 
colored areas labeled 1 through 5 in the diagram of Figure 4.1 represent the predicted 
conformational ensembles of IDPs which are determined by the f+ and f-.151,152 Region 1 is 
occupied by IDPs with a low number of charged residues and a high number of non-charged 
polar residues and are known as weak polyampholytes. IDPs in this region take on globular 
conformations. Region 3 is occupied by IDPs that are strong polyampholytes meaning they 
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contain a high number of both positively and negatively charged residues. These IDPs form 
non-globular conformations including hairpins and coils. Regions 4 and 5 are occupied by 
IDPs with large f- and f+, respectively. Likely conformations in regions 4 and 5 are swollen 
coils which are relatively extended compared to the other regions of the Das-Pappu diagram. 
The conformational ensemble of IDPs in region 3 is more compact than those in regions 4 and 
5, but more extended than those IDPs that are in region 1. Region 2, which borders 1 and 3, 
represent a continuum of conformations adopted by IDPs in the 1 and 3 regions.  
 Hairpin, coil, and tadpole are descriptors for a generalized conformational ensemble 
of IDPs, and have no precise definition. This is because these conformations are a borderless 
continuum of structures that can be adopted by IDPs.87 Shown in Figure 4.1B are two 
idealized representations of the coil conformation and globule conformation. Coils have a 
relatively extended conformation compared to the globule and a high degree of accessibility 
of the protein backbone to solvent. The globule conformation is more compact and would 
have a lower degree of solvent accessibility to the protein backbone. The hairpin ensemble 
results from complementary charges interacting with one another. Like the name suggests, 
tadpoles are a combination of the globule and coil conformations. IDPs most likely do not 
adopt just one of the types of conformation described above, but twist and turn into the 
various conformations in the continuum of conformational ensembles. 
 The net charge distribution of IDPs important not only for the conformational 
ensemble, but also for when the IDP contains a SLiM which mediates protein:protein 
interaction. Electrostatic forces can affect association rate kinetics.103,153 Before two proteins 
can interact they must encounter each other. This process is mediated by translational 
diffusion and eventually results in the contact between the surfaces of the proteins, forming 
the “encounter complex”. Since proteins are not equally reactive over their entire surfaces, 
not all protein collisions result in stable complex formation. Electrostatic forces between two 
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proteins in an encounter complex can increase the rate at which they find each other in the 
proper relative orientation through the attraction of complementary charges on the reactive 
surfaces. 
Despite association rate kinetics and IDP conformational ensembles being 
interconnected through the influence of charged residue distribution, there are few studies 
characterizing this relation. We chose to study this relationship using calmodulin (CaM) and 
calcineurin (CaN) as our interacting pair. 
 CaN is a Ser/Thr phosphatase that regulates T-cell activation, long-term potentiation, 
and pathological cardiac hypertrophy (Figure 4.2A).4,30,62 CaN is heterodimeric with a 
catalytic A-chain and a regulatory B-chain.66 At low intracellular calcium concentrations 
([Ca2+]), the autoinhibitory domain (AID) of the A-chain occupies the catalytic cleft of CaN and 
keeps CaN inactive. As intracellular [Ca2+] rises, 4 Ca2+ will bind to the B-chain which results 
in a small increase in activity.62 Four Ca2+ will also bind to the intracellular Ca2+-sensing 
protein CaM. Ca2+-loaded CaM then binds to the intrinsically disordered region of CaN known 
as the regulatory domain or RD. The binding of CaM to CaN results in a conformational 
rearrangement of the RD that results in the dissociation of the AID from the catalytic site of 
CaN and full activation.62,63,88  
 The Pappu lab has created a tool for estimating the influence of the electrostatic forces 
on the ensemble of structures of an IDP called the Classification of Intrinsically Disordered 
Ensemble Regions or CIDER. CIDER can calculate the net charge per residue of an IDP.  The 
linear net charge per residue is determined by scanning the IDP with a 5-residue window and 
averaging the charge within that window. The net charge of the window is assigned to the 
residue in the center of the 5-residue window. CIDER results of the linear net charge per 
residue of the RD of CaN are shown in Figure 4.2B. The CaM-binding site is shown as the 
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highly positively charged region and there are highly negatively charged regions surrounding 
it.  
 The Debye-Hückel approximation was used to estimate the influence of electrostatic 
force between CaM and CaM-substrates. The Debye-Hückel approximation is: 
ln 𝑘𝑜𝑛 = ln 𝑘𝑜𝑛,𝑏𝑎𝑠𝑎𝑙 + (
𝑈
𝑅𝑇
) 
1
1+𝜅𝑎
  (1) 
where kon is the observed on-rate constant between CaM and the CaM-substrate. kon,basal is the 
on-rate constant at infinite ionic strength and is equal to the y-intercept of ln 𝑘𝑜𝑛 vs. 
1
1+𝜅𝑎
 . U 
is the energy of electrostatic interaction and is equal to the slope of ln 𝑘𝑜𝑛 vs. 
1
1+𝜅𝑎
. R is the 
gas constant, T is temperature, κ is the inverse of the Debye length, and 𝑎 is the minimal 
distance of approach which is set to 6Å, and is an experimentally determined value.103 
 The Debye length is the measure of the net electrostatic effect of a charged particle 
and how far those effects persist in solution. That is to say that a charged particle with a 
longer Debye length contributes an electrostatic force that extends farther than a particle 
with a shorter Debye length. As the distance separating two particles increases, the 
electrostatic forces between these particles are electrically screened. The inverse of the 
Debye length, 𝜅, can be determined from the temperature and the ionic strength:  
𝜅 =  √
ɛ𝑟ɛ0𝑅𝑇
2𝐹2𝐶0
     (2) 
where ɛ0 is the permittivity of free space, ɛ𝑟 is the dielectric constant, F is the Faraday 
constant, and C0 is the molar concentration of electrolytes. 
 The Debye-Hückel approximation gives us two important pieces of information about 
an interacting protein pair; the contribution of electrostatic forces to the association rate 
which is determined from U, and the association rate in the absence of electrostatic forces 
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which is the kon,basal. Non-electrostatic forces will affect the kon,basal and include steric forces 
that can decrease the accessibility of the CaM-binding site.  
 In this study, the importance of electrostatic forces to the association rate kinetics of 
CaN and CaM were determined using constructs of CaN ranging in chain length and net 
electrostatic charge. We measure the influence of electrostatic forces between CaM and 
various CaM substrates to investigate how important electrostatic forces are to the 
interaction of CaM and CaN. Our working hypothesis is electrostatic forces are not only 
important in determining the conformational ensemble of the RD, but electrostatic forces also 
strongly influence the rate at which CaM and CaN interact.  
 We predict that added chain length (RD compared to pCaN) and the folded parts of 
CaN create a steric hindrance in the interaction of CaM and the CaM-binding site. It is 
important to note that the CaM-binding site is surrounded by well-conserved negatively 
charged patches (Figure 4.3). Our pCaN peptide construct does not contain these net 
negatively charged patches surrounding the CaM-binding site, but the RD and CaN do. CaN 
also has potential complexities in the electrostatic force contribution from the folded 
domains of CaN. Due to the close proximity of these flanking net negatively charged patches 
to the CaM-binding site and the potential electrostatic force contributions from the folded 
domains of CaN, we speculate that the electrostatic force between CaM and pCaN, RD, and 
CaN will be different.  
 To perturb the conformational ensemble of the RD and alter the accessibility of the 
CaM-binding site, we made two CaN mutants in which we inserted positively charged 
residues to each of the net negatively charged patches surrounding the CaM-binding site. We 
predict that by increasing or decreasing the accessibility of the CaM-binding site, we could 
increase or decrease the association rate constant of CaM and CaN.  
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4.2 Results 
Here we used calcineurin (CaN) and calmodulin (CaM) to study the electrostatically 
driven association rate of a disordered:folded protein pair. CaN and CaM are an interesting 
protein pair for studying electrostatic influences and kinetics for the following reasons:  
1. Net negatively charged CaM interacts with a net positively charged binding site on CaN.  
2. The CaM-binding site is located on a 100-residue intrinsically disordered region of CaN. 
3. There are well-conserved acidic patches flanking the CaM-binding site that have the 
potential to modulate CaM/CaN binding kinetics. 
4. The intrinsically disordered domain of CaN is tethered to well-folded and net negatively 
charged domains. 
Three constructs were tested to determine the electrostatic and steric influences of 
the interaction between CaM and CaN; pCaN, the regulatory domain (RD), and full-length CaN. 
Figure 4.4 shows the sequences of pCaN and the RD. These constructs differ in their chain 
length and net charge (Table 4.1).  
4.2.1 Fluorescence intensity changes can be used to track CaM:CaM-substrate interaction 
 To measure the association rates of CaM and CaN, we constructed a fluorescencely 
labeled CaM construct whose fluorescence intensity can be tracked to measure substrate-
binding. We tagged CaM with the fluorescent label acrylodan. Acrylodan is an 
environmentally sensitive dye that can be used to probe the environment of proteins and 
track events such as unfolding, binding, and conformational changes.89,99,154–156 This method 
of fluorescent tracking was adapted from Quintana et al who also used acyldoan labeled CaM 
to tracking binding to CaM-substrates.89 Acylodan covalently attaches to proteins through 
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free cysteines. Since wild-type CaM does not have any endogenous cysteines, a CaM mutant 
containing a cysteine had to be generated. The N-terminal region of CaM is disordered and 
we hypothesized that labeling this region with acrylodan would impose little to no structural 
effect of the rest of CaM. Therefore, CaM D3C was generated. CaM D3C was labeled with 
acrylodan and CaM-D3C labeled with acrylodan will be known as CaM-Acr.  
 Our lab has discovered a novel interaction between CaM and the distal helix of the 
regulatory domain (RD) of calcineurin (CaN).63,88 The distal helix is a regulatory element that 
forms in the C-terminal end of the RD upon CaM binding to CaN. The distal helix has been 
shown previously to be critical for full CaN activation by CaM by promoting the dissociation 
of the AID from the active site of CaN. It has yet to be determined where on CaM the distal 
helix interacts, so in order to avoid potential disruption of this critical structure, the 
disordered N-terminal region of CaM was reasoned to be the best choice to place the 
acrylodan dye. 
 We speculated that by chemically modifying CaM that we might be altering its 
structure and thereby altering CaM’s affinity for a target substrate. Far-UV circular dichroism 
(CD) was performed on CaM and the CaM:pCaN complex as well as the RD and CaN by itself 
to determine if any gross changes in secondary structure were occurring due to modulation 
in the ionic strength. α-Helices are prominent in CaM as well as the CaM:CaM-substrate 
complex which is indicated by the double local minima of our CD spectra (Figure 4.5A).92,157 
The ellipticity at 222nm is typically utilized to monitor changes in α-helical content. The 
ellipticity at 222nm changes less than 3% for CaM and CaM-Acr as the [NaCl] changes from 
0.25M to 2M (Figure 4.5A, 4.6A). Similarly, the ellipticity at 222nm changes less than 2% for 
both CaM:pCaN and CaM-Acr:pCaN as the [NaCl] changes from 0.25M to 2M (Figure 4.5B, 
4.6B). The ellipticity of CaM:pCaN (both labeled and unlabeled) does not change significantly 
from 0.25M to 2M NaCl (Figure 4.6A, B). 
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 CD of CaN shows that the molar ellipticity at 222nm of CaN changes by 8% as the [NaCl] 
is adjusted from 0.25M to 2M NaCl (Figure 4.5C, 4.7A). The ellipticity at 222nm of CaN at 
0.25M and 2M NaCl were found not be significantly different from one another using two 
tailed t-test (p > 0.05). There was no detected secondary structural change in the RDs at 0 
and 2M NaCl when comparing the molar ellipticity at 222nm (Figure 4.7B). 
Since labeling CaM with acrylodan introduces a large bulky hydrophobic fluorophore 
onto the surface, we investigated if this addition had an effect on binding to its ligands. To 
compare the binding of labeled and unlabeled CaM, we used isothermal titration calorimetry 
from which we can derive enthalpic, entropic, and affinity changes due to labeling.  CaM’s 
dissociation constant for CaN is estimated to be in the range of 0.24-28pM.89,90 It is not 
possible to resolve affinities in this range using ITC because generated thermograms show a 
step-function around the stoichiometric ratio. Therefore, we used a peptide derived from 
CaMKI, a CaM ligand that interacts with CaM in a similar way to that of CaM:pCaN (Fig 4.8). 
The backbone atoms of CaM:pCaN and CaM:pCaMKI align with an RMSD of 2.6Å. Our ITC 
results indicate that CaM and CaM-Acr have no significant difference in the binding entropy 
(ΔS), binding enthalpy (ΔH), or dissociation constant (KD) (Figure 4.9). 
4.2.2 High ionic strength decreases CaM:Ca2+ affinity 
Since we will be determining the electrostatic influence of CaM and CaM-substrate by 
modulating the NaCl concentration, we surmise that we will also be modulating CaM’s affinity 
for Ca2+. CaM’s interactions with pCaN, RD, and CaN are dependent on CaM being in the Ca2+-
loaded state, therefore any modulation in Ca2+ affinity may affect CaM/CaM-substrate 
affinity.90 The interaction of Ca2+ with CaM is electrostatically driven through the 
coordination of aspartate and glutamate residues and are necessary for Ca2+-binding.158 CaM 
has two globular lobes separated by a flexible linker, and each lobe contains a pair of EF-hand 
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motifs. Therefore, CaM can interact with four Ca2+. We want to ensure that at the range of 
ionic strengths in which we are measuring CaM/CaM-substrate association rates our 
solutions contain a saturating concentration of Ca2+. Due to the presence of the intrinsic 
fluorescence amino acids phenylalanine and tyrosine, the Ca2+-binding constants of each lobe 
of CaM can be determined by tracking the fluorescence intensity of CaM.102 Measurement of 
changes in phenylalanine fluorescence (excitation: 250nm, emission: 280nm) is indicative of 
the N-terminal lobe binding to Ca2+, while changes in tyrosine fluorescence (excitation: 
277nm, emission: 320nm) is indicative of the C-terminal lobe binding to Ca2+.  
Comparing our results of the Ca2+-binding constants of CaM in the presence of either 
250mM or 2M NaCl indicates that the Ca2+-binding constants of both lobes are weakened by 
increasing the ionic strength (Figure 4.10A,B). We see that the Ca2+ affinity for the N-terminal 
lobe decreases by ~20-fold and the C-terminal lobe by ~400-fold (Table 4.2). Therefore, we 
included 10mM CaCl2 which is sufficient to saturate both lobes of CaM at the range of ionic 
strengths utilized when the association rates of CaM and its ligands were measured.  
4.2.3 CaM-Acr binding to CaM-substrates results in fluorescence quenching 
The fluorescence emission spectrum of CaM-Acr was measured in the presence and 
absence of pCaN, the RD, and CaN (Figure 4.11A). The addition of either 2μM of pCaN, the RD, 
or CaN to 0.2μM CaM-Acr resulted in the quenching of CaM-Acr fluorescence emission. In this 
way, we can study the interaction between CaM and CaN from the basic units to the more 
complex full-length enzyme. 
Tracking the fluorescence intensity of acrylodan (excitation: 365nm, emission: 490nm) 
and using a stopped-flow apparatus for fast mixing, observed association rates can be 
measured (Figure 4.11B). Figure 4.11B shows reaction traces of the mixing of CaM with CaN 
in the presence of either 10mM CaCl2 or 10mM EGTA. EGTA chelates Ca2+ and reduces the 
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availability of Ca2+. In the presence of excess CaCl2, there is an observed binding reaction 
between CaM-Acr and CaN, while in the presence of excess EGTA this reaction is absent. This 
recapitulates the fact that CaM is known to bind to CaN in a Ca2+-dependent manner.90  
4.2.4 Screening of Electrostatic Interactions Decrease Association Rates 
 To measure the association kinetics, we utilized stopped-flow spectroscopy to mix a 
solution of CaM-Acr with excess pCaN, RD, or CaN and tracked the fluorescence intensity of 
the acrylodan dye as a function of time. The kinetics traces of CaM-Acr binding to pCaN, RD, 
and CaN were found to best fit a single exponential decay model (Fig 4.12, Table 4.3).  Fits for 
all kinetic traces can be found in Appendix I.  
 Electrostatic forces between interacting proteins can be screened out by modulating 
the ionic strength of solution as shown by the Fersht group and others.103,159–162 From the 
Debye-Hückel approximation, useful parameters can be derived by measuring the effects of 
ionic strength on the observed kon. These include the kon,basal, and the energy of electrostatic 
interaction (U) (Equation 1).163 The kon,basal is the estimated kon at an infinite ionic strength 
and at which electrostatic forces between two proteins have been screened out. The energy 
of electrostatic interaction (U) is free energy contribution of electrostatic forces to the kon.  
We determined the association rate constant, kon, at various ionic strengths by 
modulating the NaCl concentration (Figure 4.13A). The kon of CaM-Acr and each of the three 
substrates decreased as the ionic strength increases. To put this data into the Debye-Hückel 
approximation we plotted the ln|kon| vs. 1/(1+κα) (Figure 4.13B). The x-axis, 1/(1+κα), is 
determined from the inverse of the Debye length, κ, and the distance of closest approach, α, 
which is set to 6Å. The kon,basal can be determined from the y-intercept and the energy of 
electrostatic interaction (U) from the slope (Table 4.4).  
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Despite the difference in the net charge of pCaN, RD, and CaN, their energies of 
electrostatic interaction (U) are equal within error. In contrast, the kon,basal is greatest for 
pCaN, with association with the RD being slightly slower possibly due to steric effects from 
increased chain length. The kon,basal for CaN:CaM-Acr is an order of magnitude slower than that 
for pCaN or the RD, which could be attributed to the addition of the bulky and folded portion 
of CaN.    
The CaM-binding site is surrounded by well-conserved acidic patches (Figure 4.3), which 
could modulate the association rate of CaM with the CaM-binding site. Given that the energy 
of electrostatic interaction of CaM-Acr with pCaN, the RD, and CaN was equal, it would not 
appear the flanking acidic patches contribute a significant electrostatic force. Would an 
alteration in the net charge of one of these acidic patches affect CaM binding to the CaM-
binding site?  
Two mutants were generated that altered each of the acidic patches surrounding the 
CaM-binding site; CaN E376R, E381R and CaN E415K, E418K (Figure 4.4, underlined 
residues). The CaN E376R, E381R mutant makes the net negatively charged patch N-terminal 
to the CaM-binding site less negative (Figure 4.4, underlined residues in red). The CaN E415K, 
E418K mutants the C-terminal net negatively charged patch to a net positively charged patch 
(Figure 4.4, underlined residues in orange). Figure 4.14 shows the net charge per residues of 
wild-type RD, RD E376R, E381R, and RD E415K, E418K to illustrate how the mutation of 
positively charged residues into the RD of CaN affects its charge distribution. 
The association rate of each these mutants and CaM-Acr was measured at various NaCl 
concentrations to derive the Debye-Hückel parameters stated above. The association of CaM-
Acr with the CaN E376R, E381R yielded an energy of electrostatic interaction and a kon,basal 
that were very similar to wild-type CaN (Table 4.4). The energy of electrostatic interaction 
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for the CaN E415K, E418K mutant increases 2-fold relative to the other constructs. This result 
is statistically different from CaN using a two-tailed t-test (p < 0.0001). The kon,basal of the CaN 
E415K, E418K showed a 16-fold decrease compared to CaN which is also statistically 
significant (p < 0.0001).  
4.3 Discussion 
Electrostatic forces are known to help drive the association of folded protein pairs 
such as net positively charged barnase interacting with a net negatively charged barstar.103 
Electrostatic forces allow the association rate of barstar:barnase to reach >5x109M-1 s-1. This 
rate is close to the Einstein-Smoluchowski limit which is the maximum rate of association 
between interacting molecules.162 Mutation of residues important for electrostatic 
complementarity to nonionic or hydrophobic residues decreases the association rate 
between the pair.  Folded proteins can have patches of negatively or positively charged 
residues on the surface that direct substrate binding.164 In contrast, the class of proteins 
known as intrinsically disordered proteins (IDPs) have no well-defined three-dimensional 
structure due to the lack of hydrophobic and aromatic amino acids and a high proportion of 
polar and charged amino acids.141 Thus, the influence of electrostatic forces on the association 
rate kinetics of IDPs is not entirely clear because the conformational space occupied by IDPs 
can be large. 
4.3.1 Acrylodan does not affect the structure or binding affinity of CaM to the CaM-binding 
site 
We considered that possibility that labeling CaM with a fluorescent dye could alter its 
binding affinity for its substrates. The binding affinity of CaM and CaM-Acr to a CaM-substrate 
was determined using isothermal titration calorimetry (ITC). The binding affinity of CaM and 
the CaM-binding site of CaN is too high to be measured by ITC (KD = 0.24-28pM).89,90. We chose 
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a CaM-substrate that interacts with CaM in a similar manner as the CaM-binding site of CaN 
but has an affinity in a range that can be measured by ITC. The pCaMKI peptide interacts with 
CaM in a similar fashion to the CaM-binding site of CaN (Figure 4.8) and has an affinity in the 
nanomolar range.165 We observed through ITC (Figure 4.9) that neither the enthalpy nor 
affinity of CaM-Acr was different from wild-type CaM at binding to our test peptide pCaMKI.  
Using circular dichroism (CD), we found that the secondary structure of CaM and 
CaM-Acr were nearly identical suggesting that the acrylodan label has little to no effect on the 
structure.(Figure 4.5A,B, 4.6A,B). Also, the structure of CaM:pCaN or CaM-Acr:CaM shows no 
statistically significant change at different ionic strengths using a two-tailed t-test (p > 0.05). 
CaM is known to be a stable protein especially when bound to a substrate such as pCaN and 
is resistant to structural changes in response to ionic strength differences.88,144,166 CaN 
showed a slight decrease in the CD signal as the ionic strength increased, but this change was 
not found to be significant (Figure 4.7A). No significant changes in the CD spectra of the RD 
were observed (Figure 4.7B).  
4.3.2 High ionic strength decreases CaM’s affinity for Ca2+ 
The Ca2+-binding affinity of CaM is known to be ionic strength dependent (i.e the 
higher the ionic strength, the lower the affinity).167 The reason why ionic strength affects the 
Ca2+-binding properties is disputed but is hypothesized to be due to either the effects of 
electrostatic screening from high concentrations of ions, or Na+ and other ions directly 
competing with Ca2+ for the Ca2+-binding site on CaM. Because the binding of CaM to CaN is 
dependent on CaM being in its Ca2+-bound state, and we wanted to study the effects of ionic 
strength on the association rate of CaM and CaM-substrates, we needed to control for the 
Ca2+-binding affinity of CaM at different ionic strengths. To ensure we are saturating CaM with 
Ca2+ we measured the Ca2+-binding affinity of CaM at an ionic strength of 0.278M and 2.078M 
which are the lowest and highest ionic strengths used throughout this study.  
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CaM is a two-lobe protein with each lobe containing two Ca2+-binding sites.158 The 
binding of the N- and C-terminal lobes of CaM to Ca2+ can be measured by tracking the 
fluorescence emission of phenylalanine and tyrosine respectively.102 Note here that we are 
not measuring the affinity of Ca2+ to each Ca2+-binding site of CaM, but rather we are 
determining the macroscopic Ca2+-binding affinity of Ca2+ to each of lobes of CaM. The Ca2+-
binding affinity for the N- and C-terminal lobe of CaM at an ionic strength of 0.278M is similar 
to previous reports (Table 4.2, Figure 4.10A).102,168  
The C-terminal lobe of CaM was shown to bind Ca2+ with a greater affinity than the N-
terminal lobe at an ionic strength of 0.278M, but this relationship is reversed at an ionic 
strength of 2.03M. As mentioned above, the Ca2+-binding lobes of CaM may be able to bind 
Na+. Therefore, Na+ may be directly competing with Ca2+ for CaM’s Ca2+-binding site which 
would decrease the apparent affinity of CaM for Ca2+. If Na+ competes for the Ca2+-binding 
sites on the C-terminal lobe with a greater affinity compared to the N-terminal lobe, this 
might explain why the C-terminal lobe of CaM has a low apparent affinity for Ca2+ at high a 
[NaCl]. Another hypothesis is that the increase in the electrostatic screening from high 
concentrations of NaCl affects the C-terminal lobe much more so than the N-terminal lobe 
possibility due to different electrostatic charge contents of the two lobes of CaM (Figure 4.16).  
The Ca2+ affinity of each of the lobes of CaM is lower at an ionic strength of 2.078M 
compared to 0.278M (Table 4.2, Figure 4.10A,B). The KD of N- and C-terminal lobes for 
Ca2+increases by 20 and 400 fold respectively. Therefore, we included 10mM CaCl2 during all 
of our CaM and CaM-substrate measurements to ensure CaM is fully bound to Ca2+, and we 
can potentially avoid any effects due to the decrease in affinity of CaM and Ca2+. 
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4.3.3 The CaM-binding site confers electrostatic attraction to CaM 
We derived the energy of electrostatic interaction (U) and the kon,basal  from the Debye-
Hückel approximation (Equation 1). The value of U has been shown to estimate the strength 
of electrostatic attraction between interacting proteins.169 The kon,basal refers to the basal 
association rate or the rate of interaction given that intermolecular electrostatic interactions 
are negligible. Steric forces can reduce reaction rates by increasing the non-reactive surface 
area of the protein in question and decreasing the accessibility of a binding site which would 
be apparent as a decrease in the kon,basal. Models for protein:protein interaction predict that 
before two proteins form their final and relatively stable complex, they form a loosely bound 
“encounter complex”. In this encounter complex, the protein pair is thought to bounce and 
slide across each other’s surfaces and sample many orientations. This pair might eventually 
find the proper orientation to form a stable and specific complex. In the encounter complex 
electrostatic forces assist proteins in finding the proper relative orientation in which to form 
a stable complex.169   For example, a protein may have a binding site composed of a large 
amount of positively charged residues, and its binding partner’s interface may be mostly net 
negatively charged. Thus, the electrostatic attraction may help these two complementary 
charged binding sites collide more frequently than if both sites were uncharged. Electrostatic 
forces are only significant when two molecules are within a certain distance from one 
another. This distance is called the Debye length and is the distance at which electrostatic 
forces persist for a given molecule. At physiological ionic strength, the Debye length is less 
than 10Å. So, a protein pair will have to be in close proximity for electrostatic forces to be 
significant. 
Using constructs derived from CaN (pCaN, RD, and CaN itself) we sought to determine 
the role of electrostatic forces in the CaM:CaM-substrate interaction. The small peptide pCaN 
represents our smallest unit CaM-substrate which just contains the net positively charged 
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CaM-binding site of CaN. By including the rest of the disordered chain (in the RD) or the rest 
of the full-length enzyme, we can compare the effects of the added chain length, electrostatic 
charge, and steric hindrances to the association rates of CaM with the CaM-binding site. 
Previously, Quintana, et al. measured the association of a CaM-Acr construct labeled at the 
C75 position to full-length CaN.89 The association traces determined from their lab fit a single 
exponential model that is consistent with our data. Their data showed that the association 
rate of CaN and CaM in 20mM MOPS (pH 7.0), 150mM KCl, and 5mM CaCl2 at 25°C was 4.7 x 
107M-1s-1.89  This was similar to our data collected in 20mM HEPES (pH 7.5), 250mM NaCl, 
and 10mM CaCl2 at 37°C which was 3.7 ± 0.3 x 107M-1s-1. 
The association rate of pCaN and CaM was higher across all ionic strengths tested 
(Figure 4.13A,B and Table 4.4) and also had the highest kon,basal compared to other CaM-
substrates. pCaN was our smallest CaM-substrate, so we hypothesize that this high kon,basal is 
due to the low amount of steric hindrance and a high degree of accessibility of the CaM-
binding site to CaM. pCaN is a strong polyampholyte located in the dark green region of the 
Das-Pappu phase diagram in Figure 4.15 which form hairpins, coils, or chimera. The presence 
of many positively charged residues that are well distributed across the sequence and the fact 
that the f+ of pCaN almost puts it in the positively strong polyelectrolyte region suggests coil 
conformational ensembles. Coil conformations might be of functional significance to the CaM-
binding site as they could promote exposure and fast binding to CaM. 
The association rate of CaM and the RD was lower than the association of CaM and 
pCaN at every ionic strength. The addition of the acidic patches on either side of the CaM-
binding site (RD compared to pCaN) did not appear to weaken the energy of electrostatic 
interaction of the substrate and CaM (Table 4.4, Figure 4.13B). This suggests that the flanking 
acidic patches do not contribute an electrostatic force that perturbs the association of CaM 
and the CaM-binding site. The kon,basal of CaM and the RD was 70% that of CaM and pCaN 
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indicating a potential steric influence. This would suggest that the added chain length of the 
RD decreases the accessibility of the CaM-binding site.      
Further investigation of segments of RD reveals interesting predictions about the 
conformational ensemble of the RD. Segments of IDPs can take on conformational ensembles 
that are not necessarily dependent on the other segments of the IDP in question. As such, 
different segments of the RD may have different conformational ensembles.  
To get a general idea of the conformational ensemble of segments of the RD we 
analyzed the two halves of the RD using CIDER. Figure 4.15 shows an analysis of the fraction 
of negatively and positively charged residues of four constructs; pCaN, RD, RDN-term, and 
RDC-term. RDN-term and RDC-term represent the two halves of the RD split into an equal 
number of residues. The N-terminal half of the RD has a higher charged residue content than 
the C-terminal half of the RD and also contains the complete CaM-binding site. The 
conformational ensemble of the RDN-term is predicted to be hairpin, coil, or chimera (which 
is composed of both hairpins and coils). The RDC-term is a weak polyelectrolyte which is 
predicted to be globular or tadpole-like.  These predictions suggest that the N-terminal RD 
has a conformational ensemble that promotes exposure of the CaM-binding site, and the C-
terminal end of the RD adopts a globular conformational ensemble that could lead to steric 
hindrance in the binding of CaM to the CaM-binding site. The C-terminal end of the RD may 
act similarly to a bulky folded domain. Because the C-terminal region has a lower fraction of 
charged residues, it could decrease the kon,basal without significantly altering the energy of 
electrostatic interaction. 
We have noted in previous studies that structural changes occur in the RD upon CaM 
binding and multiple sites of the RD interact with CaM, but the CaM-binding site accounts for 
most of the binding energy between CaM and the RD.63,88  When CaM binds to the RD, two 
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regions undergo a disorder to order transition. These are the CaM-binding site and distal 
helix region both of which fold into a α-helix upon binding to CaM.63,88 The residues of the RD 
that compose the distal helix are located on the C-terminal end of the RD and are predicted 
to be between residues 78-90 of our RD construct (Figure 4.4). The CaM-binding site imparts 
high CaM-binding affinity in the 0.24-28pM.89,90. The binding affinity of distal helix to CaM is 
currently unknown. The distal helix has been shown to have a Tm of 38°C which is far less 
stable than the CaM:CaM-binding site complex (Tm > 80°C).166 These data would suggest that 
the most of the binding affinity of CaM to CaN is due to the CaM-binding site, not the distal 
helix. That is not to say that the binding of the distal helix to CaM is not important because it 
is known to be critical for the full activation of CaN.88 The effects of the distal helix on the 
association rate of CaM and the CaM-binding site are currently unknown. Further 
deconvolution of the effects of the distal helix may be investigated with RD constructs that 
contain distal helix-disrupting mutations and our CaM-Acr tracking method.  
The kon,basal of CaM-Acr binding to CaN was reduced (~10-fold reduction) compared 
to CaM-Acr binding to pCaN or the RD. CaN is composed of more than just a CaM-binding site. 
It also has a large folded part including the catalytic domain, CaNB, and the rest of the RD. If 
CaM interacts with a part of CaN that is outside the CaM-binding domain, then that could 
result in a non-productive interaction (no final CaM:CaN complex formation). The energy of 
electrostatic interaction of CaN and CaM was the same within the error of CaM binding to 
either pCaN or the RD. This suggests that the well-folded and net negatively charged portion 
of CaN does not interact with the CaM-binding site in such a way as to perturb the 
electrostatic attraction between CaM and the CaM-binding site. This idea is supported by 
previous reports that the RD does not interact with folded parts of CaN.63 
There is more to consider about what influences the conformational ensemble of the 
RD than just the electrostatic component. In full-length CaN the RD is tethered at both ends. 
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The N-terminus of the RD is covalently attached to the B-chain binding helix. Because the 
autoinhibitory domain (AID) is at the C-terminal end of the RD, the C-terminus of the RD is 
attached to the active site of CaN. The tethering of the both ends of the RD might create 
limitations on its conformational ensemble. Tethering would prevent the RD from extending 
its end-to-end distance farther than ~52Å (the distance between the beginning and end of 
the RD).  
We found it curious that the energy of electrostatic (U) was the same for pCaN, the 
RD, and CaN. While all contain an identical CaM-binding site, they all differ greatly in terms 
of chain length/protein size and potential electrostatic force contributions from residues 
outside the CaM-binding site. For instance, in the context of the RD or CaN, the CaM-binding 
site has flanking net negatively charged patches that were hypothesized to decrease the 
electrostatic attraction of the CaM-binding site to CaM. This did not appear to be the case. 
Therefore, we revised our hypothesis suggesting that electrostatic forces outside the CaM-
binding site do not influence CaM associating with the CaM-binding site. To extend on this 
hypothesis, we surmised that altering the net charge of these negatively charged patches 
should affect the binding of CaM to the CaM-binding site. To alter the net charge, we made 
two mutants; CaN E376R, E381R and CaN E415K and E418K.  
The energy of electrostatic interaction (U) of CaM and CaN E415K, E418K was 
approximately twice  as favorable of that of pCaN, RD, or CaN suggesting that the added basic 
residues are contributing a more favorable attractive interaction between the CaM-binding 
site and CaM. In contrast, CaN E376R E381R did not show a significant change in the energy 
of electrostatic interaction compared to wild-type CaN. One explanation is that the positive 
charges that were introduced in the E415K, E418K mutant were much closer to the CaM-
binding site (Figure 4.4, underlined orange residues, Figure 4.12C) than the E376R, E381R 
mutant. Thus, the positively charged residues K415 and K418 could be close enough to the 
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CaM-binding site so that they are directly interacting with CaM as CaM approaches the CaM-
binding site. These added positively charged residues might act to attract the incoming CaM, 
and once bound may form a salt bridge or hydrogen bond with the residues of CaM. Salt 
bridge formation could make the complex more stable and could be studied by determining 
the dissociation rate constant of these mutants. This might lead to a decrease in the apparent 
dissociation rate assuming that this additional electrostatic force results in a significant 
change in complex stability. Introducing a favorable salt bridge would also increase the 
apparent affinity between the CaM and the CaN which can be determined by measuring the 
KD using association/dissociation rate measurements using CaM-Acr system described here. 
CaN E376R E381R mutations decreased but did not eliminate the net-negative charge 
of the acidic patch N-terminal to the CaM-binding site (Figure 4.12B). A 2-fold reduction in 
the kon,basal of CaN E376R E381R was observed. Together with the CaN E415K, E418K, 
changing either of the acidic patches surrounding the CaM-binding site decreased the 
accessibility of the CaM-binding site for CaM. These mutants could favor a higher proportion 
of collapsed states in the RD’s conformational ensemble. 
The conformational ensemble of IDPs has been shown to be influenced by the linear 
distribution of the charged amino acids.152  By reversing the charge on the acidic patch C-
terminal to the CaM-binding site (in the CaN E415K, E418K mutant), we have potentially 
altered the conformational ensemble which could be the reason we observe a decrease in the 
kon,basal. The decrease in the kon,basal represented decreased accessibility of the CaM-binding 
site by CaM. In contrast, our CaN E376R, E381R mutant altered the net charge of the RD to 
the same degree, but did not alter the kon,basal as much as E415K, E418K did. Besides the 
E415K, E418K mutants being closer to the CaM-binding site than the E376R, E381R mutants, 
the E4155,E418K mutants also completely reversed the charge of the C-terminal acidic patch, 
whereas the E376R, E381R mutation decreased but did not reserve the N-terminal acidic 
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patch. The E376R, E381R mutations might have perturbed the net charge of the N-terminal 
acidic patch enough to affect the conformational ensemble of the RD which led to a 2-fold 
reduction in the kon,basal. . There is also the obvious difference that lysine residues could affect 
the structural ensemble of the RD differently than arginine residues. Further studies with 
E376K, E381K, and E415R, E418R mutants will report on the possible differences of basic 
residue identity.  
CIDER analysis of these two mutants puts them in the same location of the Das-Pappu 
plot since they both have the same f+ and f-  as shown in Figure 4.13 as “RDmut”. Since these 
two mutants of CaN have the same net charge, and the location of these mutants are different 
we surmise that these two acidic patches play different roles in the conformational ensemble 
or accessibility of the CaM-binding site. Smaller sections of the RD were inspected to predict 
what sort of conformational ensembles occur. Figure 4.13 shows the results of sequences that 
represent the RD cut into 5 sections of equal amino acid length (shown as 1-5). The general 
trend of the fragments of the RD show that the N-terminal residues points 1 and 2, are closer 
to the strong polyampholyte regions show in dark green, and points 3, 4, and 5 are closer to 
the weak polyampholyte region in light green. Care must be taken to not over interpret these 
results, but this would suggest that the first 2/5 of the RD take on conformational ensembles 
of a strong polyampholyte (hairpin, coil, or chimera), and the last 3/5 of the RD take on 
conformational ensembles of a weak polyampholyte (globule or tadpole). We hypothesized 
that the decrease in the kon,basal of CaM and pCaN compared to the RD was due to a decrease 
in the accessibility of the CaM-binding site. The energy of electrostatic interaction of the 
association of CaM to pCaN or RD were the same and the kon,basal of the CaM and the RD was 
reduced compared to pCaN. We suspect the C-terminal end of the RD of reducing accessibility 
of the CaM-binding site rather than the acidic patches flanking the CaM-binding site that has 
a strong negative charge.  The E376R, E381R and E415K, E418K mutants suggest that 
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modifying the acidic patches flanking the CaM-binding site modifies accessibility of the CaM-
binding site. If the conformational ensemble of the CaM-binding site is coil-like that confers a 
high degree of exposure, then modification of either the of acidic patches surrounding the 
CaM-binding site might lead to collapse of the CaM-binding site to more collapsed ensembles 
such as hairpins or globules. The E376R, E381R and E415K, E418K mutations conferred the 
same change in the overall net charge, but seeing as the E415, E418K mutation resulted in a 
greater effect on not only the electrostatic energy of interaction and the kon,basal, we surmise 
that location of charge alterations is more important. 
While we did see an effect on the association rate kinetics of adding positively charged 
residues to the flanking acidic patches surrounding the CaM-binding site, we cannot conclude 
from our data set that these effects are solely due to the addition of positive charges vs. 
elimination of negative charges. To distinguish the effects of removing a negative charge from 
adding a positive charge, we would need to perform follow up experiments. We will make the 
corresponding CaN E376Q, E381Q and CaN E415Q, E418Q mutants which removes two of the 
negatively charged glutamates by replacing them with a non-charged, but still polar 
glutamines. Glutamine mimics the steric qualities of glutamate without the net negatively 
charged side chain. We hypothesize that the energy of electrostatic interaction of the CaN 
E376Q, E381Q and CaN E415Q, E418Q mutants will be the same as wild-type CaN since the 
presence of the net negatively charged patches did not have an effect on the energy of 
electrostatic interaction in cases of pCaN compared to RD and wild-type CaN. We also 
hypothesize that the CaN E376Q, E381Q and CaN E415Q, E418Q mutants will not greatly alter 
the conformational ensemble of the RD. Hence accessibility of the CaM-binding site should 
not be affect since the flanking acidic patches will still be net negatively charged even with 
the glutamate to glutamine mutations. 
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Altogether, the salt dependence of association rates yields valuable information on 
electrostatic and steric influences between interacting proteins.  These differences in the 
CaM-substrates give us clues as to the accessibility of the CaM-binding site. Studying the 
structure of IDPs is difficult because IDPs tend to take on an ensemble of conformations 
ranging from extended coils to compact globules. The conformational ensemble of IDPs is at 
least partially determined by the f+ and f-.151,170,171 In this work we sought to characterize the 
functional effect of perturbing the conformational ensemble of an IDP by altering the f+ and f- 
as well as the distribution of the charged residues. The “function” in this case was the 
association rate constants of CaM and CaM-substrates. Our data suggests that the 
conformational ensemble can play a very important role in the binding of folded proteins to 
IDPs. Many IDPs contain a protein-binding site, and while this data should not be applied to 
all IDPs, it does raise an interesting observation. Despite IDPs having no persistent or stable 
three-dimensional structure, disturbances in their conformational ensemble can affect their 
function. We speculate that certain conformational ensembles might be functionally 
important for promoting protein:IDP interactions such as coil ensembles that expose a 
relatively large amount of surface area to solvent.  
Speeding up protein:protein association rates might be critical for certain 
intracellular responses. CaN is a Ca2+-activated phosphatase important in long term 
depression and regulation of neuronal networks.4 Ca2+-transients in neuron signaling occur 
in the millisecond range, and, therefore, quick binding of CaM to CaN is needed if CaN 
activation and downstream signaling transduction is to occur.172  
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4.4 Chapter 4 figures and tables 
 
 
 
 
Figure 4.1. Das-Pappu phase diagram and model IDPs. 
A) Das-Pappu phase diagram showing conformational ensembles adopted by intrinsically 
disordered proteins depending on the fraction of positively and negatively charged residues. 
B) Idealized representation of the “coil” and “globule” conformations.  
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Figure 4.2. Structure of CaN and net charge per residue plot of the RD.  
A) Ribbon representation of CaN B) Linear net charge per residue plot of the regulatory 
domain of CaN obtained using CIDER. The net charge per residue is plotted as a function of 
the residue number of the RD.  The net charge of this window is assigned to the center residue. 
CIDER is available for public use at the following URL: “http://pappulab.wustl.edu/CIDER”.152 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
92 
H.sapiens    YWLPNFMDVFTWSLPFVGEKVTEMLVNVLNICSDDELGSE-EDGFDG-------------  
M.musculus   YWLPNFMDVFTWSLPFVGEKVTEMLVNVLNICSDDELGSE-EDGFDG-------------  
G.gallus     YWLPNFMDVFTWSLPFVGEKVTEMLVNVLNICSDDELGTE-EDGFDG-------------  
C.elegans    YWLPNFMDVFTWSLPFVGEKVTEMLVHILNICSDDELMAECDDTFEG-------------  
S.cerevisiae YWLPDFMDVFTWSLPFVGEKVTEMLVAILNICTEDELENDTPVIEELVGTDKKLPQAGKS  
A.fumigatus  YWLPNFMDVFTWSLPFVGEKITDMLIAILNTCSKEELEDETPTSVSPS------------  
 
H.sapiens    -----------------ATAAARKEVIRNKIRAIGKMARVFSVLREESESVLTLKGLTPT  
M.musculus   -----------------ATAAARKEVIRNKIRAIGKMARVFSVLREESESVLTLKGLTPT 
G.gallus     -----------------ATAAARKEVIRNKIRAIGKMARVFSVLREESESVLTLKGLTPT  
C.elegans    -----------------GVGSARKEVIRHKIRAIGKMARAFSVLREESESVLALKGLTPT  
S.cerevisiae EAAPQPATSASPKHASILDDEHRRKALRNKILAVAKVSRMYSVLREETNKVQFLKDH-NS  
A.fumigatus  --AP-----SPPLPMDVESSEFKRRAIKNKILAIGRLSRVFQVLREESERVTELKTA-AG  
 
Figure 4.3. CLUSTAL Omega alignment of the intrinsically disordered regulatory domain of 
orthologous calcineurins.173  
The CaM-binding site is shown in blue and has a net positive charge. On either side of the 
CaM-binding site are well-conserved acidic patches shown in red. 
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Regulatory domain (RD) construct: 
        10         20         30         40         50         60 
MAGSDDELGS EEDGFDGATA AARKEVIRNK IRAIGKMARV FSVLREESES VLTLKGLTPT  
        70         80         90        100        110 
GMLPSGVLSG GKQTLQSATV EAIEADEAIK GFSPQHKITG WGGGLEHHHH HH 
 
 
pCaN peptide: 
 
        10         20  
CGARKEVIRN KIRAIGKMAR VFSVLRGGW 
 
 
Figure 4.4. Sequence information for the RD and pCaN constructs used in this project.  
The RD construct is a 112-residue protein containing the entire intrinsically 
disordered region of CaN. The RD contains the CaM-binding site (shown in blue) surrounded 
by two highly conserved acidic patches (shown in red and orange). Underlined residues 
represent residues that were mutated to positively charged residues in full-length CaN to 
investigate the role of the flanking net negatively charged patches.  
The RD contains a His-tag on the C-terminal end to aid in its purification. The pCaN 
peptide contains the net-positively charged CaM-binding site of the RD. An N-terminal 
cysteine and glycine linker was added to pCaN so that it can labeled with cysteine reactive 
fluorescence dyes for future experiments. A C-terminal tryptophan was mutated into the 101 
position of the RD construct and added the C-terminus of pCaN to increase the accuracy of 
protein concentration determination by UV/Vis. 
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Figure 4.5. CD to measure the effects of ionic strength on CaM, CaM:pCaN, the RD, and CaN.  
A) and B) CD of CaM and CaM:pCaN complex in 20mM Tris (pH 7.5) and either 0.25M, 1M, or 
2M NaCl at 37°C. A) Comparison of the CD of CaM and CaM-Acr in the presence of either 0.25M 
or 2M NaCl. B) Comparison of the CD of CaM:pCaN and CaM-Acr:pCaN in the presence of 
either 0.25M or 2M NaCl.  
C) CD of CaN and the RD in 20mM Tris (pH 7.5) and either 0.25M, 1M, or 2M NaCl at 
37°C. Signal noise was observed below 205nm for all CD spectrum with either 1M or 2M NaCl 
present which is due to the high concentrations of salt. CD spectra shown are the average of 
three independent experiments. 
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Figure 4.6. Molar ellipticity at 222nm of CaM and CaM-Acr. 
Molar ellipcitiy at 222nm of CaM and CaM-Acr in the absence A) or presence B) of pCaN at 
0.25M, 1.0M, and 2.0M NaCl. These data include are the average of 3 independent CD 
experiments and error bars represent the standard deviation.  
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Figure 4.7. Molar ellipticity at 222nm of CaN  
Molar ellipticity at 222nm of CaN A) and the RD B) construct at 0.25M, 1.0M, and 2.0M NaCl. 
These data include are the average of 3 independent CD experiments and error bars 
represent the standard deviation. 
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Figure 4.8. Comparison of CaM:pCaN (green) and CaM:pCaMKI (gray) complexes showing 
close similarities in the binding modes. RMSD = 2.6Å. CaM:pCaN from 4Q5U92, and 
CaM:pCaMKI from 2L7L157  
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Figure 4.9. ITC of CaM and CaM-Acr binding to pCaMKI.  
Representative ITC titrations of pCaMKI injected into either CaM A) or CaM-Acr B). A) 50μM 
pCaMKI injected into 5μM unlabeled CaM. B) 50μM pCaMKI injected into 5μM CaM D3C 
labeled with acrylodan (CaM-Acr). All ITC was performed under identical conditions and 
buffers. The jacket temperature was set to 37°C. Proteins and peptides were buffer exchanged 
into 20mM HEPES (pH 7.5), 250mM NaCl, and 10mM CaCl2. Two independent ITC 
experiments were performed for each CaM-Acr and CaM. 
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Figure 4.10. Ca2+-binding affinities for the N-lobe and C-lobe of CaM in A) 20mM HEPES (pH 
7.5) and 250mM NaCl and B) 20mM HEPES (pH 7.5) and 2M NaCl. The Ca2+-binding affinity 
for both lobes decreases significantly due to electrostatic screening. Titration curves are the 
average of three independent experiments. 
B 
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Figure 4.11. A) Fluorescent emission spectra of 0.2μM CaM-Acr in the presence and absence 
of 2μM pCaN, RD, and CaN at 37°C. Samples were excited at 365nm and contained 20mM 
HEPES, 250mM NaCl, and 10mM CaCl2. Fluorescence emission data are the average of two 
independent experiments. B) The injection of 200μM CaN into 48μM CaM-Acr resulted in 
quenching of CaM-Acr fluorescence when 10mM CaCl2 was present but not in the presence of 
10mM EGTA. 
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Figure 4.12. Representative association data for CaM-Acr binding to pCaN, RD, and CaN. 
Experimental data were fit to either a single (Equation 1) or double exponential decay 
(Equation 2). Both models resulted in randomly distributed residuals.  
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Figure 4.13. A) Association rate constants of CaM-Acr interacting with pCaN, RD, CaN, CaN 
E376R, E381RC or CaN E415K, E418K at varying ionic strengths B) Debye-Hückel plot of the 
association rate constants. Electrostatic energy of interaction (U) is calculated from the slope 
of ln kon vs. 1/1+κa. Each association rate constant was the average of two independent 
experiments. 
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Figure 4.14. Net charge per residue (NCPR) of the RD (A), RD E376R, E381R (B), and RD 
E415K, E418K (C).  
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Figure 4.15. Das-Pappu plot of pCaN, RD, and the two halves of the RD construct; N-termRD 
and C-termRD. While the RD is predicted to be in the “buffer” region between weak and strong 
electrolytes, the two halves of the RD, N-termRD and C-termRD are considered weak and 
strong polyampholytes, respectively. The amino acid sequence of the RD was sectioned into 
1/5ths to analyze the conformational ensemble of small sections of the RD (i.e 1 is the first 
1/5 of the RD, 2 is the second 1/5 of the RD) 
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Figure 4.16. Linear net charge per residue plot of CaM using CIDER. The 75th residue (also 
shown as a highly positively charged region in blue) represents the center linker connecting 
the two lobes of CaM.  
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Table 4.1. Net charges of protein constructs at pH 7.5 were calculated using Protein Calculator 
v3.4 (protcalc.sourceforge.net). The net charges of CaM, CaN, and CaN E415K, E418K were 
increased by +8 to account for the Ca2+-bound state of these molecules. 
Protein/Peptide: Net Charge at pH 7.5: 
CaM - calmodulin -16.2 
pCaN (peptide of CaM-binding region) +6.7 
RD – regulatory domain -3.7 
CaN – full-length calcineurin 
CaN E376R, E381R 
CaN E415K, E418K 
-13.7 
-9.7 
-9.7 
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Table 4.2. The Ca2+-binding affinity of CaM at 0.25M and 2.0M NaCl at 37°C. 20mM HEPES (pH 
7.5) was present is all samples.  
 KD at 0.25M NaCl (μM) KD at 2.0M NaCl (μM) 
CaM N-terminal lobe 4.0 ± 0.5 77 ± 18 
CaM C-terminal lobe 0.40 ± 0.05 160  ± 20 
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Table 4.3. R2 values for the fit of single and double exponential decay equations to the kinetics 
traces shown in Figure 4.8. Single exponential decay model was chosen because double 
exponential models did not give a significantly better fit. Also, some of the rate values of the 
double exponential gave impossibly long rates. See Appendix for a complete list of fits. 
CaM-substrate Single Exponential R2 Double Exponential R2 
pCaN 0.516 0.518 
RD 0.970 0.970 
CaN 0.959 0.964 
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Table 4.4. Estimated energies of electrostatic interaction and kon basal values for the 
association of CaM-Acr with pCaN, RD, CaN, CaN E415K, E418K, and CaN E376R, E381R. 
CaM substrate kon,basal  
(x 107 M-1 s-1) 
Energy of Electrostatic Interaction 
(U) (kcal mol-1) 
pCaN 2.16 ± 0.05 -6.7 ± 0.6 
RD 1.5 ± 0.04 -5.8 ± 0.6 
CaN 
CaN E415K, E418K 
CaN E376R, E381R 
0.21 ± 0.01 
0.013 ± 0.0006 
0.11 ± 0.01 
-6.3 ± 0.8 
-12 ± 0.8 
-7.1 ± 0.8 
 
 
 
 
 
 
 
 
 
Copyright ©  Erik Curtis Cook 2016 
 
 
114 
CHAPTER 5: SLiMs of RCAN1-4 and inhibition of calcineurin activity 
 
5.1 Introduction 
Calcineurin(CaN) is a Ser/Thr phosphatase which connects Ca2+-signaling to 
intracellular responses.4,62 Some of these intracellular responses include those important for 
immune system activation, pathological cardiac hypertrophy, and long-term potentiation. 
Several studies have suggested that the overexpression of CaN or its chronic activation can 
directly lead to detrimental phenotypes in the heart such as hypertrophy, fibrosis, and 
eventually cardiac cell death.27,30,31,174,175  
CaN inhibitors such as cyclosporine A can prevent the development of pathological 
cardiac hypertrophy.32 Cyclosporine A is a common immunosuppressant used in organ 
transplantation to prevent rejection of transplanted organs.176 Cyclosporine A forms a 
complex with the immunophilin cyclophilin, and this complex binds directly to and inhibits 
CaN activity.177 FK506 is another commonly used CaN inhibitor and immunosuppressant 
which forms a complex with the immunophilin known as FK506-binding protein (FKBP). 
Although FK506 and cyclosporine A are excellent CaN inhibitors, they “hijack” their 
respective immunophilins and inhibit their activity.178–180 The immunophilins cyclosporine 
and FKBP are known as peptidyl-prolyl cis-trans isomerases (PPIases) which catalyze the 
interconversion between cis and trans proline rotamers. The interconversion between 
proline rotamers is one of the rate-limiting steps in protein folding, and PPIases assist 
proteins in forming their final native structure.178,181–183 Thus, CaN inhibition by FK506 and 
cyclosporine A have potential side effects arising from immunophilin inhibition which as of 
yet have not been distinguished from CaN inhibition. Structural information needed to 
develop CaN specific drugs could be derived from the study of CaN with endogenous 
inhibitors. One such inhibitor described here is the regulator of calcineurin or RCAN. 
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CaN is a heterodimer with a catalytic A chain which houses the catalytic, B-chain 
binding, regulatory, and autoinhibitory domains. In its inactive state, the active site of CaN is 
occupied by the autoinhibitory domain which prevents the hydrolysis of any phosphorylated 
serine or threonine.66 It is not until CaM binds to the intrinsically disordered regulatory 
domain of the CaN A chain that the autoinhibitory domain is released and CaN is fully 
active.3,63 The B chain of CaN is a Ca2+-binding subunit that is structurally homologous to 
calmodulin (CaM) and forms a critical binding site with the A chain needed for CaN-ligand 
interactions.34,66 This ligand interaction site at the interface between the A and B chains of 
CaN is known as the LxVP-binding site (Figure 5.1, orange site) because it binds the consensus 
amino acid motif ”LxVP” where “x” is any amino acid. CaN’s other known substrate binding 
site is known as the PxIxIT-binding site (Figure 5.1, green site) which interacts with 
substrates that contain the consensus motif, “PxIxIT”.  
An endogenous CaN inhibitor known as the regulator of calcineurin 1 (RCAN1) can 
attenuate the pathological signaling leading to cardiac hypertrophy. There are three isoforms 
of RCAN; RCAN1, RCAN2, and RCAN3.184 All three RCAN gene families express proteins that 
are capable of binding to and inhibiting CaN activity.16,185–187 The RCAN1 family has two main 
transcripts; RCAN1-1 and RCAN1-4. The amino acid sequence of RCAN1-1 and RCAN1-4 are 
shown in Figure 5.2. The only difference between RCAN1-4 and RCAN1-4 is that RCAN1-1 
contains an extra 55 amino acids on the N-terminus, but all other residues are identical 
between these two isoforms.  RCAN1-1 is upregulated by glucocorticoid and Notch-
dependent signaling.188,189 RCAN1-4 is upregulated in response to CaN signaling and 
represents a negative feedback mechanism for CaN signal transduction.61,190 Rothermel et al. 
and others have shown that overexpression of a constitutively active mutant of CaN in the 
hearts of mice led to the development of pathological cardiac hypertrophy. This transgenic 
model showed similar phenotypes to pathological cardiac hypertrophy in humans, namely, 
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cardiac fibrosis, increased cell death, and enlargement of the cardiac muscles.5 The 
overexpression of RCAN1 along with the constitutively active form of CaN prevented the 
development of the hypertrophy phenotype.174 This makes the study of the RCAN/CaN 
interaction a promising venture for the development of CaN inhibitors.174 
The CaN-binding domain of all RCANs is an intrinsically disordered region which 
contains little to no stable three-dimensional structure and it is known that multiple different 
regions of RCAN1-4 interact with CaN.20 Intrinsically disordered regions commonly contain 
linear binding motifs to which other proteins can interact and form higher order 
structures.191,192 These linear motifs are commonly referred to as short linear motifs or SLiMs 
and serve as protein binding sites.87 SLiMs can be identified by analyzing the binding of small 
peptides that resemble sections of the IDP in question. There have been studies investigating 
the interaction of the CaN-binding domain of RCAN1-4 with CaN, and four SLiMs have been 
identified. Many proteins, including RCAN1-4 and CaN, contain at least a 30-residue long 
intrinsically disordered region (IDR).150  It is important to identify and understand all SLiMs 
in a protein to further elucidate how the protein interacts with its partners.  
The four SLiMs identified in RCAN1-4 are shown in Figure 5.2. There is also one 
putative SLiM, the “HLAPP” motif, that is included in this list, but there is no direct evidence 
for its interaction with CaN. In the list below, the motifs have been given shorter names for 
brevity. The actual motif which has been shown to bind is much larger than the short motif 
names given. Currently, the following SLiMs in RCAN1-4 have been identified;  
1. The “LxVP” motif is shown in yellow and red. The “FLISPP” motif shown in yellow 
in Figure 5.2 is known to interact with CaN and inhibit its activity. The FLISPP motif is very 
well conserved throughout all three RCAN genes (named RCAN1, RCAN2, and RCAN3).57 
Despite this common motif in all the RCAN families, its role in CaN inhibition is not well 
described.20,58 Thus, we aim to investigate this region further. Another LxVP-like motif in 
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RCAN1-4 is the “HLAPP” motif shown in red in Figure 5.2. There is no current information on 
the HLAPP motif to suggest that it inhibits or binds to CaN. The HLAPP motif is a putative 
LxVP-like substrate which we characterize here, and was initially recognized by Grigoriu et 
al. as a potential LxVP motif.95  
2. The “ELHA” motif is shown in purple. This motif has a low affinity compared to 
other RCAN1-4 motifs discussed here.58 These same studies show that this motif is required 
for in vivo inhibition of the CaN signaling pathway, but is not necessary for CaN binding.  
3. The “PxIxIT”-like motifs shown in green. There are two proposed PxIxIT motifs in 
the sequence of RCAN1-4.21 Each of these PxIxIT motifs is proposed to bind to the PxIxIT-
binding site of CaN (Figure 5.1, green site). The N-terminal “PxIxIT”-like motif in RCAN with 
the sequence identity “PSVVVH” is known to bind to CaN and competes with the PxIxIT motif 
of NFAT. 
The exact mechanism by which the RCAN1-4 SLiMs inhibit CaN activity is unknown 
although some mechanisms have been proposed. Previous reports suggest that RCAN1-4 
inhibits CaN activity by competing with CaN-substrates for CaN binding. CaN-substrates 
share common mechanisms of CaN-binding by utilizing similar binding sites on CaN. A shared 
binding site on CaN utilized by CaN-substrates is the PxIxIT-binding site which is located near 
the green region in Figure 5.1. Only the PSVVVH motif of the PxIxIT motifs in the RCAN1-4 
sequence (Figure 5.2, green residues) has experimental evidence that shows it inhibits CaN 
activity.21 
Many known CaN-substrates bind to CaN at the interface of A and B chains (Figure 1, 
orange region).34,35,94,95 This binding site shown in orange in Figure 5.1 is known as the LxVP-
binding site because typically SLiMs with the consensus sequence “LxVP” interact with this 
site. There are two putative LxVP motifs in RCAN1-4; the FLISPP motif (Figure 5.2, yellow 
residues) and the HLAPP motif (Figure 5.2, red residues). The FLISPP motif has been shown 
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to be sufficient for CaN inhibition, but no structural information has been elucidated. The 
HLAPP region is another LxVP-like motif which has not been characterized previously, but 
we begin to characterize here. Our starting hypothesis was that the HLAPP and FLISPP motifs 
are both LxVP-binding site ligands, and that they confer the competitive inhibition seen in 
RCAN1-4 for the LxVP-binding site. We focus on characterizing the LxVP-like motifs of RCAN 
because they are well-conserved throughout RCAN1, RCAN2, and RCAN3 genes from yeast to 
humans.20,57,187 We show that not only does a peptide of the HLAPP motif interact with CaN, 
but also inhibits CaN activity in a similar mechanism to the FLISPP motif.  
  
5.2 Results 
 5.2.1 RCAN1-4 Structure 
No reports exist on the structure of full-length RCAN1-4, so we probed the structure 
of RCAN1-4 using circular dichroism. Previous reports of different constructs of RCAN1-4 
suggest that the C-terminal half of the protein is intrinsically disordered.20 The Predictor of 
Naturally Disordered Regions (PONDR) program on the sequence of RCAN1-4 predicts the 
occurrence of intrinsically disordered regions given only a protein sequence.104–106 
Intrinsically disordered proteins or intrinsically disordered regions have a relatively high 
proportion of polar and charged residues and a low proportion of aromatic and non-polar 
residues. PONDR predicts intrinsically disordered regions based on these sequence 
parameters common to IDPs.85 Around 25% of RCAN1-4 is predicted to be intrinsically 
disordered (Figure 5.3). Most of this disordered content is contained in the C-terminal half of 
RCAN1-4 which houses the known CaN-binding motifs.  
An NMR solution structure of the first 104 residues of the N-terminus of RCAN1-4 in 
the PDB shows that the residues 1-80 of RCAN1-4 adopts an RNA-recognition motif (RRM) 
domain configuration (http://www.rcsb.org/pdb/explore/explore.do?structureId=1WEY), 
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but no publication is associated is associated with this PDB entry (Figure 5.4). At the time of 
writing, no known substrates of the RMM domain of RCAN1-4 are known. To begin to 
investigate the structure of RCAN1-4 circular dichroism (CD) was performed on the full 
RCAN1-4 construct (Figure 5.5A). CD can be used to measure the secondary structural 
content of a protein. CD spectra can be analyzed using DiChroWeb, an online web service 
which predicts the amount of α-helices, β-strands, and disordered segments. We used 
DiChroWeb to predict the secondary structural content of our RCAN1-4 construct and the 
results are shown in Table 5.1. Analysis of RCAN1-4 indicates the presence of β-strands and 
α-helices, which is consistent with the NMR structure of the N-terminus of RCAN1-4 shown 
in Figure 5.4. Our DiChroWeb results also predict that most of RCAN1-4 (54.1%) is 
disordered. Folded proteins can be induced to unfold by subjection to high temperatures. 
Observations of an unfolding process can confirm the presence of a folded structure. 
Collecting CD spectra from 5-45°C indicate no variation in protein structure at low 
temperatures, but aggregation was observed above 50°C. The aggregation of RCAN1-4 at high 
temperatures indicate non-reversible unfolding, but further experiments will need to be 
performed to show this is the case. 
 5.2.2 IC50 and KD of RCAN1-4 
We hypothesized that if the key CaN-binding and inhibitory motifs are contained in 
the CaN-binding domain of RCAN1-4, then our full-length RCAN1-4 construct should inhibit 
and bind to CaN with a similar affinity compared to the previously reported protein construct 
of the containing only the CaN-binding domain of RCAN1-4. Consequently, this we would 
predict that RRM domain does not contain any significant CaN-binding motif. To test the 
inhibitory potential of RCAN1-4, we utilized a CaN/RII assay which measures the 
phosphatase activity of CaN against a peptide of one of its endogenous-like substrates, the 
regulatory subunit type II of protein kinase A or RII for short. We determined the IC50 of 
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RCAN1-4 to be 134 ± 25nM with a Hill coefficient of 1.5 ± 0.2(Figure 5.6A, Table 5.2). A Hill 
coefficient of >1 would suggest that the stoichiometric ratio of RCAN1-4:CaN is 2:1 or greater. 
The IC50 of RCAN1-4 is comparable to other inhibitors of CaN, such as cyclosporine A, which 
has an IC50 in the nanomolar range.176 
We investigated the affinity of RCAN1-4 and CaN further to corroborate our IC50 and 
to see what we could learn from the direct interaction of CaN and RCAN1-4. To measure the 
binding affinity, we utilized fluorescence anisotropy. The RCAN1-4 construct was labeled 
with a thiol-reactive dye, Alexa-488 maleimide. There is one endogenous cysteine which is 
located in the RRM domain (Figure 5.3) and is distal to the proposed CaN-binding sites on the 
C-terminus. Thus, the presence of the Alexa 488 dye should not greatly affect the interaction 
between RCAN1-4 and CaN. Different upper baseline at saturating concentrations of CaN 
were observed in our anisotropy data (Figure 5.6B). We speculate that is due to alterations 
in the conformation of CaN due to Ca2+-binding. The binding of the N-terminal lobe of CaNB 
to CaNA is dependent on the presence of Ca2+.64 The radius of gyration and the change in 
anisotropy of RCAN1-4:CaN complex could be different depending on whether CaNB is bound 
to Ca2+. The KD of CaN and RCAN1-4-488 was found to be Ca2+-dependent. The presence of 
2mM CaCl2 increased the affinity of RCAN1-4 and CaN by 2-fold relative to in the presence of 
2mM EGTA (Table 5.3, Figure 5.6B). In contrast, adding CaM did not appear to affect the KD 
between RCAN1-4 and CaN.  
 5.2.3 RCAN1-4 is a competitive inhibitor of CaN/RII activity 
While the IC50 is an indicator of RCAN1-4’s affinity, it cannot tell us the mode of 
inhibition (i.e competitive, non-competitive, or uncompetitive). Determining the type of 
inhibition can also give structural information of the RCAN1-4 binding site. To achieve this, 
the Michaelis-Menten kinetic parameters (Vmax and Km) must be determined. At each 
concentration of RCAN1-4, the Vmax of the CaN/RII assay remained constant, but the Km 
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increased (Table 5.4, Figure 5.7). Modulation of the Km of the CaN/RII reaction as a function 
of [RCAN1-4] is an indicator of competitive inhibition where the inhibitor (RCAN1-4) and 
substrate (RII) directly compete for the one or more of the same binding sites.193 The RII 
peptide is known to bind to two sites on CaN: the LxVP-site (orange in Figure 5.1) and the 
active site (black circle in Figure 5.1). Therefore, RCAN1-4 must interact with at least one, if 
not both, of these sites. The question then becomes, “Which site does RCAN1-4 interact with?” 
Occlusion of the active site of CaN can be determined by measuring the activity of CaN with 
para-nitrophenyl phosphate (pNPP) as the phosphorylated substrate.83 The substrate pNPP 
binds directly to the active site of CaN. RCAN1-4 concentration appeared to have no 
measurable effect on the activity of CaN towards pNPP, suggesting that RCAN1-4 does not 
bind to the active site of CaN (Table 5.5).   
 5.2.4 Two LxVP motifs in RCAN1-4? 
Analysis of the sequence of RCAN1-4 suggests two potential LxVP motifs (highlighted 
in red and orange in Figure 5.2).  Two non-overlapping peptides were synthesized 
corresponding to these regions, pHLAPP (Figure 5.2, red) and pFLISPP (Figure 5.2, orange). 
The sequence of these peptides are: 
pHLAPP:  CGSSHLAPPNPGW 
pFLISPP: CGKQFLISPPASPPVGW 
A C-terminal Trp was added to each of these peptides to increase the accuracy of peptide 
concentration determination by UV/Vis.  An N-terminal Cys was added so these peptides 
could be fluorescently labeled with thiol-reactive fluorescent dyes. 
Interestingly, both of these peptides inhibited CaN/RII activity (Fig 5.9A). The IC50 
and Hill coefficient were determined using Equation 5.4. In contrast, a control peptide had no 
effect on CaN/RII activity. The control peptide has the sequence CKKAAAGAAAKKW and does 
not bind to CaN, but was used to measure the effects of other compounds which are co-
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purified with synthesized peptides (such as trifluoroacetic acid and β-mercaptoethanol). It 
was observed in our IC50 data with pFLISPP that there is a sharp downward trend in the 
activity of CaN/RII shown in Figure 5.9A (shown using dotted line) and no baseline at low 
concentrations of pFLISPP. Thus, the true IC50 for our pFLISPP inhibition data should be 
regarded as equal to less than what was calculated by fitting to equation 5.4 (≤ 2.5µM) (Table 
5.2).  The IC50 of pFLISPP was found to be lower compared to that of pHLAPP, suggesting that 
pFLISPP has a higher affinity. Consistent with the full-length RCAN1-4 construct, these 
peptides were also competitive inhibitors of CaN/RII activity (Table 5.6, Figure 5.8B) as noted 
by the higher Km in the presence of inhibitor and no effect on the Vmax.  
Further information on the binding of each of the pHLAPP and pFLISPP was gathered 
by fluorescently labeling pHLAPP and pFLISPP with acrylodan. Acrylodan was chosen as the 
fluorescent dye because it is relatively small compared to other dyes commonly used to 
measure fluorescence anisotropy and ligand binding. The KD was determined by plotting the 
measured fluorescence anisotropy of either pHLAPP-Acr or pFLISPP-Acr against the various 
concentration of CaN in the presence of 5mM Ca2+ and CaM (Table 5.7, Figure 5.8C). The KDs 
for pFLISPP and pHLAPP were found to be 5.6µM (±0.8) and 12µM (±1) respectively. 
Consistent with the IC50 determined for pHLAPP and pFLISPP, pFLISPP binds to CaN with a 
higher affinity.  
5.3 Discussion 
 5.3.1 RCAN1-4 structure and function 
The C-terminal half of RCAN1-4 is sometimes known as the calcineurin-binding 
module (CBM) and contains four discrete sites that are known to be sufficient for CaN binding 
and inhibition and one site that is putative for CaN-binding.20,21,59 RCAN1-4 is identified as 
being at least partially disordered from experimental data from Chan et. al. and predictions 
from PONDR (Figure 5.3).20 Figure 5.3 shows our PONDR prediction for RCAN1-4 showing 
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that the RRM domain is predicted to be folded, and most of the CBM of RCAN1-4 is predicted 
to be disordered. Our DiChroWeb analysis of the CD spectrum of RCAN1-4 predicts that 
54.1% of RCAN1-4 is disordered. PONDR predicted that around 25% of RCAN1-4 contained 
disordered regions. The reason for this discrepancy could be due to way in which we quantify 
disordered content from CD spectra. CD is an excellent tool for quantifying the content of α-
helices and β-strands because CD spectra in the 200-260nm range is reflective of the φ and 
ψ angles of a polypeptide. The φ and ψ angles for α-helices and β-strands can be rather 
similar from protein to protein, but disordered proteins take on different ensembles of φ and 
ψ angles which leads to different disordered proteins having different CD spectra.101 Our 
DiChroWeb analysis of RCAN1-4’s CD spectrum uses CD spectra of proteins that are known 
to be disordered as a reference to estimate the disordered content. This quantification of 
disordered content from CD spectra may be quite limited in its accuracy relative to α-helices 
and β-strands. 
The fact that the CBM of RCAN1-4 is disordered comes with a great experimental 
advantage. Peptides representative of the CBM of RCAN1-4 can be generated without 
disruption of any stable three-dimensional structure. Binding and inhibition mechanisms of 
specific regions of RCAN1-4 can be studied. 
Full-length RCAN1-4 is a tight-binding inhibitor with an IC50 of 134 ± 25nM with a Hill 
coefficient of 1.5 ± 0.2 (Figure 5.6A, Table 5.2). We observed that the maximal anisotropy 
observed for the RCAN1-4 binding to CaN in the absence of Ca2+ was higher than that of 
RCAN1-4 binding to CaN in the presence of Ca2+. We speculate that this might be due to 1) 
conformational differences in the structure of Ca2+-bound CaN from apo-CaN and/or 2) 
RCAN1-4 interacts with Ca2+-bound CaN differently than apo-CaN.  Previous data from Yang 
and Klee suggest that in apo-CaN the LxVP-bindign site of CaN interacts with the CaM-binding 
site which may lead to discreased accesbility of the LxVP-binding site. Exposure of the LxVP-
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binding site upon the addition of Ca2+ to CaN allows RCAN1-4 to bind tighter to CaN perhaps 
leading to a more collapsed state of RCAN1-4. A Hill coefficient of 1.5 would indicate more 
than one RCAN1-4 could bind to CaN, and that this binding is cooperative. More on the 
significance of cooperativity and multiple binding events of CaN and RCAN1-4 will be 
discussed below. In comparison, the well-studied CaN inhibitors, FK506/FKBP, and 
cyclosporin A/cyclophilin have an IC50 ranging from 47 to 17,000nM.194,195 There are 6 known 
FKBPs with different affinities for FK506. These FK506/FKBP complexes also show a wide 
range of affinities for CaN resulting in different inhibitory potentials.194  A238L, a CaN 
inhibitor encoded by the African Swine Fever Virus, is one of the tightest binding inhibitors 
of calcineurin with an IC50 less than 1nM.95  Since the absolute value of the IC50 for an inhibitor 
is dependent on the concentration of substrate (in our case RII), it is not always valid to 
compare IC50 values across experimental studies.  
We can determine how RCAN1-4 binds in relation to the RII peptide by determining 
the type of inhibition; competitive, non-competitively, and uncompetitive. Since these types 
of inhibition affect the Michaelis-Menten parameters Km and Vmax in different ways, we can 
determine the mode of inhibition of RCAN1-4 by performing CaN/RII assays at a range of RII 
concentrations with various concentrations of RCAN1-4 present (Figure 5.7, Table 5.4). The 
observed changes in the Km of the CaN/RII assay as a function of [RCAN1-4] were similar to 
what we expected for an inhibitor with a KD of 38nM. The apparent effects of a competitive 
inhibitor on the Km of an enzymatic reaction is related via the equation: 
𝐾𝑚,𝑎𝑝𝑝 = 𝐾𝑚 [1 + 
[𝐼]
𝐾𝑖
] 
where Km,app is the observed Km in the presence of inhibitor, Km is the Km of the 
enzyme/substrate reaction in the absence of inhibitor, [I] is the concentration of inhibitor, 
and Ki is the concentration of inhibitor that results in half complete inhibition. Thus, if the Ki 
of CaN and RCAN1-4 is similar to the KD, we would expect that the Km,app of a CaN/RII assay in 
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the presence of 0.2µM RCAN1-4 to be around 200µM which is close to our actual data point 
of 105µM. 
 Since the variation in the Km and the Vmax are fundamental in the understanding the 
type of inhibition, it is important to understand the nature of these values. The Vmax is the 
maximal activity of an enzyme (in our case CaN) given that the substrate (i.e RII) is at 
saturating concentration. The Km is the concentration of substrate that results in half-
maximal activity. The Km is indirectly related to the affinity, so as the affinity of the inhibitor 
to the enzyme increases, the Km will decrease.   
The exact way in which an inhibitor will alter these values will depend on how it 
interacts with the enzyme relative to the substrate. For instance, a noncompetitive inhibitor 
interacts with a site on the enzyme that does not overlap with the substrate-binding site. The 
binding of the inhibitor results in a conformational change of the enzyme that prevents the 
substrate from binding and a decrease in the Vmax, but the Km is not affected. In uncompetitive 
inhibition, the inhibitor binds the enzyme substrate complex, resulting in a greater affinity 
for the substrate for the enzyme and a decrease in the Km, but the inhibitor blocks enzymatic 
activity, shown as a decrease in the Vmax. The third type of inhibition is competitive inhibition, 
where an inhibitor more or less mimics the enzyme substrate and, thus, the inhibitor directly 
competes for binding sites that overlap with the substrate. Competitive inhibition results in 
an increase in the Km and the Vmax is not affected.196  
From our CaN/RII assay data, increasing concentrations of RCAN1-4 increase the Km, 
but do not affect the Vmax, which suggests competitive inhibition. Therefore, RII and RCAN1-4 
must at have at least partially overlapping binding sites on CaN. The RII peptide is known to 
interact with two sites on CaN: the LxVP-binding site (Figure 5.7, orange) and the active site 
(Figure 5.7, circled).35 Thus, RCAN1-4 may be interacting with the LxVP-binding site and/or 
active site.  
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We chose to investigate these results further and elucidate which sites (perhaps both) 
RCAN1-4 binds. If RCAN1-4 binds to the active site, then CaN activity with the small 
phosphatase substrate para-nitrophenyl phosphate (pNPP) should decrease because of the 
occlusion of the active site. If RCAN1-4 is binding to the active sites, then pNPP diffusion into 
the active site should be reduced as well. Binding of the C-terminal autoinhibitory domain 
(AID) to the active site of CaN has been shown to decrease CaN/pNPP activity.143 We did not 
see a decrease in CaN/pNPP activity with a similar concentration of RCAN1-4 that inhibited 
CaN/RII activity (Figure 5.8). Thus, this would seem to suggest that RCAN1-4 competes with 
the LxVP motif of the RII peptide. The fact that RCAN1-4 did not inhibit CaN/pNPP activity 
was surprising because Chan et al. had shown that a smaller protein construct of a section of 
the CaN-binding domain of RCAN1-4 was a competitive inhibitor of CaN/pNPP activity. This 
would suggest that the region of RCAN1-4 that they investigated occluded the active site of 
CaN, but we are unsure why it was not observed in our CaN/pNPP assays.  
 
5.3.2 RCAN1-4 interacts with the LxVP-binding site of CaN 
The LxVP motif is a common CaN-binding motif present in many CaN targets.34,94–96 
The Cyert and Peti groups have shown that peptides containing LxVP motifs bind to CaN at 
the interface between the A and B chain (Figure 5.1, orange).35,95 Two LxVP-like motifs were 
found when investigating the sequence of RCAN1-4 (Figure 5.2, red and yellow regions). One 
of these regions, the “FLISPP” site shown in orange, is the highly conversed and defining 
sequence for all RCAN family members.57 Interestingly, another LxVP-like motif was found 
within 10-residues N-terminal to the FLISPP motif (Figure 5.2, red), the HLAPP motif. Two 
peptides were synthesized that contain non-overlapping sequences identical to the “HLAPP” 
or “FLISPP” motifs. Both the pFLISPP and pHLAPP peptides were shown to bind to CaN 
(Figure 5.8C, Table 5.7). Also, both peptides inhibited CaN/RII activity (Figure 5.8A,B, Table 
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5.6). The peptides pFLISPP and pHLAPP both had inhibitory potentials that were weaker 
compared to full length RCAN1-4. IC50 of each of the two peptides were estimated to be in the 
low micromolar range while the full-length RCAN1-4 had an IC50 in the low nanomolar range, 
suggesting that joining of the two inhibitory SLiMs (along with the other SLiMs) increases the 
overall affinity of inhibitor. This lends support for the hypothesis that these two regions could 
be potential LxVP motifs.  
The question then becomes, “What is the significance of two LxVP motifs?” IDPs can 
have multiple low-affinity binding sites utilized for interacting with their target proteins.87,197 
Thus, through the addition of numerous binding sites, the overall protein interacts with its 
target with a much higher affinity (process termed avidity). An alternative hypothesis could 
be that CaN has multiple LxVP-binding sites. Recently, NMR data published by the Wagner 
lab proposed that another LxVP-binding site exists that overlaps with the PxIxIT-binding site 
(Figure 5.1, green).198 The CaN construct used for NMR contained only the catalytic domain 
of the A-chain and did not have the LxVP-binding site at the interface of the A-chain and the 
B-chain. Further studies of these binding sites and their ability to bind LxVP motifs will need 
to be performed. 
An alternative hypothesis is that the two LxVP-motifs in RCAN1-4 could bind to both 
LxVP-binding sites of CaN, but only one interaction is occurring at a certain time. Thus, 
further investigation must be made to elucidate the mechanisms of RCAN1-4’s interaction 
with CaN. Discussion of the work by Mittag et al. on Sic1 interacting with Cdc4 will help to 
clarify this hypothesis. Sic1 is an intrinsically disordered protein that contains many 
phosphorylated repeat domains known as Cdc4-phophodegrons (CPD) domains which 
interact with the protein Cdc4.199 Sic1 and Cdc4 regulate the cell cycle and G1/S and G2/M 
transition.200s Interestingly, Cdc4 has a single CPD binding domain. Peptides with the 
sequence identity of a single CPD domain bind to Cdc4 in the high micromolar range, but Sic1 
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binds in the low micromolar range. Using NMR, Mittag et al. were able to show that multiple 
low affinity CPD domains conferred high affinity binding of the overall Sic1 protein. Perhaps 
a similar situation occurs between CaN and RCAN1-4. RCAN1-4 contains two LxVP-like motifs 
and maybe each low affinity LxVP-like motif of RCAN1-4 confers higher affinity of the overall 
RCAN1-4 protein to CaN. 
Despite there being two potential LxVP binding site that could interact with the two 
LxVP-like motifs in RCAN1-4, it is unlikely that these two LxVP motifs in RCAN1-4 could 
stretch the 38Å required to occupy both sites (Figure 5.1, dotted arrow). The “HLAPP” and 
“FLISPP” are only separated by around 5 residues which could only stretch ~17.5Å given 
these 5 residues were in a β-strand conformation. But, the affinity of RCAN1-4 is much higher 
than the affinity of either the pHLAPP or pFLISPP peptide. If we assume that either the 
“HLAPP” or “FLISPP” motif, but not both, bind to CaN, then we hypothesize other SLiMs of 
RCAN1-4 are important for coordinating a higher affinity.  
There is also the possibility that the sequence similarities on the HLAPP and FLISPP 
are coincidental and one of them is not an LxVP-binding site substrate. Recently, the Juvvadi 
et al. have discovered a potential substrate binding site on CaN which spatially lies between 
the LxVP-binding site and the PxIxIT-binding site.201 Figure 5.9 shows the structure of CaN 
with the novel interaction site called the FMDVF motif which is in red. This FMDVF site is 
directly in between the residues of the A-chain of CaN that form the PxIxIT-binding and LxVP-
binding sites. The PxIxIT-binding site is shown as a green β-strand on the catalytic domain. 
The LxVP-binding site is composed of both residues from the A-chain and B-chain of CaN and 
is shown in orange.  Juvvadi et al. found that mutation of the FMDVF motif in CaN disrupted 
substrate binding in the CaN-signaling pathway in A. fumigatus possibly due to 1) FMDVF is 
a substrate binding site, and its mutation results in loss of substrate binding, or 2) FMDVF 
motif plays some sort of structural role in CaN that is important for CaN-substrate binding to 
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the LxVP-binding or PxIxIT-binding sites. It is possible that one of the CaN-binding motifs of 
RCAN1-4 binds to the FMDVF motif of CaN. 
The affinity of RCAN1-4 and CaN has previously been reported to be 65nM using 
fluorescence anisotropy which is the same within the error of the data shown here.20 Chan et. 
al. reported on the binding affinity of RCAN1-4 and CaN only in the absence of Ca2+ or CaM. 
CaM and Ca2+ binding to CaN is critically important for the full and robust activation of CaN.62  
From our data, this would suggest that Ca2+ plays an important role in increasing the affinity 
of CaN for RCAN1-4. In the Ca2+-free state, the N-terminal lobe of the B-chain of CaN is not 
bound to the A-chain and the CaM-binding site interacts with the A-chain:B-chain interface 
which occludes the LxVP-binding site.64 Once the B-chain of CaN is saturated with Ca2+, the N-
terminal lobe binds to the A-chain and the CaM-binding site is released from the A-chain:B-
chain interface. Since RCAN1-4’s affinity for CaN is responsive to Ca2+, the B-chain of CaN 
would be a probable target for RCAN1-4 interaction. Exposure of the LxVP-binding site of CaN 
when CaN is bound to Ca2+ may help to mediate the observed 2-fold increase in affinity of 
RCAN1-4 and CaN. Further evidence that the LxVP-binding site mediates Ca2+-dependent 
affinity of CaN and CaN-substrates can be determined by perhaps inserting disruptive 
mutations in the LxVP-binding site of CaN or by deleting the LxVP-motifs of RCAN1-4 and 
measuring the binding affinity. We should observe no change in affinity of RCAN1-4 and CaN 
due to the addition of Ca2+ if the LxVP-binding site mediates Ca2+-dependent affinity changes. 
 
5.3.3 Cooperativity of binding of RCAN1-4 to CaN 
The Hill slope of the IC50 data of RCAN1-4 and CaN indicate potential cooperative 
binding because the Hill slope was greater than one. Cooperative binding of RCAN1-4 and 
CaN indicate conformational changes of either RCAN1-4 or CaN upon binding that promote 
higher order complex formation. Cooperativity necessitates a binding stoichiometry other 
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than 1:1. Based on this data we cannot definitively say whether two CaN are interacting with 
1 RCAN1-4 or if 2 RCAN1-4 proteins are interacting with one CaN. Determination of the 
stoichiometry of CaN and the pHLAPP and pFLISPP peptides can be achieved through 
isothermal titration calorimetry which is included in the future directions of these studies. 
Structural determination of CaN with these peptides or the full-length RCAN1-4 would be 
ideal and could answer not only binding stoichiometry but also specific interaction between 
RCAN1-4 regions and CaN which have yet to be determined.   
The pHLAPP and pFLISPP peptides showed a higher degree of cooperativity 
compared to RCAN1-4 (Table 5.2). The Hill coefficients for the pHLAPP and pFLISPP peptides 
was greater than 2.3, and RCAN’s Hill coefficient was 1.5. If the pHLAPP and pFLISPP peptides 
bind to CaN cooperatively, then more than one peptide must be binding to a single CaN. These 
data would support that there are two LxVP-binding sites on CaN’s surface and that the 
HLAPP and FLISPP region could bind to both regions. Moreover, assuming there are two 
LxVP-binding sites on CaN, the occupation of one LxVP-binding site allosterically regulates 
the other LxVP-binding site. Through site-direct mutagenesis of the known LxVP-binding site 
and introduction of residues that could disrupt quaternary structure, we can determine if 
these peptides are interacting with more than one LxVP-binding site.  
 Cooperativity could be achieved through the binding of inhibitors to non-specific 
regions of CaN, a hypothesis known as transient patch binding.202,203 We are assuming that 
the HLAPP and FLISPP regions have specific and stable binding sites on CaN (i.e LxVP-binding 
site). Before either the HLAPP and FLISPP interact with the specific binding site on CaN, these 
regions could interact with non-specific patches on the surface on CaN. Saturation of the non-
specific binding site of CaN with inhibitors could help “funnel” other inhibitor molecules to 
the specific inhibitor binding site which would represent a cooperative process. Prinz et al. 
has discussed this possibility by analyzing 280 different phosphatase inhibitor compounds 
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interacting with 7 different phosphatases.202 Hill coefficients of these data sets were shown 
to be determined by the structure of the phosphatase suggesting that specific structure of the 
phosphatase can more or less promote cooperative binding. In this case the pHLAPP or 
pFLISPP peptides could be binding to anywhere on the surface of CaN. But, as pHLAPP or 
pFLISPP concentrations rise, the surface of CaN becomes saturated with inhibitor molecules, 
and binding of the pFLISPP or pHLAPP peptides to the LxVP-binding site becomes more 
likely.  
5.3.4 Conclusion 
RCAN1-4 is a CaN inhibitor that is upregulated in response to CaN signaling.61 RCAN1-
4 upregulation could represent a negative-feedback mechanism that prevents runaway CaN 
activity. It has been shown that mice overexpressing a constitutively active form of CaN in the 
heart can lead to upregulation of CaN signaling and cardiac remodeling. This results in the 
loss of contractility and increase in cell death in the heart muscle.5  
If RCAN1-4 is indeed a negative feedback inhibitor, then why is constitutively active 
CaN signaling not halted in these transgenic mice? Understanding the stoichiometric ratio 
might present an interesting avenue of research for understanding how RCAN1-4 works. 
Does CaN bind more than one RCAN1-4? If so, are multiple bound RCAN1-4s required for CaN 
inhibition? Is the upregulation of RCAN1-4 brought on by CaN signaling not sufficient for 
complete CaN inhibition? There is much we don’t understand about the role of RCAN1-4 in 
regulating CaN activity. Some studies have even shown that RCAN1-4 can act as an activator 
of CaN activity at low [RCAN1-4].204 It’s important to note that these observations were made 
in vivo, so the precise concentration at which RCAN1-4 switches from an activator to an 
inhibitor is unknown. There are also other proteins in in vivo systems, and could mediate 
activation of RCAN1-4 toward CaN or perhaps post-translational modification of RCAN1-4 
could affect its inhibitory potential toward CaN.205  
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5.4 Chapter 5 figures and tables 
 
 
Figure 5.1. Surface representation of CaN with highlights of the commonly used binding 
utilized by CaN-substrates; LxVP-binding site in orange; PxIxIT-binding site in green; black 
circle centered on the active site. The LxVP site and PxIxIT site are ~38Å apart (dotted line). 
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RCAN_used       ------------------------------------------------------------ 
RCAN1-4         ------------------------------------------------------------ 
RCAN1-1         -------------------------------MEDGVAGPQLGAAAEAAEAAEARARPGVT  
 
 
RCAN_used       ------------------------GSMDFRDFSYNFSSLIACVANDDVFSESETRAKFES 
RCAN1-4         --------------------------MHFRNFNYSFSSLIACVANSDIFSESETRAKFES 
RCAN1-1     LRPFAPLSGAAEADEGGGDWSFIDCEMEEVDLQDLPSATIACHLDPRVFVDGLCRAKFES  
 
 
RCAN_used       LFRTYDKDTTFQYFKSFKRVRINFSNPLSAADARLRLHKTEFLGKEMKLYFAQTLHIGSS 
RCAN1-4         LFRTYDKDITFQYFKSFKRVRINFSNPFSAADARLQLHKTEFLGKEMKLYFAQTLHIGSS 
RCAN1-1         LFRTYDKDITFQYFKSFKRVRINFSNPFSAADARLQLHKTEFLGKEMKLYFAQTLHIGSS  
 
 
RCAN_used       HLAPPNPDKQFLISPPASPPVGWKQVEDATPVINYDLLYAISKLGPGEKYELHAATDPTP  
RCAN1-4         HLAPPNPDKQFLISPPASPPVGWKQVEDATPVINYDLLYAISKLGPGEKYELHAATDTTP  
RCAN1-1         HLAPPNPDKQFLISPPASPPVGWKQVEDATPVINYDLLYAISKLGPGEKYELHAATDTTP  
 
 
RCAN_used       SVVVHVCESDQENEEEEEEMERMKRPKPKIIQTRRPEYTPIHLS  
RCAN1-4         SVVVHVCESDQEKE-EEEEMERMRRPKPKIIQTRRPEYTPIHLS  
RCAN1-1         SVVVHVCESDQEKE-EEEEMERMRRPKPKIIQTRRPEYTPIHLS  
 
 
                 
 
Figure 5.2. Known RCAN1 isoforms from H. sapiens compared to RCAN1-4 construct used in 
this study which is from Mus musculus. Validated RCAN1 isoforms from H. sapiens were taken 
from NCBI’s Protein database and aligned using EMBL-EBI Clustal Omega with default 
settings.173  
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Figure 5.3. PONDR prediction suggesting the N-terminal half of RCAN1-4 containing the RRM 
domain (residues 1-80) is ordered and most of the CaN-binding domain (CBD) is disordered. 
 
 
 
 
 
 
 
RRM 
CBD 
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Figure 5.4. The NMR solution structure of the RNA-recognition motif (RRM) domain of RCAN 
from PDB entry 1WEY.  The residue in red is the only cysteine contained in the sequence and 
was labeled with Alexa-488. 
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Figure 5.5. A) CD spectrum of RCAN in 20mM Tris (pH 7.5) and 200mM NaCl at 20°C perhaps 
indicating a mixed α-helical and β-sheet secondary structural content. B) CD spectra of RCAN 
in 20mM HEPES (pH 7.5) and 200mM NaCl at 5, 10, 15, 20, 25, 30, 35, 40, and 45°C. HEPES 
was used as the pH buffer because its pKa has a smaller temperature dependence compared 
to Tris, but HEPES shows a strong absorption in the CD spectra below 215nm. CD spectra 
shown are from a single experiment. 
A 
B 
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Figure 5.6. A) Inhibition analysis of CaN/RII activity by RCAN. RII was present at 30µM and 
assay was performed at 30°C. Concentration of CaN, CaM, and CaCl2 was 30nM, 90nM, and 
1mM respectively.  The IC50 was determined to be 134 ± 25nM and a Hill coefficient of 1.5 ± 
0.2 (N=3). B) Binding analysis of RCAN1-4 labeled with Alexa-488 and CaN in either 2mM 
EGTA, 2mM CaCl2, or 10mM Ca2+ + 10μM CaM (N=3).  
A 
B 
138 
 
Figure 5.7. CaN/RII assay with various concentrations of RCAN present. Km and Vmax were 
determined by fitting to the Michealis-Menten equation (Equation 2) (N=3). The Km increased 
and the Vmax did not change with various [RCAN] suggesting RCAN is a competitive inhibitor. 
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Figure 5.8. A) pHLAPP and pFLISP peptides derived from sequences found in RCAN are 
effective inhibitors of CaN/RII activity with pFLISPP showing greater inhibitor potential 
A 
B 
C 
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(pFLISPP N=9, pHLAPP N=9, control peptide N = 3). B) Michaelis-Menten parameters were 
determined from CaN/RII assays in the presence or absence of 10μM of inhibitor peptides 
derived from RCAN. A greater decrease in the Km was noted for pFLISPP than for pHLAPP. 
Vmax was unaffected by the presence of inhibitor. N = 3 for all no inhibitor, pFLISPP, and 
pHLAPP assays. C) Fluorescence anisotropy of acrylodan labeled peptides binding to CaN in 
the presence of excess Ca2+/CaM with pFLISPP shows a higher affinity for CaN than pHLAPP. 
N=2 for pHLAPP and pFLISPP binding measurements. 
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Figure 5.9 Ribbon representation of CaN (PDB: 1AUI). The A-chain of CaN is shown in blue, 
and the B-chain of CaN is shown in gray. The PxIxIT-binding site is shown as the green β-
strand located on the catalytic domain. The LxVP-binding site is shown in orange at the 
interface between the A-chain and the B-chain. The FMDVF-motif is shown as a red loop 
connecting the PxIxIT-binding site and the LxVP-binding site. 
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Table 5.1. CONTIN analysis of the CD spectrum of RCAN1-4 from Figure 5A. Analysis was 
performed using the DiChroWeb web service and the SMP180 reference set for estimations 
of secondary structural content.101 
Type of Structure α-Helix β-strand Disordered 
Secondary Structure Content (%) 6.9 39 54.1 
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Table 5.2. IC50 data for RCAN1-4 and peptides derived from the sequence of RCAN1-4; 
pHLAPP and pFLISPP. RII peptide was constant at 30μM. The concentration of RCAN1-4 
ranged from 0μM to 2.0μM. Each of the two peptide’s concentration ranged from 0µM to 
25µM. All assays were performed at 30°C. 
 IC50  Hill Coefficient 
RCAN1-4 134 ± 25nM 1.5 ± 0.2 
pHLAPP 10 ± 0.3µM 2.4 ± 0.1 
pFLISPP ≤ 2.5 ± 0.9µM 2.5 ± 0.5 
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Table 5.3. KD values for RCAN1-4 and CaN in the presence of either 2mM EGTA, 2mM CaCl2, 
or 2mM CaCl2 + 10µM CaM 
Condition KD (nM) 
+ 2mM EGTA 76 ± 14 
+ 2mM CaCl2 39 ± 3 
+ 10mM CaCl2 + 10μM CaM 38 ± 5 
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Table 5.4. Michaelis-Menten parameters for CaN/RII assays containing various 
concentrations of RCAN.  
[RCAN1-4] (µM) Km (µM) Vmax (nmol min-1 mg) 
0 32 ± 2 1.69 ± 0.03 
0.100 45 ± 3 1.8 ± 0.04 
0.125 50 ± 6 1.7 ± 0.06 
0.150 87 ± 8 1.8 ± 0.07 
0.200 105 ± 14 1.9 ± 0.1 
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Table 5.5. RCAN1-4 does not affect CaN/pNPP activity at concentration of RCAN1-4 that 
inhibited CaN/RII activity.  
[RCAN1-4] Initial Velocity (µmol min-1 mg) 
0 0.83 ± 0.05 
250 0.87 ± 0.06 
500 0.86 ± 0.08 
1000 0.87 ± 0.05 
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Table 5.6.  Michaelis-Menten parameters for CaN/RII assays containing various 
concentrations of peptide inhibitors. 
[Inhibitor] Km (µM) Vmax (nmol min-1 mg) 
No inhibitor 31 ± 4 1.3 ± 0.05 
10µM of pHLAPP 52 ± 7 1.4 ± 0.05 
10µM of pFLISPP 93 ± 14 1.4 ± 0.07 
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Table 5.7. KD of peptide:CaN binding. KD was determined by fitting to a general ligand binding 
model (Equation 1).  
Peptide KD (µM) 
pHLAPP-Acr 12 ± 1 
pFLISPP-Acr 5.6 ± 0.8 
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CHAPTER 6: Conclusion and Future Directions for Study of Calcineurin 
 
In this dissertation, we discovered that 1) CaN activity increases due to 
macromolecular crowding, 2) electrostatic forces between CaN and calmodulin (CaM) speed 
up their association rate and 3) RCAN1-4 is a competitive inhibitor of CaN activity using RII 
as the phosphorylated substrate. While the aim of this dissertation was to be as thorough as 
possible in exploring these facets of CaN activation and substrate-binding there are 
experiments and hypotheses that need to be explored. Here, future directions of these 
projects are presented.  
 
6.1 Review of calcineurin structure and function 
Calcineurin’s (CaN) function is simple, dephosphorylation of a substrate. CaN is 
involved in a number of biological pathways such as immune system activation and long-term 
depression.4 CaN activity has also been shown to be implicated in pathological cardiac 
hypertrophy and tauopathies.4,62 Pathological cardiac hypertrophy is detrimental and leads 
to reduced cardiac efficiency and fibrotic inclusion which reduces contractility.206 In the 
heart, CaN promotes upregulation of Nuclear factor of activated T-cells (NFAT) signaling that 
leads to pathological cardiac hypertrophy.30,175 Reduction in CaN activity through the use of 
CaN inhibitors prevents the development of pathological cardiac hypertrophy in mouse 
models of pressure overload.32 Understanding the regulation of CaN and its signaling 
pathways is a potentially rich field of study for the development of novel drugs and 
treatments. 
CaN, also known as protein phosphatase 3, is a heterodimer with a catalytic A-chain 
(CaNA, 58-64kDa) and a regulatory B-chain (CaNB, 19kDa).4,62  CaNA contains a well-
conserved phosphodiesterase domain structurally similar to the catalytic domain of other 
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protein phosphatase families such as PP1 and PP2A.4 CaNA also contains a CaNB-binding, 
regulatory (RD), and autoinhibitory (AID) domains.66 The RD is an intrinsically disordered 
domain and contains a CaM-binding site (Figure 1).63  The AID occludes the active site of CaNA 
when the RD is not bound to CaM.82  
Many but not all CaN-substrates have been shown to contain two common SLiMs 
(short linear motifs) which confer CaN binding; the LxVP and PxIxIT motifs. The PxIxIT-
binding site is located on the catalytic domain and is adjacent to the active site while the LxVP-
binding site is located on the interface between CaNA and CaNB.35,97 NFAT contains both LxVP 
and PxIxIT motifs which are important for the interaction of CaN with NFAT.34 The binding 
affinity of the LxVP and PxIxIT motif segments and CaN are estimated to be in the low to mid-
micromolar range, but it is hypothesized that the presence of multiple low-affinity SLiMs 
increases the overall affinity of NFAT for CaN.35,97  
The RCAN (Regulator of calcineurin) family are known to be CaN inhibitors which 
contain two known PxIxIT motifs and two proposed LxVP motifs.21,59 Although other SLiMs 
in RCAN have been identified, such as the “EHLA” motif, their role in CaN binding/inhibition 
is currently unknown.21 RCAN1-4 is expressed in response to CaN activation. The 
upregulation of RCAN1-4 negatively feeds back to inhibit the CaN-signaling pathway. 
Constitutive CaN signaling in the hearts of mice results in symptoms analogous to 
pathological cardiac hypertrophy in humans which is a detrimental cardiac condition that 
results in cardiac failure and death. Understanding the interaction between RCAN1-4 and CaN 
will help us to understand how CaN is inhibited by RCAN1-4. The sequence of RCAN1-4 is 
very similar to other RCAN family members, and thus, studies of RCAN1-4 and CaN may be 
able to be applied to other RCANs.  
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6.2 Summary of results 
In chapter 3 we explored how macromolecular crowding alters the stability of the 
CaM:CaN complex. Previous reports in our lab suggest that a structure, which is called the 
“distal helix”, critical for CaN activity forms upon CaM binding to the intrinsically disordered 
RD of CaN.63,88 The distal helix is marginally stable at average human body temperature 
(37°C). In chapter 3, we sought to answer how an apparently critical structure important for 
CaN activity could be so unstable at native temperatures. We found that macromolecular 
crowding through the use of inert polymers increases the stability of the distal helix and this 
increase in the stability of the distal leads to an increase in CaN activity.166 There are several 
hypotheses as to why macromolecular crowding could stability proteins. Two of these 
hypotheses are excluded volume and intermolecular interaction. Excluded volume predicts 
that restriction of volume available for protein components promotes a more collapsed and 
folded state. Intermolecular interaction suggests that changes in protein stability are due to 
specific chemical reactions between the crowding reagent and protein in question. By using 
monomeric homologs of our polymeric reagents, we could test if intermolecular interactions 
were responsible for the apparent increase in CaN activity. We observed no change in the 
activity of CaN relative to dilute non-crowded solutions suggesting that the increase distal 
helix stability from our inert polymers is not due to intermolecular interaction.  
In chapter 4 we studied the interaction between CaN and CaM and the contribution 
of electrostatic forces to the association rate. It is known that electrostatic forces play a direct 
role which in some instances can increase the association rate of two proteins through the 
attraction of complementary charges.103 The influence of electrostatic interaction between 
CaM and the tested CaM-substrates was determined using the Debye-Hückel approximation 
from which an electrostatic influence and steric repulsion estimation can be determined. The 
CaM-binding site of CaN was found to contain net negatively charged residues on either side 
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of the CaM-binding site. By comparing association rates of CaM-substrates with the flanking 
net negatively charged patches to a CaM-substrate without these patches, we determined 
how these net negatively charged patches might affect electrostatic forces between CaM and 
the CaM-binding site. We found that net-negative charges flanking the net negatively charged 
CaM-binding site of the RD of CaN did not significantly affect the electrostatic interaction with 
CaM. This was surprising given the proximity of these patches to the CaM-binding site. When 
positively charged residues were mutated into the net negatively charged patches 
surrounding the CaM-binding site, we noticed an alteration in the electrostatic influence, but 
also a steric component which we hypothesized was due to alteration in the conformational 
ensemble of the RD that led to decreased accessibility of the CaM-binding site. This suggests 
that alteration of the conformational ensemble of an intrinsically disordered protein can lead 
to functional consequences. 
In chapter 5, we chose to ascertain the mechanism of inhibition of RCAN1-4, an 
endogenous inhibitor of CaN. While sections of RCAN1-4 have been analyzed for CaN-binding 
potential, an analysis on the inhibitory potency of full-length RCAN1-4 has yet to be 
determined. Furthermore, how RCAN1-4 inhibits CaN activity has yet to be determined. Using 
enzymatic assays, we determined that RCAN1-4 is a competitive inhibitor of CaN activity 
when we used the RII peptide as a phosphorylated endogenous-like CaN-substrate. We 
concluded that RCAN1-4 competes for the LxVP-binding site of CaN using two putative LxVP 
motifs; the FLISPP or HLAPP motif. Peptides derived from these two LxVP motifs were shown 
to not only bind to CaN but also competitively inhibit CaN activity.  
 
6.3 Macromolecular crowding and stability of the distal helix 
Chapter 3 was dedicated to investigating the effects of the environment on the 
stability of the distal helix. Previous studies investigated the stability of the distal helix in 
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dilute aqueous solutions of salts and proteins.88 However, the native environment of CaN is 
inside the cell. The inside of the cell is a crowded environment of proteins, lipids, nucleic 
acids, and small molecules that occupy around 20-30% of the intracellular volume depending 
on the compartment and cell type in question (Figure 6.2).120 Allen Minton coined the term 
“macromolecular crowding” and formed the initial theories on the effects of crowding on 
proteins.116,207 
Why does disruption of the distal helix result in an increase of the Km? pNPP is a 
generic phosphatase substrate which binds to the active site of CaN. An increase in the Km 
suggests either pNPP’s affinity for the active site of CaN is decreased, or the autoinhibitory 
domain is binding and occluding the active site of CaN. The autoinhibitory domain, in this 
case, would act as a competitive inhibitor of pNPP. Thus, the distal helix would appear to 
increase exposure of the active site to phosphorylated residues. The enzymatic data collected 
in Chapter 3 appears to be consistent with Dunlap et. al. in that increasing distal helix stability 
by adding ficoll 70 or dextran 70 decreases the Km.166 This suggests that if the crowding effects 
in cells are similar to those imparted by dextran 70 or ficoll 70, the distal helix would have a 
greater fraction folded compared to if the environment was a dilute buffer. 
While ficoll 70 and dextran 70 represent crowding mimics which provide useful data 
on the effects of crowding on a particular protein, the intracellular environment is much 
different than a solution containing high concentrations of ficoll 70 or dextran 70. Recently, 
Gary Pielak’s group has been using in-cell NMR to study the effects of a crowded intracellular 
environment on proteins.136 In-cell NMR utilizes Escherichia coli as the cellular environment 
which represents a closer approximation of the intracellular crowded environment 
compared to just the use of inert polymers like ficoll 70 and dextran 70. In-cell NMR can 
measure the effects of crowding with proteins of various sizes, shapes, and charge content. 
While an E. coli intracellular environment is not a perfect mimic of CaN’s proper eukaryotic 
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intracellular environment it is a closer approximation of some of the combined effects that 
cannot be observed with ficoll 70 and dextran 70. Ideally, we would like to know how stable 
the distal helix is in CaN’s native environment. The Pielak group’s work with measuring 
protein stability in E. coli using NMR-based methods would provide further data on the 
dynamics and stability of the distal helix in a more native-like environment. The stability of 
the distal helix in the context of full-length CaN would be difficult if not impossible using this 
NMR-based method due to line broadening in NMR spectra and difficulty in peak 
assignment.208 So, to overcome this we could express just the RD of CaN along with CaM. The 
size of the RD construct (~11kDa) is appropriate for NMR studies. 
In our crowding studies, we measured the activity of CaN as a function of crowder 
concentration using pNPP as the phosphatase substrate, but pNPP is not an endogenous 
substrate of CaN. How does crowding affect CaN activity against a more endogenous 
substrate such as NFAT or RII? An increase in the viscosity due to macromolecular crowding 
would predict a slower diffusion of CaN and CaN-substrates. A slower diffusion could 
decrease the rate at which CaN interacts with its substrates. How much would 
macromolecular crowding decrease the association of CaN and CaN-substrates? What would 
this mean in the context of the basic biology of the cell?  
We can explore these questions further by measuring the affinities of CaN and CaN-
substrates in crowded solutions using inert crowders like dextran 70 or ficoll 70. Measuring 
the enzyme kinetics of CaN and full-length CaN-substrates in crowded solutions would be 
difficult due to limitations of experimental setup we experienced in chapter 3. We found when 
performing the kinetics experiments with crowding reagents in chapter 3, the time required 
to properly mix our assay solutions was too long compared to the linear range of CaN activity 
using the RII peptide as a substrate. To properly measure CaN enzyme kinetics, the product 
released vs. time is determined for the initial linear portion of the reaction. The linear range 
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represents of the enzyme assay represents conditions where less than ~10% of the 
phosphorylated substrate has been dephosphorylated. The reason why it is important to 
measure enzyme kinetics in the linear range is because the concentration of phosphorylated 
substrate changes very little during this time. As the reaction proceeds and most of the 
phosphorylated substrate has been dephosphorylated, the reaction velocity will slow. For 
CaN, the linear range is the first 10 minutes of the reaction after the RII peptide and CaN have 
been combined. During initial experiments it took a significant amount of time (>2 minutes) 
to properly mix the viscous and crowded enzyme solutions. To remedy this, we turned to 
using pNPP as a substrate system which has a linear range of around 2 hours.    
While solutions of these polymers do not recapitulate the intracellular environment, 
they provide a preliminary method to access the effects of crowding on protein:protein 
interactions and kinetics. To gain insight into the how crowding might influence CaN enzyme 
kinetics, we can measure the binding affinity of various CaN-substrate and CaN as a function 
of the concentration of crowding reagent. For instance, we speculate that if the binding 
affinity of CaN-substrates and CaN increases, then the enzymatic rate of CaN for a particular 
CaN-substrate would also increase.  Aside from affinity differences of CaN and CaN-substrates 
as a function of the concentration of crowding reagent, the rate of association of CaN and CaN-
substrate could also be affected by crowding reagents. We hypothesize that the association 
rates of CaN and CaN-substrates would decrease due to a decrease in the rate of diffusion. 
Using stopped-flow spectroscopy, association rates between CaN and CaN-substrates could 
be determined as a function of the concentration of crowding reagent. Our main goal would 
be to understand how crowding in the cell affects the association rates and affinities of 
proteins.  
Finally, a major question which we would like to investigate is “How does 
macromolecular crowding affect the conformational ensemble of intrinsically disordered 
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proteins?” It has been observed that macromolecular crowding can destabilize, stabilize, or 
have no effect on the structure of a folded protein (Table 1). IDPs can take on a multitude of 
conformations which may be expanded into swollen coils or collapsed into molten globules 
depending on the sequence identity of the IDP.152 To investigate the conformational ensemble 
of the RD the radius of gyration is typically utilized a measure of protein compactness. We 
would expect from excluded volume theory that in crowded solutions, a collapsed ensemble 
would be favorable over a relatively extended or swollen coil state. Coeur et al. reported that 
small-angle neutron scattering could be used to obtain the radius of gyration of a protein in 
the presence of high molecular weight background molecules like ficoll 70 or dextran 70.209 
Therefore, we can directly compare the radius of gyration to the concentration of crowder in 
solution. While initially we would want to determine the effect of crowding on the ensemble 
of the RD of CaN, we would also like to investigate other IDPs. Many IDPs, including the RD, 
contain protein binding sites whose accessibility may be affected by the conformational 
ensemble.87 If crowding favors more collapsed conformational ensembles, then this might 
lead to a decrease in the accessibility of protein binding sites located on IDPs. 
 
 
6.4 Future studies on the role of the regulatory domain in calcineurin activity  
 In Chapter 4 we discussed charge distribution as it pertained to association rates. We 
investigated the electrostatic forces between the net positively charged calmodulin (CaM)-
binding site of the regulatory domain (RD) and net negatively charged CaM. To investigate 
the strength of the electrostatic forces between CaN and CaM, we measured the association 
rate constants at a variety of ionic strengths. Modulation of the ionic strength changes the 
electrostatic forces between proteins and can affect the association rate in accordance with 
the Debye-Hückel approximation.103 Two parameters can be derived from the Debye-Hückel 
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approximation; the kon,basal and the energy of electrostatic interaction (U). The kon,basal is the 
predicted association rate constant at an infinite ionic strength and would be affected by 
steric hindrances such as decreased accessibility of the CaM-binding site to CaM. The energy 
of electrostatic interaction is related to the electrostatic attraction between CaM and the CaM-
binding site (e.g strong negative charge attracting a strong positive charge).  
 The conformation ensemble of IDP can be influenced by the intramolecular 
electrostatic forces. For instance, if an IDP contains several lysine residues in succession, then 
this IDP would likely contain swollen coils in its conformational ensemble. In contrast, if the 
IDP sequence is 10 lysines followed by 10 glutamates, then the IDP would likely take on a 
hairpin conformational ensemble because the net positively charged region will interact 
favorably with the net negatively charged region. 
 We utilized the following constructs derived from CaN with which CaM can interact; 
pCaN, the RD, and full-length CaN. pCaN is a 27-residue peptide corresponding to the CaM-
binding region of CaN. pCaN has a net positive charge at a pH of 7.5. The RD is a protein 
construct of the intrinsically disordered regulatory domain of CaN and contains the CaM-
binding site and has an overall net negative charge. In our data, we found that the electrostatic 
force between CaM and CaN was attractive. The magnitude of the energy of electrostatic 
interaction between CaM and each the three ligands was the same. This would suggest that 
the CaM-binding site is responsible for the attractive interaction between CaN and CaM, and 
electrostatic influences outside the CaM-binding site are negligible.  
 The CaM-binding site of CaN is flanked by two net negatively charged patches that are 
very well conserved from yeast to humans. Two mutants of CaN were made that altered the 
net charge of these two patches; CaN E376R, E381R and CaN E415K, E418K. CaN E376R, 
E381R mutation decreased the net negative charge of the net negatively charged patch N-
terminal to the CaM-binding site but did not neutralize it. The CaN E415K, E418K converted 
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the charge of the net negatively charged patch C-terminal to the CaM-binding site to a net 
positively charged patch. CaN E376R, E381R had the same energy of electrostatic interaction 
as pCaN, RD, and CaN. The energy of electrostatic interaction of CaN E415K, E418K was 2-
fold greater compared to the other substrates suggesting that the positively charged residues 
mutated into the sequence are contributing an attractive force toward CaM. We speculated 
that the energy of electrostatic interaction was greater with the CaN E415K, E418K mutant 
because the mutated residues were closer in sequence to the CaM-binding site, and thus 
might add to the electrostatic attraction of the positively charged CaM-binding site to CaM.  
Further studies to investigate this hypothesis would be to make mutants adding 
positively charged residues at various distances from the either side of the CaM-bindings site. 
Our initial hypothesis for these studies would be that the closer an added positively charged 
residue is to the CaM-binding site, the more favorable the energy of electrostatic interaction 
between CaM and CaM-binding site will be. We can test this hypothesis by measuring the 
association rate constant of CaM-Acr and CaM-substrates containing our desired mutants at 
various ionic strengths in the same fashion as was described in chapter 4. 
 The kon,basal differences between our CaM-substrates report on the steric hindrances 
that would affect the accessibility of the CaM-binding site to CaM. The kon,basal varied for each 
of the CaM-substrates, but pCaN had the highest kon,basal. CaN’s kon,basal was 10-fold lower than 
that of pCaN. We hypothesize this is due to CaN having more surface area that could block 
CaM from interacting with the CaM-binding site. CaN E415K, E418K had more than a 100-
fold reduction in the kon,basal compared to pCaN which we hypothesize is due to an altered 
conformational ensemble of the RD that decreases the accessibility of the CaM-binding site 
for CaN.  
 We have noted in Chapter 4 that the RD of CaN has segregated patches of negatively 
and positively charged residues. The CaM-binding site has a strong net positive charge. The 
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CaM-binding site is flanked by net negatively charged patches. Do the negatively charged 
patches interact with the positively charged CaM-binding site? Does the conformational 
ensemble of the RD affect the association rates between CaN and CaM? Further studies will 
entail investigating the influence of these negatively-charged patches by generating more 
mutants that have neutralizing mutations in these regions. Association rates of CaM and these 
mutants can be determined by methods shown in Chapter 4. Further studies on the 
conformational ensemble of RD with altered net charged can be investigated by determining 
the radius of gyration of the RD and any mutants. A more globular or expanded coil state of 
the RD would manifest as a decrease or increase in the radius of gyration, respectively. We 
can measure the association rate of these mutants and determine the relationship to the 
radius of gyration.  
 There is still much to learn about the kinetics of CaM and CaN including what has been 
described above. What role do the acidic patches flanking the CaM-binding site have on the 
function or signaling of CaN? Do they play a role in determining the conformational ensemble 
of the disordered RD? Predictions from the Pappu lab’s CIDER program suggest that the 
conformational ensemble of the N-terminal half of the RD is coil-like and the C-terminal half 
is globular. If we modify the charge content of the acidic patches flanking the CaM-binding 
site, does the conformational ensemble of the N-terminal half of the RD change? Further 
investigation would entail making mutants altering the net charge of regions surrounding the 
CaM-binding site of the RD construct and in the full-length CaN protein. Thereby, we can 
correlate structural changes in the RD with functional effects on full-length CaN. 
 Finally, we would eventually want to look at the functional effects of disrupting the 
conformational ensemble of the RD of CaN in the cell. If we can introduce these CaN mutants 
in which the RD’s conformation ensemble is altered, we can measure the rate of CaN-signaling 
transduction using previously reported fluorescence-based NFAT assays.210 The 
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fluorescence-based NFAT assay developed by Rinne and Blatter allows the continuous 
monitoring of transcriptional activity of NFAT, and thus CaN activity. In this assay, the 
production of red fluorescence protein (RFP) is under the control of a NFAT-sensitive 
promoter taken from IL-2. Upon application of ionomycin, in the intracellular concentration 
of Ca2+ increases which leads to activation of the CaM/CaN pathway. CaN dephosphorylates 
NFAT and the upregulation of RFP will occur. The production of RFP can be read using 
fluorescence spectrometer or fluorescence microscopy. Results of this assay can be compared 
to wild-type CaN. If disruption of the conformational ensemble of the RD leads to alterations 
in the association rate constant of CaM-binding to CaN, then we would expect slower CaN-
signaling transduction in response to ionomycin application. 
 The association rates of proteins are known to be affected by electrostatic forces, but 
we are unsure if electrostatic forces have an effect on the dissociation rate.  Currently, there 
is very little data on the effects of electrostatic forces on dissociation rates, but studies suggest 
that modulation of the electrostatic forces through variation in the ionic strength does not 
greatly affect dissociation rates of IDPs from their folded binding partners.153,211,212 To 
investigate this further, we measured the dissociation rates of CaM-Acr (acrylodan-labeled 
CaM) from three substrates used for measuring the association rates in Chapter 4: pCaN, the 
RD, and CaN (Figure 6.3).  
 Whereas binding of CaM-Acr to a ligand leads to its decrease in the fluorescence 
emission intensity, dissociation results in the recovery of that fluorescence emission 
intensity. Single and double exponential rise-to-maximum equations were used to fit the data 
from the dissociation kinetic traces (Figure 6.3). Interestingly, analysis of the residuals 
suggests that a double exponential rise-to-maximum (that is two off-rates) was a superior fit 
than a single exponential. A single exponential fit for the association of CaN and CaM is 
consistent with previous reports.89 We interpret that the two dissociation rates stem from 
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the two binding lobes of CaM. It is known that the two lobes of CaM can each bind to a CaM-
substrate independently.90 Most likely, we are not observing two rates in our association rate 
kinetics because we do not have the resolution to distinguish multiple rates.  
 The two dissociation rates of CaM can be investigated further by measuring the 
dissociation rates of the two lobes of CaM separately. Plasmids containing genes encoding 
each of lobes of CaM have been made. Each construct contains a Cys on the terminus that can 
be used to label with acrylodan and track binding to a CaM-substrate. Dissociation rates of 
the two separate lobes can be compared to the two dissociation rates from full-length CaM. 
Why should we care about the dissociation mechanism of CaM? Studies on the Ca2+-binding 
affinity of CaM suggest that the C-terminal lobe of CaM is bound to Ca2+ around 100nM Ca2+ 
which is the basal intracellular concentration of Ca2+.213 By studying the ability of the C-
terminal lobe of CaM, we can determine if it is able to bind a substrate at concentrations of 
Ca2+ similar to that in the intracellular space. If the basal concentration of Ca2+ is high enough 
to saturate the C-terminal lobe, is it by default able to bind to CaN? 
 Dissociation kinetics were determined at various ionic strengths, and the two rates 
(fast and slow) were plotted against the ionic strength (Figure 6.4). No clear trends are 
indicated in the dissociation rates, but given our data, it would not appear ionic strength has 
an obvious effect on the dissociation rate. While increasing the ionic strength can weaken 
electrostatic forces, it may also strengthen hydrophobic interactions.214,215 If this is the case, 
then the dissociation rates of CaM and pCaN, RD, and CaN should show a comparable drop 
which is not observed.  
 This data would suggest that CaM/CaN signaling is sustained by an exceptionally slow 
off rate when Ca2+-levels are sufficient to activate CaM. Ca2+ concentrations are tightly 
regulated in the cell by SERCA pumps which force Ca2+ into the endoplasmic reticulum and 
by PMCA pumps that pump Ca2+ outside the cell.216 In disease states such as Alzheimer’s 
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disease, the concentration of intracellular Ca2+ has been shown to be elevated leading to 
activation of CaN.217–220 A common phenotype in patients with Alzheimer’s disease is the 
presence of elevated Aβ, a 40- or 42-residue peptide, in the brain.  Aβ binds to α-7 nicotinic 
receptor to promote the influx of Ca2+ in the cell leading to activation of Ca2+-dependent 
pathways such as the CaN-signaling pathway. Activation of the CaN-signaling pathway leads 
to depressed NMDA-evoked currents which have shown to affect memory and behavior in 
rodents.220,221  
 
6.5 RCAN1-4; Determining the mode of binding 
 One of the goals of this dissertation was to determine how RCAN binds to CaN and 
how this interaction results in the inhibition of CaN activity. In Chapters 1 and 5 the 
importance of RCAN1-4 and some initial data on its interaction with CaN were presented, 
respectively. Possibly the most striking reason for why the interaction of CaN and RCAN1-4 
is important is its application to pathological cardiac hypertrophy. It has been shown that 
over-activation of the CaN-signaling pathway upregulates cardiac hypertrophy.28,30 
Overexpression of the RCAN1, one of the three families RCANs, prevents the pathological 
remodeling process that results in the cardiac hypertrophy.174 
 For our studies of CaN and RCAN, we used the isoform that is expressed in cardiac 
tissues and is upregulated by CaN-signaling, RCAN1-4.222–224 Briefly, we showed that RCAN1-
4 is a competitive inhibitor of CaN/RII activity. The CaN/RII utilizes the RII peptide which is 
derived from an endogenous substrate of CaN; the regulatory type II subunit of protein kinase 
A.96 The RII peptide is known to interact with CaN at two distinct locations; the active site and 
the LxVP-binding site.34,35,96 Since RCAN1-4 did not decrease the activity of CaN against the 
generic phosphatase substrate pNPP which only binds to the active site, we predicted that 
RCAN1-4 did not occlude the active of CaN. Thus, RCAN1-4 binding to the LxVP-binding site 
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was suggested. Although only the RCAN1-4 isoform was studied, we could attribute similar 
qualities to the other RCAN isoforms based on a high degree of sequence identity between 
RCAN1-4 and other RCAN isoforms. 
 Examination of the sequence of RCAN1-4 yielded two potential LxVP motifs known 
as the “FLISPP” and “HLAPP” motifs. Non-overlapping peptides of both of these regions were 
synthesized and each was found to bind to and inhibit CaN activity although the “FLISPP” 
peptide was shown to bind and inhibit ~3-4 fold more effectively. The presence of two 
potential LxVP motifs in the sequence of RCAN1-4 is curious. This raises the question as to 
the stoichiometry of the RCAN1-4:CaN complex or possibly the number of LxVP-binding sites 
on CaN. Does CaN have more than one LxVP-binding site to bind these two potential LxVP 
motifs?  
Peptides of the FLISPP and HLAPP regions were shown to inhibit CaN activity 
cooperatively (inhibition assays for each peptide showed a Hill coefficient >2). The binding 
stoichiometry of the FLISPP and HLAPP peptides to CaN would, therefore, have to be different 
than a 1:1 binding ratio. It could be that CaN has more than one LxVP-binding site, and 
cooperativity would suggest that the occupation of one LxVP-binding site increases the 
affinity of a second LxVP-binding site for its substrate. Recently, the Steinbach lab discovered 
a potential additional binding site located between LxVP-binding site at the CaNA/CaNB 
interface and the active site.201 The Steinbach group named this new binding site the EMDVF 
site.  Given the close proximity of the HLAPP and FLISPP motifs on RCAN1-4, a second LxVP-
binding site would have to be adjacent to the known LxVP-binding site at the CaNA/CaNB 
interface. The EMDVF is such a binding site that that is in close proximity to the LxVP-binding 
site at the CaNA/CaNB interface. Thus, it would be possible for the HLAPP and FLISPP motifs 
of RCAN1-4 to occupy both the LxVP-binding site at the CaNA/CaNB interface and the EMDVF 
site.  
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 The Cyert group first determined the location of the LxVP-binding at the interface 
between the A chain and the B chain.35 The Wagner group recently discovered a second LxVP-
binding located on a region on the catalytic domain of CaN near another CaN-ligand binding 
site known as the PxIxIT-binding site.198 Thus, this new evidence would suggest that these 
two LxVP-binding sites might accommodate the two LxVP motifs from RCAN1-4. However, 
the LxVP-binding site at the CaNA/CaNB interface is too distant from LxVP-binding site 
discovered by the Wagner to allow for the simultaneous occupation of both binding sites by 
the HLAPP and FLISPP motifs. The end of the HLAPP motif and beginning of the FLISPP motif 
are only separated by 5 residues which could stretch ~17.5Å assuming a β-strand 
conformation, but Cyert’s LxVP-binding site and Wagner’s LxVP-binding site are over 30Å 
apart making simultaneous binding impossible. In contrast, the EMDVF motif discovered by 
the Steinbach group is only ~5-10Å from Cyert’s LxVP-binding site making the EMDVF site 
the more likely location of the second binding site. 
 Further elucidation of the mode in which these LxVP-like motifs interact with CaN’s 
LxVP-binding site can be determinedusing NMR and X-ray crystallography. The exact 
stoichiometry of LxVP-containing peptides to CaN can be obtained through the use of 
isothermal titration calorimetry. Location of the LxVP-binding sites can be assessed through 
mutagenesis. Disruptive mutations can be made to each or both LxVP-binding sites to assess 
their contributions to RCAN binding. For example, we can disrupt the LxVP-binding site at 
the CaNA/CaNB interface and measure the ability of FLISPP and HLAPP to interact with CaN. 
We can follow up with peptide competition assays using protein or peptide constructs with 
known LxVP binding sites such as the LxVP motif from NFAT. Does the HLAPP or FLISPP motif 
(possibly both) outcompete a known LxVP motif?   
We used the RII peptide throughout this study which contains a LxVP motif. The RII 
peptide is a 21-residue phosphorylated peptide derived the regulatory subunit of protein 
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kinase A. Protein kinase A is an endogenous substrate of CaN and can be used to measure CaN 
phosphatase activity. Investigation of the literature has shown that the LxVP motif of the RII 
peptide is thought to bind to the LxVP-binding site located at the interface between the A and 
B chain.34,35,95 But, with additional evidence from both Steinbach’s group and Wagner’s group 
about other CaN-substrate binding sites, we can’t help but wonder how this changes our idea 
of how the RII interacts with CaN.198 Does CaN bind multiple RII substrates? Certainly, 
another LxVP binding site could promote a higher catalytic rate by allowing multiple RII 
substrate to bind to CaN at once rather than one at a time. Perhaps even different CaN 
substrates could bind simultaneously. Despite the RII peptide being widely used to test CaN 
activity, there is no structural evidence on the precise binding mechanism of the RII 
peptide.67,95,195,225–231 Further studies on RII and other LxVP-containing CaN-substrates 
should unveil exactly how the commonly used RII substrate actually binds to CaN. Isothermal 
titration calorimetry (ITC) is a technique which can determine thermodynamic parameters 
of the interaction between two molecules. ITC can be used to determine the relative binding 
stoichiometry between CaN and the RII peptide. With ITC we can distinguish a 1:1 from a 
higher binding stoichiometry.  
 Other CaN-binding sites exist in the sequence of RCAN.20,21,58,59 These sites were 
discovered to bind to CaN using a pulldown assay. Various RCAN1-4 segments were tagged 
with glutathione S-transferase (GST) and applied to a GSH-column. The GST tag binds to the 
GSH-column and the RCAN1-4 segment is immobilized. CaN binds to the column if the 
RCAN1-4 segment binds CaN. GST-tagged RCAN1-4 segments and CaN are eluted by applying 
GSH to the column and CaN content is assayed using western blotting.  
 Some of the CaN-binding motifs of RCAN1-4 have not been structurally characterized 
bound to CaN which could yield valuable information on how they inhibit CaN activity.59 CaN 
binds to short linear motifs or SLiMs which include the LxVP motif and PxIxIT motif. Further 
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elucidation of the structure of the RCAN’s SLiMs bound to CaN could help to identify other 
CaN substrates or to better understand known CaN substrates which are not well 
characterized such as Bcl-2 associated death promoter (BAD) or microtubule-association 
protein tau (MAPT).  
 
6.6 Conclusions  
 IDPs are a relatively new class of proteins that have gained recognition in the past 20 
years or so as important signaling factors.87,150 CaN contains an intrinsically disordered 
region known as the RD. Interestingly, many of CaN’s binding partners are also IDPs and 
include RCAN1-4, the CaN-binding region of NFAT, microtubule associated protein tau, and 
Bcl-2 associated death promoter (BAD).20,198,232,233 We observed that crowding increased the 
stability of the distal helix on the RD of CaN when bound to CaN that resulted in an increase 
in CaN activity.  
Our hypothesis was that crowding reagents are favoring a more compact RD:CaM 
complex that leads to an increase in distal helix stability. But, how do crowding reagents affect 
the RD by itself? If crowding modulates the compactness or conformational ensemble of the 
RD, this could lead to alteration in the association rate kinetics of CaM and RD. For instance, 
a more compact RD could lead to a decrease in the accessibility of the CaM-binding site which 
would lead to a slower association rate than what we observed in dilute buffer in chapter 4. 
We can measure the association rates kinetics of CaM and the RD in crowded solutions using 
the fluorescence reporter system described in chapter 4 in combination with stopped-flow 
spectroscopy. Stopped-flow spectroscopy has been successfully used previously by Hoffman 
et al. to measure the association rate of CaM and a CaM-binding peptide derived from CaMKI. 
They observed a 2-3 fold decrease in the association rate with 200g/L of dextran 70 or ficoll 
70 compared to dilute buffer.234 Rather than using just a CaM-binding peptide like Hoffman 
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et al., we would like to extend this study to more complex CaM-substrates such as the RD and 
full-length CaN to determine the influence of macromolecular crowding. 
 We saw in chapter 5 the binding affinity of CaN and RCAN1-4 increased under 
saturating concentration of Ca2+.  Adding CaM did not affect the affinity between CaN and 
RCAN1-4 further, thus stability of the distal helix may not affect CaN-substrate binding 
affinity. Thus, the binding affinity of CaN to its substrates might be directly regulated by the 
binding of Ca2+ to CaNB. In other words, CaN-substrate binding could be controlled by Ca2+ 
binding to CaNB, and the dephosphorylation of the bound substrate is controlled by CaM. 
Previously studies of CaN by Yang and Klee suggest that the RD folds over the LxVP-binding 
site located at the interface between CaNA and CaNB.64 When CaNB is saturated with Ca2+ the 
RD is released from the CaNA/CaNB interface which exposes the LxVP-binding site. Thus, the 
RD may directly regulate the affinity of the LxVP-binding site and its substrates.  
  The influence of how crowding and electrostatic forces affect the conformation 
ensemble of IDPs has yet to be fully determined. Crowding could affect the compactness and 
thus the accessibility of binding sites on an IDP. In these cases, a decreased association rate 
would be observed between the IDP and its binding partner. While IDPs are natively 
unfolded, their conformational ensemble has been shown to be important for their 
functions.171 There are very few studies on the relationship between the conformational 
ensemble of an IDP and how it affect the IDP’s function. Thus, to understand the function of 
an IDPs, it is critical to understand what can influence the conformational ensemble of the 
IDP in its native environment (e.g crowding, electrostatic forces, ionic strength, etc.). Because 
many CaN-substrates are disordered, the CaN-signaling pathway is an excellent system to 
study the effects of IDP conformation ensemble on binding affinity, association and 
dissociation rate kinetics, and enzymatic activity. 
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6.5 Chapter 6 figures and tables 
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Figure 6.1. The heterodimeric structure of CaN (PDB ID: 1AUI) with the RD shown in green 
with the CaM-binding site in white. The catalytic domain is shown in dark blue, the CaNB-
binding domain (also known as the CaNB-binding helix) in light blue and the AID in red. The 
RD was modeled into the structure determined by Kissinger et al. (PDB: 1AUI) using the 
MODELLER program develop in the lab of Andrej Šali.235 The RD was modeled to show the 
reader a to-scale representation of the length of the RD and does not necessarily represent 
an accurate conformation. The RD is an IDP and adopts an ensemble of conformations. 
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Figure 6.2. Artist’s rendition of an E. coli cell cytoplasm crowded with biological molecules 
including proteins, DNA, and small molecules. The total volume occupied by biological 
molecules in the intracellular space is estimated to be between 30 and 40%.127  
Authorized for public use (1999). Illustration by David S. Goodsell, the Scripps Research 
Institute. URL: http://mgl.scripps.edu/people/goodsell/illustration/public 
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Figure 6.3. Kinetic traces of the dissociation of CaM-Acr from pCaN, RD, and CaN. CaM-Acr 
dissociation results in the recovery of the fluorescence intensity signal from CaM-Acr. The 
residual traces suggest dissociation kinetics fit better to a double exponential (red) than a 
single exponential (blue) rise-to-maximum. 
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Figure 6.4. Dissociation rates determined for CaM-Acr and pCaN, RD, or CaN at various ionic 
strengths. Two rates were determined from each kinetic trace and marked as “fast” and 
“slow” rate. 
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Table 6.1. Table showing that the effects of the inert polymers ficoll 70 and dextran 70 on 
protein stability vary widely. Depending on the protein, ficoll 70 and dextran 70 can be 
stabilizing or destabilizing. 
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Protein Crowding Reagent Effect Method used to 
determine stability 
Ref. 
Myoglobin 
(equine skeletal) 
Ficoll 70 
 
Dextran 70 
Destabilizing 
Destabilizing 
Destabilizing 
Stabilizing 
CD, thermal 
denaturation 
CD, urea denaturation 
CD, thermal 
denaturation 
CD, urea denaturation 
134 
Creatine kinase Ficoll 70 Stabilizing CD, thermal 
denaturation 
147 
Ubiquitin Ficoll 70 
PVP 
lysozyme 
BSA 
No change 
No change 
Destabilizing 
Destabilizing 
NMR, Amide H1 
exchange 
117 
Flavodoxin Ficoll 70 
Dextran 70 
Stabilizing 
Stabilizing 
CD, thermal 
denaturation 
CD, thermal 
denaturation 
125 
VlsE Ficoll 70 
Dextran 70 
Stabilizing 
Stabilizing 
CD, thermal 
denaturation 
CD, thermal 
denaturation 
125 
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APPENDIX 
APPENDIX I: List of abbreviations 
AID autoinhibitory domain 
Acr acrylodan 
BBH B chain binding helix 
CaM calmodulin 
CaN calcineurin 
CaNA calcineurin A subunit 
CaNB calcineurin B subunit 
CD circular dichroism 
CVD cardiovascular disease 
dex 70 dextran 70 
DSCR Down syndrome critical region 
fic 70 ficoll 70 
kDa kilodalton 
NFAT nuclear factor of activated T-cells 
NHR NFAT homology region 
pCaN calmodulin-binding peptide from calcineurin 
pNPP para-nitrophenyl phosphate 
PP protein phosphatase 
RCAN regulatory of calcineurin 
RD regulatory domain 
RHR REL homology region 
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  Single 
Exponential 
   Double 
Exponential 
   
Ligand [Ligand] 
(nM) 
[NaCl] 
(M) 
kon kon 
error 
R2  kon,1 kon,1 
error 
kon,2 kon,2 
error 
R2 
pCaN 150 0.5 8.42E+00 6.26E-01 4.45E-01  1.83E+01 3.67E+00 1.16E+00 1.27E+00 4.64E-01 
pCaN 200 0.5 1.69E+01 1.89E+00 2.46E-01  N/A N/A N/A N/A N/A 
pCaN 250 0.5 3.73E+01 7.17E+00 9.92E-02  N/A N/A N/A N/A N/A 
pCaN 150 1 8.31E+00 4.48E-01 6.05E-01  1.82E+01 6.16E+00 4.25E+00 1.54E+00 6.11E-01 
pCaN 200 1 9.83E+00 6.72E-02 4.79E-01  1.34E+01 4.45E+00 3.13E+00 4.58E+00 4.81E-01 
pCaN 250 1 1.61E+01 1.64E+00 2.84E-01  3.07E+01 2.88E+01 1.02E+01 7.24E+00 2.85E-01 
pCaN 150 1.5 1.87E+00 4.88E-02 8.64E-01  7.16E+00 6.75E-02 9.14E-01 6.72E-02 8.94E-01 
pCaN 200 1.5 2.70E+00 9.21E-02 7.81E-01  9.21E+00 1.18E+00 1.29E+00 1.25E-01 8.07E-01 
pCaN 250 1.5 1.11E+01 5.00E-01 6.67E-01  1.90E+01 3.26E+00 4.21E+00 1.20E+00 6.77E-01 
pCaN 300 1.5 1.77E+01 1.01E+00 5.52E-01  4.11E+01 2.87E+01 1.30E+01 3.77E+00 5.54E-01 
pCaN 150 2 1.26E+00 3.07E-02 8.92E-01  9.46E+00 9.55E-01 8.22E-01 3.77E-02 9.20E-01 
pCaN 200 2 3.00E+00 8.96E-02 8.21E-01  1.02E+01 8.21E-01 1.15E+00 8.95E-02 8.64E-01 
pCaN 250 2 6.43E+00 3.02E-02 6.48E-01  1.00E+01 1.50E+00 1.95E+00 7.14E-01 6.57E-01 
pCaN 300 2 1.37E+01 8.44E-02 5.16E-01  1.64E+01 2.79E+00 3.10E+00 3.52E+00 5.18E-01 
            
RD 62.5 0.25 3.84E+00 1.82E-02 8.01E-01  3.84E+00 5.24E+02 3.84E+00 6.35E+03 8.01E-01 
RD 100 0.25 6.64E+00 1.34E-02 9.53E-01  6.64E+00 6.95E+02 6.64E+00 6.74E+03 9.53E-01 
RD 150 0.25 1.47E+01 5.66E-02 8.48E-01  1.47E+01 2.71E+03 1.47E+01 2.80E+03 8.48E-01 
RD 200 0.25 2.32E+01 2.12E+00 5.02E-01  2.32E+01 2.97E+00 1.07E-16 3.27E-02 5.02E-01 
RD 250 0.25 2.58E+01 4.27E+00 2.89E-01  3.25E-16 2.90E+00 2.58E+01 1.01E+01 2.89E-01 
RD 62.5 0.5 4.06E+00 6.07E-02 9.76E-01  8.97E+00 2.26E+00 3.13E+00 3.08E-02 9.78E-01 
RD 100 0.5 8.08E+00 2.05E-02 9.27E-01  8.08E+00 1.40E+04 8.08E+00 1.71E+04 9.27E-01 
RD 150 0.5 1.14E+01 4.06E-02 8.69E-01  1.14E+01 8.58E+02 1.14E+01 1.13E+04 8.69E-01 
RD 200 0.5 1.44E+01 6.18E-02 8.35E-01  1.44E+01 1.78E+04 1.44E+01 1.73E+04 8.35E-01 
RD 250 0.5 1.60E+01 7.02E-02 8.23E-01  1.60E+01 2.31E+04 1.60E+01 2.47E+04 8.23E-01 
APPENDIX II: Data set of association rates of CaM-Acr and CaM-substrates discussed in chapter 4 
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Ligand [Ligand] 
(nM) 
[NaCl] 
(M) 
kon kon 
error 
R2  kon,1 kon,1 
error 
kon,2 kon,2 
error 
R2 
RD 62.5 1 3.73E+00 7.87E-02 9.54E-01  6.17E+00 3.60E+00 2.90E+00 9.51E-01 9.55E-01 
RD 100 1 8.03E+00 2.14E-01 9.22E-01  8.03E+00 2.53E+04 8.03E+00 2.95E+04 9.22E-01 
RD 150 1 9.60E+00 2.61E-01 9.21E-01  9.60E+00 2.94E+04 9.60E+00 3.24E+04 9.21E-01 
RD 200 1 1.06E+01 3.10E-01 9.08E-01  1.06E+01 1.11E+04 1.06E+01 1.25E+04 9.08E-01 
RD 250 1 1.32E+01 5.54E-01 8.36E-01  1.32E+01 5.76E+04 1.32E+01 6.97E+04 8.36E-01 
RD 62.5 1.5 1.59E+00 4.08E-02 9.65E-01  2.22E+00 6.32E-01 3.00E-02 1.38E+00 9.66E-01 
RD 100 1.5 2.85E+00 5.49E-02 9.66E-01  4.24E+00 9.02E-01 1.32E+00 7.61E-01 9.68E-01 
RD 150 1.5 4.32E+00 9.60E-02 9.47E-01  7.15E+00 1.16E+00 2.15E+00 5.66E-01 9.52E-01 
RD 200 1.5 5.45E+00 1.67E-01 9.00E-01  1.50E+01 3.47E+00 3.54E+00 4.29E-01 9.08E-01 
RD 250 1.5 7.43E+00 2.49E-01 8.83E-01  1.07E+01 4.31E+00 4.56E+00 2.56E+00 8.84E-01 
RD 62.5 2 2.03E+00 3.15E-02 9.83E-01  3.08E+00 4.56E-02 4.96E-01 5.44E-01 9.85E-01 
RD 100 2 2.59E+00 3.73E-02 9.82E-01  3.93E+00 7.76E-01 1.32E+00 5.87E-01 9.83E-01 
RD 150 2 3.16E+00 3.80E-02 9.86E-01  8.68E+00 2.20E+00 2.63E+00 1.58E-01 9.87E-01 
RD 200 2 4.25E+00 6.27E-02 9.76E-01  6.00E+00 6.64E-01 1.94E+00 5.75E-01 9.79E-01 
RD 250 2 4.72E+00 7.76E-02 9.70E-01  1.09E+01 6.16E+00 4.15E+00 4.25E-01 9.70E-01 
            
            
CaN 75 0.25 7.10E-01 2.79E-02 8.59E-01  3.76E+00 2.09E+00 9.14E+01 8.12E+00 8.62E-01 
CaN 100 0.25 9.16E-01 2.16E-02 9.43E-01  2.91E+00 6.24E-01 6.48E-01 5.74E-02 9.50E-01 
CaN 150 0.25 3.59E+00 1.30E-01 8.61E-01  5.34E+00 5.08E-01 9.45E-01 2.41E-01 8.74E-01 
CaN 200 0.25 5.63E+00 2.89E-01 7.62E-01  6.74E+00 7.82E-01 7.37E-03 1.49E+00 7.68E-01 
CaN 250 0.25 6.70E+00 2.07E-01 9.00E-01  7.92E+00 6. 09E-01 1.15E-03 1.43E+00 9.05E-01 
CaN 75 0.5 2.43E-01 4.51E-03 9.71E-01  1.07E+00 1.66E-01 1.76E-01 9.90E-03 9.78E-01 
CaN 100 0.5 3.11E-01 7.00E-03 9.51E-01  6.12E-01 3.93E-02 4.36E-02 2.11E-02 9.71E-01 
CaN 150 0.5 1.27E+00 3.92E-02 8.97E-01  2.84E+00 3.52E-01 5.55E-01 7.90E-02 9.15E-01 
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Ligand [Ligand] 
(nM) 
[NaCl] 
(M) 
kon kon 
error 
R2  kon,1 kon,1 
error 
kon,2 kon,2 
error 
R2 
CaN 200 0.5 1.57E+00 6.16E-02 8.43E-01  1.71E+00 1.34E-01 7.39E-02 4.14E-01 8.44E-01 
CaN 75 1 7.66E-01 1.54E-02 9.57E-01  1.92E+00 5.89E-01 5.90E-01 6.40E-02 9.60E-01 
CaN 100 1 7.54E-01 1.51E-02 9.58E-01  1.29E+00 8.83E-02 1.74E-01 5.52E-02 9.71E-01 
CaN 150 1 1.44E+00 3.00E-02 9.50E-01  1.98E+00 1.75E-01 5.22E-01 1.45E-01 9.55E-01 
CaN 200 1 1.64E+00 4.07E-02 9.30E-01  2.90E+00 3.30E-01 7.34E-01 1.17E-01 9.40E-01 
CaN 250 1 2.04E+00 7.48E-02 8.59E-01  3.63E+00 4.85E-01 7.48E-01 1.71E-01 8.73E-01 
CaN 75 1.5 5.08E-01 7.03E-03 9.83E-01  6.88E-01 7.75E-02 1.26E-01 1.26E-01 9.85E-01 
CaN 100 1.5 5.88E-01 8.06E-03 9.82E-01  8.86E-01 8.75E-02 2.09E-01 8.04E-02 9.85E-01 
CaN 150 1.5 8.90E-01 1.60E-02 9.64E-01  1.92E+00 2.92E-01 5.58E-01 6.09E-02 9.70E-01 
CaN 200 1.5 9.91E-01 1.96E-02 9.56E-01  2.24E+00 3.30E-01 6.08E-01 6.34E-02 9.63E-01 
CaN 250 1.5 1.37E+00 3.28E-02 9.35E-01  2.52E+00 1.89E-01 4.71E-01 6.53E-02 9.53E-01 
CaN 75 2 3.36E-01 6.39E-03 9.79E-01  7.92E-01 2.69E-01 2.15E-01 6.00E-02 9.80E-01 
CaN 100 2 3.93E-01 6.98E-03 9.78E-01  9.28E-01 1.98E-01 2.29E-01 4.83E-02 9.81E-01 
CaN 150 2 6.06E-01 1.08E-02 9.69E-01  1.03E+00 1.45E-01 2.72E-01 8.24E-02 9.73E-01 
CaN 200 2 7.48E-01 1.34E-02 9.66E-01  1.38E+00 2.08E-01 4.16E-01 7.45E-02 9.71E-01 
CaN 250 2 8.26E-01 1.63E-02 9.58E-01  1.24E+00 1.19E-01 2.71E-01 9.41E-02 9.65E-01 
            
CaN E376R, E381R 125 0.5 2.38E+00 1.09E-01 7.99E-01  3.53E+00 4.94E-01 5.12E-01 3.35E-01 8.10E-01 
CaN E376R, E381R 150 0.5 2.97E+00 1.73E-01 7.09E-01  4.30E+00 5.87E-01 4.39E-01 3.62E-01 7.23E-01 
CaN E376R, E381R 175 0.5 3.47E+00 5.09E-01 2.91E-01  6.05E+00 2.93E+00 6.36E-01 1.56E+00 2.97E-01 
CaN E376R, E381R 200 0.5 3.81E+00 3.96E-01 4.45E-01  1.93E+01 4.17E+01 3.42E+00 8.12E-01 4.46E-01 
CaN E376R, E381R 225 0.5 5.16E+00 6.84E-01 3.22E-01  1.61E+01 1.82E+01 3.59E+00 1.64E+00 3.24E-01 
CaN E376R, E381R 125 1 1.18E+00 4.16E-02 8.71E-01  1.73E+00 2.41E-01 3.69E-01 1.68E-01 8.78E-01 
CaN E376R, E381R 150 1 1.34E+00 6.86E-02 7.61E-01  2.02E+00 2.60E-01 2.23E-01 1.53E-01 7.76E-01 
CaN E376R, E381R 175 1 1.67E+00 1.86E-01 4.16E-01  2.23E+00 1.13E+00 3.78E-01 1.47E+00 4.18E-01 
CaN E376R, E381R 200 1 1.87E+00 2.79E-01 2.82E-01  2.62E+00 1.70E+00 5.07E-01 1.67E+00 2.84E-01 
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Ligand [Ligand] 
(nM) 
[NaCl] 
(M) 
kon kon 
error 
R2  kon,1 kon,1 
error 
kon,2 kon,2 
error 
R2 
CaN E376R, E381R 225 1 2.58E+00 3.22E-01 4.17E-01  2.58E+00 7.66E-01 1.32E-17 2.97E-01 4.17E-01 
CaN E376R, E381R 125 1.5 5.57E-01 1.63E-02 9.12E-01  1.38E+00 2.30E-01 2.95E-01 4.44E-02 9.23E-01 
CaN E376R, E381R 150 1.5 7.00E-01 2.91E-02 8.32E-01  1.31E+00 5.56E-01 4.47E-01 1.51E-01 8.35E-01 
CaN E376R, E381R 175 1.5 1.06E+00 4.61E-02 8.12E-01  1.33E+00 9.91E-02 5.14E-04 9.01E-02 8.28E-01 
CaN E376R, E381R 200 1.5 8.05E-01 4.29E-02 7.47E-01  1.13E+00 1.19E-01 1.38E-03 1.00E-01 7.64E-01 
CaN E376R, E381R 225 1.5 6.43E-01 2.91E-02 8.08E-01  6.68E-01 8.67E-02 1.04E-03 1.07E+00 8.08E-01 
CaN E376R, E381R 125 2 3.68E-01 1.18E-02 9.00E-01  2.25E+00 4.20E-01 2.61E-01 1.70E-02 9.17E-01 
CaN E376R, E381R 150 2 4.32E-01 1.17E-02 9.23E-01  5.42E-01 7.12E-02 1.10E-01 1.24E-01 9.25E-01 
CaN E376R, E381R 175 2 4.98E-01 1.61E-02 8.99E-01  1.03E+00 6.46E-01 3.84E-01 1.04E-01 9.00E-01 
CaN E376R, E381R 200 2 4.61E-01 1.63E-02 8.83E-01  8.70E-01 3.26E-01 2.76E-01 1.04E-01 8.87E-01 
CaN E376R, E381R 225 2 1.84E-01 1.37E-02 7.98E-01  6.97E-02 3.61E-01 3.21E-01 4.81E-01 7.99E-01 
            
CaN E415K, E418K 300 0.5 4.73E+00 9.38E-01 1.31E-01  9.57E+00 7.44E+00 7.50E-03 4.68E+00 1.34E-01 
CaN E415K, E418K 350 0.5 5.92E+00 9.19E-01 1.74E-01  3.37E+01 5.21E+01 4.82E+00 1.79E+00 1.76E-01 
CaN E415K, E418K 400 0.5 8.29E+00 1.23E+00 1.69E-01  2.93E+01 2.40E+01 4.84E+00 2.50E+00 1.72E-01 
CaN E415K, E418K 125 1 1.63E+00 1.60E-01 3.03E-01  2.18E+00 7.04E-01 3.62E-01 6.79E-01 3.06E-01 
CaN E415K, E418K 150 1 1.74E+00 1.53E-01 3.50E-01  3.66E+00 1.26E+00 6.81E-01 3.27E-01 3.58E-01 
CaN E415K, E418K 175 1 2.73E+00 2.80E-01 2.78E-01  4.60E+00 8.81E-01 2.60E-01 2.24E-01 2.96E-01 
CaN E415K, E418K 200 1 2.76E+00 2.92E-01 2.84E-01  2.76E+00  +Inf 3.63E-18  +Inf 2.84E-01 
CaN E415K, E418K 125 1.5 1.12E+00 8.01E-02 4.65E-01  3.83E+00 3.06E+00 8.59E-01 2.11E-01 4.67E-01 
CaN E415K, E418K 150 1.5 1.34E+00 1.01E-01 4.32E-01  1.19E+01 1.09E+01 1.17E+00 1.44E-01 4.34E-01 
CaN E415K, E418K 175 1.5 1.55E+00 1.10E-01 4.55E-01  3.86E+00 3.24E+00 1.13E+00 3.87E-01 4.57E-01 
CaN E415K, E418K 125 2 5.70E-01 5.84E-02 2.86E-01  1.10E+00 2.21E-01 1.77E-03 7.23E-02 3.09E-01 
CaN E415K, E418K 150 2 6.58E-01 5.26E-02 3.93E-01  1.55E+00 6.46E-01 3.35E-01 1.24E-01 3.99E-01 
CaN E415K, E418K 175 2 6.55E-01 6.22E-02 3.15E-01  1.34E+00 3.49E-01 1.57E-01 9.60E-02 3.26E-01 
CaN E415K, E418K 200 2 8.81E-01 9.44E-02 2.62E-01  1.34E+00 3.80E-01 1.89E-01 1.70E-01 2.69E-01 
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  Single Exponential  Double Exponential    
Ligand [NaCl] (M) koff koff error R2 koff,1 koff,1 error koff2 koff,2 error R2 
pCaN 0.25 1.11E-03 1.32E-06 9.97E-01 1.11E-03 4.24E-02 1.11E-03 6.69E-02 9.97E-01 
pCaN 0.5 1.05E-03 3.97E-06 9.80E-01 2.48E-03 1.50E-05 4.10E-04 3.86E-06 9.98E-01 
pCaN 0.75 3.55E-03 8.63E-06 9.96E-01 2.45E-02 4.83E-03 3.48E-03 1.51E-05 9.96E-01 
pCaN 1 3.26E-03 1.04E-05 9.93E-01 8.23E-03 2.46E-04 2.45E-03 2.73E-05 9.97E-01 
pCaN 1.25 4.27E-03 1.81E-05 9.95E-01 8.71E-03 6.35E-04 3.20E-03 1.18E-04 9.97E-01 
pCaN 1.5 4.66E-03 1.55E-05 9.99E-01 2.59E-02 2.59E-03 4.33E-03 3.37E-05 1.00E+00 
pCaN 1.75 4.86E-03 8.39E-06 9.99E-01 9.51E-03 9.13E-04 4.42E-03 6.79E-05 9.99E-01 
pCaN 2 4.57E-03 1.08E-05 9.97E-01 5.86E-03 5.94E-05 2.00E-03 7.24E-05 9.99E-01 
          
RD 0.25 2.63E-03 7.51E-06 9.94E-01 1.25E-02 1.38E-04 2.16E-03 4.80E-06 9.99E-01 
RD 0.5 5.27E-03 3.22E-05 9.76E-01 1.05E-02 9.33E-05 1.90E-03 2.68E-05 9.96E-01 
RD 0.75 3.26E-03 1.30E-05 9.89E-01 5.94E-03 6.07E-05 1.49E-03 2.31E-05 9.98E-01 
RD 1 3.50E-03 1.16E-05 9.94E-01 1.56E-02 1.79E-04 2.84E-03 7.04E-06 1.00E+00 
RD 1.25 3.27E-03 1.90E-05 9.83E-01 1.35E-02 1.63E-04 2.13E-03 1.19E-05 9.98E-01 
RD 1.5 2.52E-03 1.18E-05 9.89E-01 1.00E-02 1.63E-04 1.77E-03 1.14E-05 9.98E-01 
RD 1.75 8.40E-04 4.50E-06 9.36E-01 3.00E-03 1.31E-05 2.49E-04 1.71E-06 9.95E-01 
RD 2 1.87E-03 7.69E-06 9.89E-01 8.72E-03 7.45E-05 1.33E-03 4.11E-06 9.99E-01 
          
CaN 0.25 8.51E-03 5.23E-05 9.91E-01 3.86E-02 2.60E-03 7.18E-03 8.47E-05 9.95E-01 
CaN 0.5 1.10E-02 1.06E-04 9.85E-01 3.88E-02 1.58E-03 7.48E-03 1.32E-04 9.96E-01 
CaN 0.75 1.09E-02 7.64E-05 9.60E-01 4.18E-02 1.83E-03 7.65E-03 1.20E-04 9.72E-01 
CaN 1 1.15E-02 1.22E-04 9.80E-01 3.07E-02 9.91E-04 6.23E-03 1.61E-04 9.95E-01 
CaN 1.25 1.26E-02 1.54E-04 9.80E-01 2.37E-02 7.81E-04 4.17E-03 3.44E-04 9.93E-01 
CaN 1.5 1.37E-02 1.38E-04 9.90E-01 2.96E-02 1.27E-03 7.33E-03 3.38E-04 9.97E-01 
CaN 1.75 1.42E-02 1.02E-03 7.90E-01 3.08E-02 8.20E-04 5.55E-03 8.74E-05 7.92E-01 
CaN 2 1.10E-02 8.32E-05 9.88E-01 2.84E-02 1.02E-03 7.08E-03 1.43E-04 9.96E-01 
APPENDIX III: Data set of dissociation rates of CaM-Acr and CaM-substrates discussed in 
chapter 4 
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APPENDIX IV: Python script to analyze kinetic trace data obtained on ISS K2 
fluorometer 
 
Dependencies:  
1. NumPy (http://www.numpy.org/) 
2. matplotlib (http://matplotlib.org/) 
3. SciPy (www.scipy.org) 
4. Tkinter (https://wiki.python.org/moin/TkInter) 
 
Input an .ifx or .ifa file type containing stopped-flow data from the ISS K2 fluorometer. Script 
outputs a .pdf containing a graph of the experimental data fit to both single and double 
exponential decay equations and residual plot. Fit statistics are written to a .txt file which is 
also an output.. 
 
1. import numpy as np   
2. from io import StringIO   
3. from scipy import optimize   
4. from matplotlib.legend_handler import HandlerLine2D   
5. import matplotlib.pyplot as plt   
6. from matplotlib import gridspec   
7. from Tkinter import Tk   
8. from tkFileDialog import askopenfilename   
9.    
10. #Set the deadtime of your instrument   
11. deadTime = 8   
12.    
13. #Ask for input file from user   
14. Tk().withdraw() # we don't want a full GUI, so keep the root window from appearing   
15. filename = askopenfilename() # show an "Open" dialog box and return the path to the select
ed file   
16.    
17. #Create two subplot which will be printed together.   
18. f, axarr = plt.subplots(2, sharex=True)   
19. gs = gridspec.GridSpec(2, 1, height_ratios=[2,1])    
20. axarr[0] = plt.subplot(gs[0])   
21. axarr[1] = plt.subplot(gs[1])   
22.    
23.    
24. dt = np.dtype([('Iteration', int), ('Time', float), ('Intensity', float)])   
25. plt.subplots_adjust(left=None, bottom=None, right=None, top=1.5, wspace=None, hspace=None)
    
26.    
27. #Load Time and Intensity data from all iterations into an array.   
28. #Set the number of lines to skip depending on the file type.   
29. if filename.endswith('.ifx'):   
30.     inArray = np.loadtxt(filename, dtype = dt, skiprows=26)   
31. if filename.endswith('.ifa'):   
32.     inArray = np.loadtxt(filename, dtype = dt, skiprows=12)    
33.    
34. npinArray = inArray   
35.    
36. #Determine number of points and number of iterations   
37. lastArray = inArray[-1]   
38. numberOfIterations = lastArray[0]   
39. numberOfPoints = len(inArray)/numberOfIterations   
40.    
41. #Instantiate arrays and global variables.   
42. point = 0   
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43. procXArray = []   
44. procYArray = []   
45. unprocYArray = []   
46.    
47. #There will have to be at least 1 set of points   
48. #Determine X values   
49. while (point < numberOfPoints):   
50.     procXArray.append(inArray[point][1])   
51.     point = point + 1   
52.    
53. point = 0   
54.    
55. while (point < len(inArray)):   
56.     unprocYArray.append(inArray[point][2])   
57.     point = point + 1   
58.     
59. #Outer loop will evaluate number of iterations      
60. summation = 0   
61. i = 0   
62. OuterY = 0   
63. #Inner loop evaluates each point of the iteration   
64. while(OuterY < numberOfPoints):   
65.     x = OuterY   
66.     i = 0   
67.     summation = 0   
68.     while(i < numberOfIterations):   
69.         summation = summation + unprocYArray[x]   
70.         i = i + 1   
71.         x = x + numberOfPoints   
72.     addedPoint = summation/numberOfIterations   
73.     procYArray.append(addedPoint)   
74.     OuterY = OuterY + 1   
75.    
76.    
77.    
78. #Create an array that deletes data points within the deadtime of the stopped-flow   
79. aliveXArray = []   
80. aliveYArray = []   
81. ar = 0   
82. while (ar < len(procXArray)):   
83.     if procXArray[ar] > deadTime:   
84.         aliveXArray.append(procXArray[ar])   
85.         aliveYArray.append(procYArray[ar])   
86.     ar = ar + 1   
87.    
88. axarr[0].plot(aliveXArray, aliveYArray, 'o', ms = 2, color = '#00C1FF', markeredgewidth = 
0.1,label = 'Exper. data')   
89.    
90. #Fitting to an single exponential decay   
91. def singledecay(x, yIntercept, preexponential, kon):   
92.     return yIntercept + preexponential*np.exp(-kon*x)   
93.    
94. guess1 = [aliveYArray[0], (aliveYArray[0] - aliveYArray[-1]), 0.001]   
95. params1, params_covariance1 = optimize.curve_fit(singledecay, aliveXArray, aliveYArray, gu
ess1, maxfev = 10000)   
96.    
97. yIntercept = params1[0]   
98. preexponential = params1[1]   
99. kon = params1[2]   
100.   
101. X = np.array(aliveXArray)   
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102. C = np.array(yIntercept + preexponential*np.exp(-kon*X))   
103.   
104. #Plot the model for single exponential decay   
105. axarr[0].plot(X, C, color = "red", label = 'Single exp.')   
106.   
107.   
108. #Print the stats for single exponential decay   
109. output0 = "Parameters for single exponential decay: "   
110. output1 = 'Asymptote: ' + str(yIntercept)   
111. output2 = 'Pre-exponential factor: ' + str(preexponential)   
112. output3 = 'kon (M-1*s-1): ' + str(kon*1000)   
113.   
114. #Fitting to an double exponential decay   
115. def doubledecay(x, yIntercept, preexponential1, kon1, preexponential2, kon2):   
116.    return yIntercept + (preexponential1*np.exp(-kon1*x)) + (preexponential2*np.exp(-
kon2*x))   
117.       
118. guess2 = [aliveYArray[0], (aliveYArray[0] - aliveYArray[-
1]), 0.001, (aliveYArray[0] - aliveYArray[-1]), 0.01]   
119. params2, params_covariance2 = optimize.curve_fit(doubledecay, aliveXArray, aliveYArray, gu
ess2, maxfev = 10000)   
120.   
121. yIntercept = params2[0]   
122. preexponential1 = params2[1]   
123. kon1 = params2[2]   
124. preexponential2 = params2[3]   
125. kon2 = params2[4]   
126.   
127. X2 = np.array(aliveXArray)   
128. C2 = np.array(yIntercept + preexponential1*np.exp(-kon1*X2) + preexponential2*np.exp(-
kon2*X2))   
129.   
130. #Plot the model for double exponential decay   
131. axarr[0].plot(X2, C2,color = "black", label = 'Double exp.')   
132.   
133.   
134. #Print the stats for double exponential decay   
135.   
136. output4 = "Parameters for double exponential decay: "   
137. output5 = 'Asymptote: ' + str(yIntercept)   
138. output6 = '1st Pre-exponential factor: ' + str(preexponential1)   
139. output7 = '1st kon (M-1*s-1): ' + str(kon1*1000)   
140. output8 = '2nd Pre-exponential factor: ' + str(preexponential2)   
141. output9 = '2nd kon (M-1*s-1): ' + str(kon2*1000)   
142.   
143. #Writes data to text file of the filename   
144. output_textfile = open(filename + '.txt', 'w')   
145. output_textfile.write('Fitting parameters for: ' + filename + '\n\n')   
146. output_textfile.write(output0 + '\n')   
147. output_textfile.write(output1 + '\n')   
148. output_textfile.write(output2 + '\n')   
149. output_textfile.write(output3 + '\n\n')   
150. output_textfile.write(output4 + '\n')   
151. output_textfile.write(output5 + '\n')   
152. output_textfile.write(output6 + '\n')   
153. output_textfile.write(output7 + '\n')   
154. output_textfile.write(output8 + '\n')   
155. output_textfile.write(output9 + '\n')   
156.   
157. output_textfile.close();   
158.   
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159. #Format graphs to make them look good   
160. plt.xlabel('Time (seconds)', fontsize=14)   
161. axarr[0].set_ylabel('Intensity', fontsize=16)   
162. axarr[1].set_ylabel('Residual', fontsize=16)   
163.   
164. axarr[0].legend(bbox_to_anchor=(0., 0.99, 0.99, 0.), loc=1)   
165. plt.xlim([aliveXArray[0],aliveXArray[-1]])   
166.   
167. #Calculate residual arrays  
168. residuals1 = aliveYArray - C    
169. residuals2 = aliveYArray - C2   
170.   
171. #Plot the residuals from single and double exponential decay to the lower subplot.   
172. axarr[1].plot(aliveXArray, residuals1, 'o', color = 'red', markersize = 3,markeredgewidth 
= 0.1)   
173. axarr[1].plot(aliveXArray, residuals2, 'o', color = 'black', markersize = 3,markeredgewidt
h = 0.1)   
174.   
175. axarr[0].set_xlim([aliveXArray[0],aliveXArray[-1]])   
176. plt.rcParams['figure.figsize'] = (8.0, 8.0)   
177. plt.tight_layout()   
178.   
179.   
180.      
181. plt.savefig(filename + ".pdf")   
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